<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005654.pub3" GROUP_ID="INCONT" ID="126002030108272205" MERGED_FROM="" MODIFIED="2014-05-13 14:18:13 +0100" MODIFIED_BY="Muhammad Imran Omar" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;/p&gt;" NOTES_MODIFIED="2014-05-13 14:17:12 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="01" REVMAN_SUB_VERSION="5.2.11 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2014-05-13 14:18:13 +0100" MODIFIED_BY="Muhammad Imran Omar">
<TITLE>Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women</TITLE>
<CONTACT MODIFIED="2014-05-13 14:18:13 +0100" MODIFIED_BY="Muhammad Imran Omar"><PERSON ID="07BEC72582E26AA200831C1961221FFB" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Chantale</FIRST_NAME><LAST_NAME>Dumoulin</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>chantal.dumoulin@umontreal.ca</EMAIL_1><ADDRESS><DEPARTMENT>School of Rehabilitation, Faculty of Medicine</DEPARTMENT><ORGANISATION>University of Montreal</ORGANISATION><ADDRESS_1>C.P.6128 Succ. Centre-ville</ADDRESS_1><CITY>Montreal</CITY><ZIP>H3C 3J7</ZIP><REGION>Quebec</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 514 3436111</PHONE_1><FAX_1>+1 514 3432105</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2014-05-13 14:18:13 +0100" MODIFIED_BY="Muhammad Imran Omar"><PERSON ID="07BEC72582E26AA200831C1961221FFB" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Chantale</FIRST_NAME><LAST_NAME>Dumoulin</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>chantal.dumoulin@umontreal.ca</EMAIL_1><ADDRESS><DEPARTMENT>School of Rehabilitation, Faculty of Medicine</DEPARTMENT><ORGANISATION>University of Montreal</ORGANISATION><ADDRESS_1>C.P.6128 Succ. Centre-ville</ADDRESS_1><CITY>Montreal</CITY><ZIP>H3C 3J7</ZIP><REGION>Quebec</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 514 3436111</PHONE_1><FAX_1>+1 514 3432105</FAX_1></ADDRESS></PERSON><PERSON ID="4684" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>E. Jean</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Hay-Smith</LAST_NAME><EMAIL_1>jean.hay-smith@otago.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Rehabilitation Teaching and Research Unit, Department of Medicine</DEPARTMENT><ORGANISATION>University of Otago</ORGANISATION><CITY>Wellington</CITY><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 3 474 7007 ext: 8568</PHONE_1><FAX_1>+64 3 474 7620</FAX_1></ADDRESS></PERSON><PERSON ID="z1309041440260126306359271336307" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Gabrielle</FIRST_NAME><LAST_NAME>Mac Habée-Séguin</LAST_NAME><POSITION>Research Assistant</POSITION><EMAIL_1>gab_ms44@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Centre de recherche de l'Institut</DEPARTMENT><ORGANISATION>Universitaire de gériatrie de Montréal</ORGANISATION><CITY>Montreal</CITY><COUNTRY CODE="CA">Canada</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2014-04-02 13:30:43 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 01/08/08&lt;/p&gt;&lt;p&gt;New studies found but not yet included or excluded: 18/01/06&lt;/p&gt;&lt;p&gt;New studies found and included or excluded: 01/07/06&lt;/p&gt;&lt;p&gt;Conclusions changed: 01/07/06&lt;/p&gt;" NOTES_MODIFIED="2014-04-02 13:30:43 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="15" MONTH="4" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="4" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-05-13 14:17:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;One new study was found and added to the review.&lt;br&gt;Two studies were excluded (the new one and an old one as they were considered a comparison of two PFMT protocols).&lt;br&gt;One outcome measure (Pad test) was included as a secondary outcome measure.&lt;/p&gt;" NOTES_MODIFIED="2014-05-13 14:17:12 +0100" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-05-13 14:17:02 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>In this update, seven new trials have been added (<LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>). One previously included trial has been removed because the control group was deemed to be receiving a form of active treatment (<LINK REF="STD-van-Leeuwen-2004" TYPE="STUDY">van Leeuwen 2004</LINK>). Full risk of bias assessment has been completed for all trials. Data from 'Other data' tables have been incorporated into other sections. Quality of evidence was assessed by adopting the GRADE approach.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-05-13 14:17:12 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>In this update, seven new trials have been added (<LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>). One previously included trial has been removed because the control group was deemed to be receiving a form of active treatment (<LINK REF="STD-van-Leeuwen-2004" TYPE="STUDY">van Leeuwen 2004</LINK>). Full risk of bias assessment has been completed for all trials. Data from 'Other data' tables have been incorporated into other sections. Quality of evidence was assessed by adopting the GRADE approach.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2014-04-02 14:00:53 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-04-02 14:00:53 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="5" YEAR="2009"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-04-14 15:17:24 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="14" MONTH="4" YEAR="2009"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-04-02 15:13:57 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Montreal</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-04-02 15:13:57 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-04-02 15:13:57 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Incontinence Group.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2014-04-02 15:13:57 +0100" MODIFIED_BY="[Empty name]">
<NAME>Chantale Dumoulin was funded by the International Continence Society Research Fellowship</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2014-04-02 15:13:56 +0100" MODIFIED_BY="[Empty name]">
<NAME>Gabrielle Mac Habée-Séguin was funded by the University of Montreal COPSE grant</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-05-13 14:09:08 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2014-05-13 14:04:34 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-05-23 09:59:41 +0100" MODIFIED_BY="[Empty name]">Pelvic floor muscle training versus no treatment for urinary incontinence in women</TITLE>
<SUMMARY_BODY MODIFIED="2014-05-13 14:04:34 +0100" MODIFIED_BY="[Empty name]">
<P>Stress incontinence is the involuntary leakage of urine with a physical activity such as coughing or sneezing. Urgency leakage occurs with a strong need to urinate, but the person cannot make it to the toilet in time. A combination of stress and urgency leakage is called mixed incontinence.</P>
<P>The review of trials found that pelvic floor muscle training (muscle-clenching exercises) helps women cure and improve stress urinary incontinence in particular, and all types of incontinence.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-05-13 14:04:18 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-02-03 02:52:27 +0000" MODIFIED_BY="[Empty name]">
<P>Pelvic floor muscle training is the most commonly used physical therapy treatment for women with stress urinary incontinence (SUI). It is sometimes also recommended for mixed and, less commonly, urgency urinary incontinence.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effects of pelvic floor muscle training for women with urinary incontinence in comparison to no treatment, placebo or sham treatments, or other inactive control treatments.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-04-28 12:14:47 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Incontinence Group Specialised Register, which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL) (1999 onwards), MEDLINE (1966 onwards) and MEDLINE In-Process (2001 onwards), and handsearched journals and conference proceedings (searched 15 April 2013) and the reference lists of relevant articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-08-16 22:09:10 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised or quasi-randomised trials in women with stress, urgency or mixed urinary incontinence (based on symptoms, signs, or urodynamics). One arm of the trial included pelvic floor muscle training (PFMT). Another arm was a no treatment, placebo, sham, or other inactive control treatment arm.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-04-28 13:13:35 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were independently assessed by two review authors for eligibility and methodological quality. Data were extracted then cross-checked. Disagreements were resolved by discussion. Data were processed as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I>. Trials were subgrouped by diagnosis of urinary incontinence. Formal meta-analysis was undertaken when appropriate.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-05-13 14:04:18 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-one trials involving 1281 women (665 PFMT, 616 controls) met the inclusion criteria; 18 trials (1051 women) contributed data to the forest plots. The trials were generally small to moderate sized, and many were at moderate risk of bias, based on the trial reports. There was considerable variation in the interventions used, study populations, and outcome measures. There were no studies of women with mixed or urgency urinary incontinence alone.</P>
<P>Women with SUI who were in the PFMT groups were 8 times more likely than the controls to report that they were cured (46/82 (56.1%) versus 5/83 (6.0%), RR 8.38, 95% CI 3.68 to 19.07) and 17 times more likely to report cure or improvement (32/58 (55%) versus 2/63 (3.2%), RR 17.33, 95% CI 4.31 to 69.64). In trials in women with any type of urinary incontinence, PFMT groups were also more likely to report cure, or more cure and improvement than the women in the control groups, although the effect size was reduced. Women with either SUI or any type of urinary incontinence were also more satisfied with the active treatment, while women in the control groups were more likely to seek further treatment. Women treated with PFMT leaked urine less often, lost smaller amounts on the short office-based pad test, and emptied their bladders less often during the day. Their sexual outcomes were also better. Two trials (one small and one moderate size) reported some evidence of the benefit persisting for up to a year after treatment. Of the few adverse effects reported, none were serious.</P>
<P>The findings of the review were largely supported by the summary of findings tables, but most of the evidence was down-graded to moderate on methodological grounds. The exception was 'Participant perceived cure' in women with SUI, which was rated as high quality.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-04-28 12:16:26 +0100" MODIFIED_BY="[Empty name]">
<P>The review provides support for the widespread recommendation that PFMT be included in first-line conservative management programmes for women with stress and any type of urinary incontinence. Long-term effectiveness of PFMT needs to be further researched.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-05-13 14:09:08 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2014-05-06 10:31:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<CONDITION MODIFIED="2014-04-28 12:30:34 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Urinary incontinence</HEADING>
<P>Urinary incontinence is a common problem amongst adults living in the community. It is more frequent in women, increasing with age, and is particularly common amongst those in residential care (<LINK REF="REF-Hunskaar-2002" TYPE="REFERENCE">Hunskaar 2002</LINK>). Estimates of prevalence are influenced by the definition of incontinence, the sample population, and the format of questions about incontinence. In addition, figures are unlikely to reflect the true scope of the problem because embarrassment and other factors may lead to under-reporting. Estimates of prevalence of urinary incontinence in women vary between 25% to 45% in most studies (<LINK REF="REF-Milsom-2013a" TYPE="REFERENCE">Milsom 2013a</LINK>). Data from the widely cited EPICONT study of urinary incontinence in women (27,936 Norwegian women) suggest a gradual increase in prevalence with age to an early peak prevalence around midlife (50 to 54 years) which coincides with menopause, followed by a slight decline or stabilisation until about 70 years of age when the prevalence begins to rise steadily (<LINK REF="REF-Hannestad-2000" TYPE="REFERENCE">Hannestad 2000</LINK>). Pregnancy, labour and vaginal delivery (versus caesarean section) are significant risk factors for later urinary incontinence, but the strength of this association diminishes substantially with age (<LINK REF="REF-Milsom-2013a" TYPE="REFERENCE">Milsom 2013a</LINK>).</P>
<P>Isolated stress urinary incontinence (SUI) accounts for half of all urinary incontinence (UI), with most studies reporting 10% to 39% prevalence. With few exceptions, mixed urinary incontinence (MUI) is found to be next most common, with most studies reporting 7.5% to 25% prevalence. Isolated urgency urinary incontinence (UUI) is uncommon, with 1% to 7% prevalence (<LINK REF="REF-Milsom-2013b" TYPE="REFERENCE">Milsom 2013b</LINK>). The type of urine leakage is classified according to what is reported by the woman (symptoms), what is observed by the clinician (signs), and on the basis of urodynamic studies. The definitions of the different types of urinary incontinence given below are those of the International Continence Society (<LINK REF="REF-Haylen-2010" TYPE="REFERENCE">Haylen 2010</LINK>).</P>
<P>Not only is urinary incontinence a serious medical condition in that it can lead to perineal rash, pressure ulcers and urinary tract infections (<LINK REF="REF-Resnick-1989" TYPE="REFERENCE">Resnick 1989</LINK>), it is also an undeniable social problem, creating embarrassment and negative self-perception (<LINK REF="REF-Hunskaar-1991" TYPE="REFERENCE">Hunskaar 1991</LINK>; <LINK REF="REF-Johnson-1998" TYPE="REFERENCE">Johnson 1998</LINK>). UI has been found to reduce both social interactions and physical activities (<LINK REF="REF-Resnick-1989" TYPE="REFERENCE">Resnick 1989</LINK>) and is associated with poor self-rated health (<LINK REF="REF-Johnson-1998" TYPE="REFERENCE">Johnson 1998</LINK>), impaired emotional and psychological well-being (<LINK REF="REF-Johnson-1998" TYPE="REFERENCE">Johnson 1998</LINK>) and impaired sexual relationships (<LINK REF="REF-Temml-2001" TYPE="REFERENCE">Temml 2001</LINK>). Women with urinary incontinence often find themselves, in the medium or long term, isolated and relatively inactive (<LINK REF="REF-Fantl-1996" TYPE="REFERENCE">Fantl 1996</LINK>). Moreover, urinary incontinence in older women doubles the risk of admission to a nursing home, independent of age or the presence of co-morbid conditions (<LINK REF="REF-Hunskaar-1991" TYPE="REFERENCE">Hunskaar 1991</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Stress urinary incontinence (SUI)</I>
</HEADING>
<P>If a woman reports involuntary urine leakage with physical exertion (symptom) or a clinician observes urine leakage at the same time as the exertion (sign) this is called stress urinary incontinence (SUI). When urodynamic studies demonstrate involuntary loss of urine during increased intra-abdominal pressure, but the leakage is not accompanied by a contraction of the detrusor muscle (bladder smooth muscle), this is called urodynamic stress incontinence (USI) (<LINK REF="REF-Haylen-2010" TYPE="REFERENCE">Haylen 2010</LINK>). SUI is likely to be due to anatomical defects in the structures that support the bladder and urethra, resulting in suboptimal positioning of these structures at rest or on exertion, or dysfunction of the neuromuscular components that help control the urethral sphincter or urethral pressure. As a result, the bladder outlet (urethra) is not closed off properly during exertion and this results in leakage.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Urgency urinary incontinence (UUI)</I>
</HEADING>
<P>The symptom of urgency urinary incontinence (UUI) is present when a woman reports involuntary leakage associated with or immediately preceded by a sudden compelling need to void (that is urgency). The sign of UUI is identified by the observation of involuntary urine leakage from the urethra synchronous with the sensation of a sudden, compelling desire to void that is difficult to defer. UUI usually results from an involuntary increase in bladder pressure due to contraction of the detrusor muscle. If there is a known neurological cause for the detrusor muscle dysfunction this is called neurogenic detrusor overactivity, but if the cause is not known the condition is called idiopathic detrusor overactivity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Mixed urinary incontinence (MUI)</I>
</HEADING>
<P>Many women have symptoms or signs of both stress and urgency urinary incontinence, and urodynamic studies sometimes reveal that urine leakage results from a combination of USI and detrusor overactivity. When women have symptoms and/or signs of both SUI and UUI this is called mixed urinary incontinence (MUI).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2014-05-06 10:31:08 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Treatment of urinary incontinence</HEADING>
<P>A wide range of treatments have been used in the management of urinary incontinence, including conservative interventions (such as physical therapies, lifestyle interventions, behavioural training, and anti-incontinence devices), pharmaceutical interventions and surgery. This review will focus on one of the physical therapies, specifically pelvic floor muscle training.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Pelvic floor muscle training (PFMT)</HEADING>
<P>Pelvic floor muscle training (PFMT) has been part of exercise programs in Chinese Taoism for over 6000 years (<LINK REF="REF-Chang-1984" TYPE="REFERENCE">Chang 1984</LINK>). It first entered modern medicine in 1936; a paper by Margaret Morris describing tensing and relaxing of the pelvic floor muscles introduced the use of PFMT as a preventative and treatment option for urinary and faecal incontinence to the British physiotherapy profession (<LINK REF="REF-Morris-1936" TYPE="REFERENCE">Morris 1936</LINK>). However, PFMT as a treatment for SUI did not become widespread until after the mid-1900s when the American gynaecologist Arnold Kegel reported on the successful treatment of 64 cases of female SUI using pelvic floor muscle exercises with a pressure biofeedback perineometer (<LINK REF="REF-Kegel-1948" TYPE="REFERENCE">Kegel 1948</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2014-05-06 10:31:21 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">
<I>Biological rationale for PFMT for SUI and MUI</I>
</HEADING>
<P>The biological rationale is two-fold. Firstly, an intentional, effective pelvic floor muscle contraction (lifting the pelvic floor muscles in a cranial and forward direction) prior to and during effort or exertion clamps the urethra and increases the urethral pressure, preventing urine leakage (<LINK REF="REF-DeLancey-1988a" TYPE="REFERENCE">DeLancey 1988a</LINK>). Ultrasonography and magnetic resonance imaging (MRI) studies have demonstrated the cranial and forward movement of the pelvic floor muscles during active contraction and the resulting impact on the urethral position, which supports this rationale (<LINK REF="REF-B_x00f8_-2001" TYPE="REFERENCE">Bø 2001</LINK>; <LINK REF="REF-Thompson-2003" TYPE="REFERENCE">Thompson 2003</LINK>). Miller et al (1998) named this counter-balancing pelvic floor muscle contraction prior to a cough as the 'knack' and assessed its effectiveness in a randomised controlled trial (RCT) (<LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>); they demonstrated that a voluntary pelvic floor muscle contraction before or during coughing can reduce leakage after only one week of training. Other published research, employing the term 'pelvic floor muscle functional training', recommends pre-contracting the pelvic floor muscles not only during a cough but for any daily task that results in increased intra-abdominal pressure (<LINK REF="REF-Carri_x00e8_re-2006" TYPE="REFERENCE">Carrière 2006</LINK>). Thus, research suggests that the timing of a pelvic floor muscle contraction might be an important factor in the maintenance of urinary continence.</P>
<P>However, the optimal strength required to clamp the urethra and prevent urine leakage has not yet been determined. In healthy continent women, activation of the pelvic floor muscles before or during physical exertion seems to be an automatic response that does not require conscious effort (<LINK REF="REF-B_x00f8_-1994" TYPE="REFERENCE">Bø 1994</LINK>; <LINK REF="REF-Deindl-1993" TYPE="REFERENCE">Deindl 1993</LINK>; <LINK REF="REF-Peschers-2001" TYPE="REFERENCE">Peschers 2001</LINK>). There is some evidence that this pelvic floor muscle 'reflex' contraction is a feed-forward loop and might precede a bladder pressure rise by 200 to 240 msec (<LINK REF="REF-Constantinou-1982" TYPE="REFERENCE">Constantinou 1982</LINK>; <LINK REF="REF-Thind-1990" TYPE="REFERENCE">Thind 1990</LINK>). For incontinent women, learning to rapidly perform a strong, well-timed pelvic floor muscle contraction may actively prevent urethral descent during an intra-abdominal rise in pressure (<LINK REF="REF-B_x00f8_-1995" TYPE="REFERENCE">Bø 1995</LINK>).</P>
<P>Secondly, the bladder neck receives support from strong, toned pelvic floor muscles (resistant to stretching), thereby limiting its downward movement during effort and exertion, thus preventing urine leakage (<LINK REF="REF-B_x00f8_-2004" TYPE="REFERENCE">Bø 2004</LINK>; <LINK REF="REF-DeLancey-1988b" TYPE="REFERENCE">DeLancey 1988b</LINK>; <LINK REF="REF-Peschers-2001" TYPE="REFERENCE">Peschers 2001</LINK>). Bø has suggested that intensive strength training may build up the structural support of the pelvis by permanently elevating the levator plate to a higher position inside the pelvis and by enhancing the hypertrophy and stiffness of its connective tissues (<LINK REF="REF-B_x00f8_-2004" TYPE="REFERENCE">Bø 2004</LINK>). In line with and supporting this hypothesis, differences in the anatomical position of the pelvic floor muscles have been demonstrated between continent and incontinent women (<LINK REF="REF-Hoyte-2001" TYPE="REFERENCE">Hoyte 2001</LINK>; <LINK REF="REF-Peschers-1997" TYPE="REFERENCE">Peschers 1997</LINK>; <LINK REF="REF-Pontbriand_x002d_Drolet-2012" TYPE="REFERENCE">Pontbriand-Drolet 2012</LINK>). Additionally, dynamometric studies have shown that women with SUI or MUI demonstrate less pelvic floor muscle tone, maximal strength, rapidity of contraction and endurance as compared to continent women (<LINK REF="REF-Morin-2004" TYPE="REFERENCE">Morin 2004</LINK>; <LINK REF="REF-Pontbriand_x002d_Drolet-2012" TYPE="REFERENCE">Pontbriand-Drolet 2012</LINK>; <LINK REF="REF-Verelst-2004" TYPE="REFERENCE">Verelst 2004</LINK>).</P>
<P>Further, in an uncontrolled MRI reconstruction study, a significant reduction in the internal surface area of the levator ani was observed after PFMT suggesting an increase in passive stiffness of the levator ani, which is indicative of the state of pelvic floor muscle tone (<LINK REF="REF-Dumoulin-2007" TYPE="REFERENCE">Dumoulin 2007</LINK>). Griffin (1994), using a pressure probe inside the vagina, also showed a significant difference in individuals' pelvic floor muscle resting pressure three to four weeks after starting PFMT and increased resting pressure after PFMT was completed (<LINK REF="REF-Griffin-1994" TYPE="REFERENCE">Griffin 1994</LINK>). Furthermore, <LINK REF="REF-Balmforth-2004" TYPE="REFERENCE">Balmforth 2004</LINK> reported increased urethral stability at rest and during effort following 14 weeks of supervised PFMT and behavioural modifications.</P>
<P>Thus, there is a growing body of evidence to support the rationale that PFMT improves pelvic floor muscle tone and that it may facilitate more effective automatic motor unit firing of the PFM, preventing pelvic floor muscle descent during increased intra-abdominal pressure, which in turn prevents urine leakage (<LINK REF="REF-B_x00f8_-2007" TYPE="REFERENCE">Bø 2007</LINK>). Given the above biological rationale, the objective of PFMT for SUI is usually to improve the timing (of contraction), strength, endurance and stiffness of the pelvic floor muscles.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Biological rationale for PFMT for UUI</I>
</HEADING>
<P>PFMT can also be used in the management of UUI. The biological rationale is based on Godec's observation that a detrusor muscle contraction can be inhibited by a pelvic floor muscle contraction induced by electrical stimulation (<LINK REF="REF-Godec-1975" TYPE="REFERENCE">Godec 1975</LINK>). Further, de Groat (1997) demonstrated that during urine storage there is an increased pudendal nerve outflow response to the external urethral sphincter increasing intraurethral pressure and representing what he termed a 'guarding reflex' for continence (<LINK REF="REF-de-Groat-1997" TYPE="REFERENCE">de Groat 1997</LINK>; <LINK REF="REF-de-Groat-2001" TYPE="REFERENCE">de Groat 2001</LINK>).</P>
<P>Additionally, <LINK REF="REF-Morrison-1995" TYPE="REFERENCE">Morrison 1995</LINK> demonstrated that Barrington's micturition centre excitatory loop switches on when bladder pressures are between five to 25 mmHg, while the inhibitory loop is predominantly active above 25 mmHg. Inhibition involves an automatic (unconscious) increase in tone for both the pelvic floor muscle and the urethral striated muscle. Thus, voluntary pelvic floor muscle contractions may be used to control UUI. After inhibiting the urgency to void and the detrusor contraction, the woman can reach the toilet in time to avoid urine leakage. However, the number, duration, intensity and timing of the pelvic floor muscle contraction required to inhibit a detrusor muscle contraction is not known.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">
<I>Types of PFMT programmes</I>
</HEADING>
<P>There is not an absolute dividing line that differentiates strength from endurance-type exercise programmes; it is common for both strength and fatigue resistance to improve in response to an exercise programme, although one may be affected more than another. Characteristic features of strength training include low numbers of repetitions with high loads; where ways to increase load include increasing the amount of voluntary effort with each contraction and performing exercise with and then against gravity. Endurance training is characterised by high numbers of repetitions or prolonged contractions with low to moderate loads. Behavioural training to improve coordination and urge suppression usually involves the repeated use of a voluntary pelvic floor muscle contraction (VPFMC) in response to a specific situation, for example VPFMC prior to cough, and VPFMC with the sensation of urgency.
<BR/>

</P>
</SUBSECTION>
</THEORY>
<IMPORTANCE MODIFIED="2014-05-06 10:31:31 +0100" MODIFIED_BY="[Empty name]">
<P>Many women are referred for PFMT on the basis of symptoms or clinical signs of stress, urgency, or mixed urinary incontinence. There is currently no consensus about the need for urodynamic investigations before PFMT (<LINK REF="REF-Clement-2013" TYPE="REFERENCE">Clement 2013</LINK>; <LINK REF="REF-Lucas-2012" TYPE="REFERENCE">Lucas 2012</LINK>), but a single randomised controlled trial indicated that there was no statistically significant difference in the conservative treatment outcome if the referral was made on the basis of symptom diagnosis or urodynamics (<LINK REF="REF-Ramsay-1995" TYPE="REFERENCE">Ramsay 1995</LINK>). The sensitivity and specificity of urodynamic diagnosis seems variable depending on the expertise of the investigator, the scope of testing, and the dysfunction being investigated. For these reasons diagnoses based on symptoms, signs and urodynamic investigations were all included in this review.</P>
<P>Earlier Cochrane reviews of PFMT (<LINK REF="REF-Dumoulin-2010" TYPE="REFERENCE">Dumoulin 2010</LINK>; <LINK REF="REF-Hay_x002d_Smith-2002b" TYPE="REFERENCE">Hay-Smith 2002b</LINK>; <LINK REF="REF-Hay_x002d_Smith-2006" TYPE="REFERENCE">Hay-Smith 2006</LINK>) and other previously published systematic reviews of PFMT (<LINK REF="REF-Berghmans-1998" TYPE="REFERENCE">Berghmans 1998</LINK>; <LINK REF="REF-Berghmans-2000" TYPE="REFERENCE">Berghmans 2000</LINK>; <LINK REF="REF-B_x00f8_-1996" TYPE="REFERENCE">Bø 1996</LINK>; <LINK REF="REF-de-Kruif-1996" TYPE="REFERENCE">de Kruif 1996</LINK>; <LINK REF="REF-Fedorkow-1993" TYPE="REFERENCE">Fedorkow 1993</LINK>; <LINK REF="REF-Wilson-1999" TYPE="REFERENCE">Wilson 1999</LINK>) are outdated; new trials have been published. Although these reviews have identified a number of PFMT trials there were few data and considerable clinical heterogeneity in the studies. There is sufficient uncertainty about the effects of PFMT, particularly the size of effect, to suggest that continuing to update earlier Cochrane reviews is warranted.</P>
<P>The present review is a major update of <LINK REF="REF-Dumoulin-2010" TYPE="REFERENCE">Dumoulin 2010</LINK>. This review investigates whether PFMT is an effective treatment in the management of female urinary (stress, urgency and mixed) incontinence compared to no treatment, placebo, sham or control treatments. Other reviews address whether:</P>
<P>(a) one type of PFMT is better than another (<LINK REF="REF-Hay_x002d_Smith-2011" TYPE="REFERENCE">Hay-Smith 2011</LINK>), or whether feedback or biofeedback has a role to play (<LINK REF="REF-Herderschee-2011" TYPE="REFERENCE">Herderschee 2011</LINK>);</P>
<P>(b) PFMT is better than other treatments (for example other physical therapies, medication and surgery) (Protocol by <LINK REF="REF-Lins-2013" TYPE="REFERENCE">Lins 2013</LINK>); and</P>
<P>(c) if the addition of PFMT to other therapies adds benefit (<LINK REF="REF-Ayeleke-2013" TYPE="REFERENCE">Ayeleke 2013</LINK>).</P>
<P>A separate review considers the role of PFMT in the treatment and prevention of urinary and faecal incontinence related to childbirth (<LINK REF="REF-Boyle-2012" TYPE="REFERENCE">Boyle 2012</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-04-28 12:34:57 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the effects of pelvic floor muscle training for women with urinary incontinence in comparison to no treatment, placebo or sham treatments, or other inactive control treatments.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-05-11 19:30:16 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-05-11 19:30:16 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-04-28 12:35:04 +0100" MODIFIED_BY="[Empty name]">
<P>The review included only randomised controlled trials and quasi-randomised trials (for example using allocation by alternation). Other forms of controlled clinical trials were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-04-28 12:35:35 +0100" MODIFIED_BY="[Empty name]">
<P>All women with urinary incontinence and diagnosed as having stress, urgency or mixed urinary incontinence on the basis of symptoms, signs or urodynamic evaluation, as defined by the trialists. Trials that recruited men and women were eligible for inclusion providing demographic and outcome data were reported separately for women.</P>
<P>Trials of women with urinary incontinence whose symptoms might be due to significant factors outside the urinary tract were excluded, for example neurological disorders, cognitive impairment, lack of independent mobility and cancer or radiotherapy. Studies investigating nocturnal enuresis in women were also excluded.</P>
<P>Studies that specifically recruited antenatal or postnatal women (childbearing women) were excluded. Given the physiological changes of the pregnancy and postpartum period it is possible that the effect of PFMT might differ in this group. PFMT for the prevention and management of urinary incontinence in antenatal and postnatal women is addressed in another Cochrane review (<LINK REF="REF-Boyle-2012" TYPE="REFERENCE">Boyle 2012</LINK>).
<BR/>

</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-05-06 10:31:47 +0100" MODIFIED_BY="[Empty name]">
<P>One arm of all eligible trials included the use of a PFMT program to ameliorate symptoms of existing urine leakage. Thus, studies of PFMT for primary or secondary prevention of urinary incontinence were excluded. Another arm of the trial was a no-treatment arm, a placebo treatment arm, a sham treatment arm (for example sham electrical stimulation) or an inactive control treatment arm (for example advice on use of pads).</P>
<P>PFMT was defined as a programme of repeated voluntary pelvic floor muscle contractions taught and supervised by a healthcare professional. All types of PFMT programmes were considered, including using variations in the purpose and timing of PFMT (for example PFMT for strengthening, PFMT for urge suppression), different ways of teaching PFMT, types of contractions (fast or sustained) and number of contractions.</P>
<P>Trials in which PFMT was combined with a single episode of biofeedback (for the purposes of teaching a pelvic floor muscle contraction) or advice on strategies for symptoms of urgency or frequency (but without a scheduled voiding regime characteristic of bladder training) were eligible for inclusion. Trials in which PFMT was combined with another conservative therapy (for example bladder training, biofeedback, vaginal cones or electrical stimulation) or drug therapy (for example an anticholinergic) were excluded.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-05-11 19:30:16 +0100" MODIFIED_BY="[Empty name]">
<P>A subcommittee (Outcome Research in Women) of the Standardisation Committee of the International Continence Society suggested that research investigating the effect of therapeutic interventions for women with urinary incontinence consider five outcome categories: the woman's observations (symptoms), quantification of symptoms (for example urine loss), the clinician's observations (anatomical and functional), quality of life, and socioeconomic measures (<LINK REF="REF-Lose-1998" TYPE="REFERENCE">Lose 1998</LINK>). One or more outcomes of interest from each domain were chosen for the review.</P>
<P>The authors of the review also considered the International Classification of Function, Disability, and Health (ICF), a World Health Organization (WHO) initiative describing a conceptual framework for understanding health and the consequences of health conditions (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>), when choosing the primary outcomes of interest for the review. The framework describes the inter-relationships between a woman's impairment of body functions and structures (for example pelvic floor muscle dysfunction), limitations in activity (for example avoids running because of leakage), and restricted participation (for example decides not to go hiking with family because of leakage). Thus, the choice of condition specific quality of life as one of the primary outcome measures reflects the importance the authors place on the effects incontinence has on women's activities and participation, while a measure of impairment (for example of pelvic floor muscle function) was of secondary importance.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-05-11 19:30:16 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcomes of interest were the following.</P>
<SUBSECTION>
<HEADING LEVEL="5">A.  Patient reported measures</HEADING>
<OL>
<LI>Symptomatic cure of urinary incontinence at the end of treatment (reported by the woman and not the clinician)</LI>
<LI>Symptomatic cure or improvement of urinary incontinence at the end of treatment (reported by the woman and not the clinician)</LI>
<LI>Symptom and condition specific health measures (specific instruments designed to assess incontinence (e.g. King's Health Questionnaire (<LINK REF="REF-Kelleher-1997" TYPE="REFERENCE">Kelleher 1997</LINK>), Incontinence Quality of Life (I-QOL) (<LINK REF="REF-Donovan-2005" TYPE="REFERENCE">Donovan 2005</LINK>), Bristol Female Lower Urinary Tract Symptoms (B-FLUTS) questionnaire (<LINK REF="REF-Jackson-1996" TYPE="REFERENCE">Jackson 1996</LINK>))</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-05-06 11:05:52 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">B. Patient reported measures</HEADING>
<UL>
<LI>Longer-term symptomatic cure and improvement after stopping treatment (six months to one year after end of treatment; &gt; one year after end of treatment)</LI>
<LI>Satisfaction</LI>
<LI>Need for further treatment (e.g. surgery, drugs, PFMT)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">C. Patient reported quantification of symptoms</HEADING>
<UL>
<LI>Number of leakage episodes (per 24 h)</LI>
<LI>Number of micturitions during the day (frequency)</LI>
<LI>Number of micturitions during the night (nocturia)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">D. Clinicians' measures</HEADING>
<UL>
<LI>Pad and paper towel testing short (up to one hour) or long (24 hours) urine loss (grams of urine lost)</LI>
<LI>Number cured or improved based on pad weights in short office-based pad test</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">E. Quality of life (not condition specific)</HEADING>
<UL>
<LI>General health status measures e.g. Short Form-36 (<LINK REF="REF-Ware-1993" TYPE="REFERENCE">Ware 1993</LINK>)</LI>
<LI>Psychosocial outcome measures (e.g. Hopkins Symptoms Checklist for psychological distress (SCL-90-R) (<LINK REF="REF-Derogatis-1974" TYPE="REFERENCE">Derogatis 1974</LINK>), Hospital Anxiety and Depression Scale (HADS) (<LINK REF="REF-Zigmond-1983" TYPE="REFERENCE">Zigmond 1983</LINK>)</LI>
<LI>Sexual function or problems (e.g. leakage during intercourse, impact on sexual function)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">F. Adverse effects</HEADING>
<UL>
<LI>Adverse effects (e.g. discomfort, soreness, pain, bleeding)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">G.  Socioeconomic measures</HEADING>
<UL>
<LI>Costs of interventions</LI>
<LI>Cost-effectiveness of interventions (formal economic analysis, cost utility)</LI>
<LI>Resource implications</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">H. Measures of likely moderator variables</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Measures of pelvic floor muscle function</HEADING>
<P>a. digital evaluation,</P>
<P>b. pelvic floor muscle dynamometry,</P>
<P>c. pelvic floor muscle electromyography,</P>
<P>d. vaginal squeeze pressure,</P>
<P>e. perineal ultrasound.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Measure of adherence:</HEADING>
<P>a. number of study participants attending or completing treatment sessions,</P>
<P>b. number of study participants performing PFMT or adherence to home and clinic-based PFMT,</P>
<P>c. number of contractions completed per session, day or week.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">I. Other outcomes</HEADING>
<UL>
<LI>Non-prespecified outcomes judged important when performing the review</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of evidence (GRADE)</HEADING>
<P>Quality of evidence was assessed by adopting the GRADE approach (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>; <LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>; <LINK REF="REF-Guyatt-2013a" TYPE="REFERENCE">Guyatt 2013a</LINK>; <LINK REF="REF-Guyatt-2013b" TYPE="REFERENCE">Guyatt 2013b</LINK>). The following factors were considered for assessing the quality of evidence:</P>
<OL>
<LI>limitations in the study design;</LI>
<LI>inconsistency of results;</LI>
<LI>indirectness of evidence;</LI>
<LI>imprecision;</LI>
<LI>publication bias.</LI>
</OL>
<P>The GRADE working group strongly recommends including up to seven main outcomes in a systematic review (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>; <LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>). In this systematic review the following critical outcomes were selected for assessing the quality of evidence with the GRADE approach:</P>
<P>1) symptomatic cure of urinary incontinence (reported by the woman and not the clinician);</P>
<P>2) symptoms of cure or improvement of urinary incontinence (reported by the woman and not the clinician);</P>
<P>3) symptom and condition specific quality of life assessment (e.g. Incontinence Impact Questionnaire, King's Health Questionnaire);</P>
<P>4) number of urinary leakage episodes;</P>
<P>5) pad and paper towel testing short (up to one hour) or long (24 hours) urine loss (grams of urine lost);</P>
<P>6) treatment adherence;</P>
<P>7) formal economic analysis (for example cost-effectiveness, cost utility).</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-04-28 12:42:10 +0100" MODIFIED_BY="[Empty name]">
<P>This review drew on the search strategy developed by the Cochrane Incontinence Group. There were no language or other restrictions imposed on any of the searches described below. 
<BR/>

</P>
<ELECTRONIC_SEARCHES MODIFIED="2014-04-28 12:42:05 +0100" MODIFIED_BY="[Empty name]">
<P>Relevant trials were identified from the Cochrane Incontinence Group Specialised Trials Register. For more details of the search methods used to build the Specialised Register please see the Group's <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/INCONT/frame.html">module</A> in <I>The Cochrane Library</I>. The register contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL) (1999 onwards), MEDLINE (1966 onwards), and MEDLINE In-Process (2001 onwards), and handsearching of journals and conference proceedings. Most of the trials in the Cochrane Incontinence Group Specialised Register are also contained in CENTRAL. The date of the last search was 15 April 2013.</P>
<P>The terms used to search the Incontinence Group Specialised Register are given below:</P>
<P>(({DESIGN.CCT*} OR {DESIGN.RCT*}) AND ({INTVENT.PHYS.PFMT*} OR {INTVENT.PHYS.BIOFEED*}) AND {TOPIC.URINE.INCON*})</P>
<P>(All searches were of the keyword field of <LINK REF="REF-Reference-Manager-2012" TYPE="REFERENCE">Reference Manager 2012</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-04-28 12:42:10 +0100" MODIFIED_BY="[Empty name]">
<P>In addition, relevant conference abstracts identified from the Incontinence Group Specialised Register search were cross-referenced to determine if a full-length report had been published. Known trialists and other experts in the field have been contacted to ask for possible relevant trials, published or unpublished. Additional trials have been sought from the reference lists of included trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-05-06 10:32:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-04-28 12:42:43 +0100" MODIFIED_BY="[Empty name]">
<P>Only randomised and quasi-randomised controlled trials of PFMT for the treatment of UI were included. Two review authors (CD together with student GMS and JHS) independently screened the list of titles and abstracts generated by our search. Full-text articles of potentially relevant studies were retrieved. We also included trials for which only abstracts were available. Two review authors (CD with GMS or JHS) independently assessed the full-text articles or abstracts for eligibility. We contacted study investigators as required. Any differences of opinion were resolved by discussion or involvement of a third party. Studies formally considered for the review but excluded were listed with the reasons given for their exclusion. The selection process is documented with a PRISMA flow chart (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-04-28 12:42:58 +0100" MODIFIED_BY="[Empty name]">
<P>Data extraction was undertaken independently by two review authors (CD with GMS and JHS) and cross-checked. Any differences of opinion related to the data extraction were resolved by discussion. Where study data were possibly collected but not reported, or data were reported in a form that could not be used in the formal comparisons, further clarification was sought from the trialists. In addition, where the reported data were clearly incomplete (that is data from abstracts for ongoing trials) the trialists were contacted for data from the completed trial. When found, these data were added to the extraction sheet. For data entry, performed by CD, Review Manager software (RevMan 5.1) was used. All included trial data were processed as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Data entry was cross-checked by JHS. Any differences of opinion related to the data extraction were resolved by discussion. For categorical outcomes we related the numbers reporting an outcome to the numbers at risk in each group to derive a risk ratio. For continuous variables we used means and standard deviations to derive mean differences. We had planned to undertake formal meta-analysis, where appropriate.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-04-28 12:43:27 +0100" MODIFIED_BY="[Empty name]">
<P>The risk of bias in the included trials was assessed using the Cochrane risk of bias assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). This includes the following.</P>
<UL>
<LI>Random sequence generation (selection bias).</LI>
<LI>Allocation concealment (selection bias).</LI>
<LI>Blinding (performance bias) (because it was not possible to blind the participants or the care givers this element was not assessed).</LI>
<LI>Blinding of outcome assessment (detection bias).</LI>
<LI>Selective reporting (reporting bias) (because no trial protocols were available this element was not assessed).</LI>
<LI>Incomplete outcome data (attrition bias).</LI>
<LI>Baseline comparability of the randomised groups.</LI>
</UL>
<P>Two review authors (CD with GMS or JHS) independently assessed these domains. Any differences of opinion were resolved by consensus.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-04-28 12:43:39 +0100" MODIFIED_BY="[Empty name]">
<P>Analyses were based on available data from all included trials relevant to the comparisons and outcomes of interest. For trials with multiple publications, only the most up-to-date or complete data for each outcome were included. Meta-analysis was undertaken where data were available from more than one study assessing the same outcome. A fixed-effect model was used for calculations of pooled estimates and their 95% confidence intervals.</P>
<P>For categorical outcomes we related the numbers reporting an outcome to the numbers at risk in each group to calculate a risk ratio (RR) with 95% confidence interval (CI). For continuous variables we used means and standard deviations to calculate a mean difference (MD) with 95% CI. For positive outcomes such as cure, we altered the labelling of the forest plots. If data to calculate RRs or MDs were not given, we utilised the most detailed numerical data available to calculate the actual numbers or means and standard deviations (for example test statistics, P values).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-08-16 22:09:10 +0100" MODIFIED_BY="[Empty name]">
<P>The primary analysis was per woman randomised.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2014-05-06 10:32:37 +0100" MODIFIED_BY="[Empty name]">
<P>The data were analysed on an intention-to-treat basis, as far as possible, meaning that all participants must be analysed in the groups to which they were randomised. If this was not the case, we considered whether the trial should be excluded.</P>
<P>Data were reported as given in the trials, except if there was evidence of differential loss to follow-up from the randomised groups. In that case, the use of imputation of missing data was considered.</P>
<P>If trials reported sufficient detail to calculate mean differences but not enough information to calculate the associated standard deviation (SD), the outcome was assumed to have a standard deviation (SD) equal to the highest SD from other trials within the same analysis.</P>
<P>Attempts were made to obtain missing data from the original trialists.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-04-28 12:44:39 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were only combined if they were thought to be clinically similar. Heterogeneity between trials was assessed by visual inspection of plots of the data, the Chi<SUP>2</SUP> test for heterogeneity and the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>; <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We defined the thresholds for interpretation of the I<SUP>2</SUP> statistic according to the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-08-16 22:09:10 +0100" MODIFIED_BY="[Empty name]">
<P>In view of the difficulty of detecting and correcting for publication bias and other reporting biases, the authors aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-04-28 12:44:43 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were combined if the interventions and populations were similar, based on clinical criteria. To combine trial data, a meta-analysis was conducted and a fixed-effect model approach to the analysis was used unless there was evidence of heterogeneity across trials.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-04-28 12:45:25 +0100" MODIFIED_BY="[Empty name]">
<P>Analysis within subgroups was used to address the effect of the type of incontinence on outcome. Because the rationale for PFMT is different for the two main types of urinary incontinence (stress and urgency) it is plausible to expect a difference in the outcome of PFMT on the basis of the type of incontinence. It is commonly believed that PFMT is most effective for women with SUI and that it may be effective, in combination with behavioural interventions, for women with MUI. In the past, PFMT has rarely been the first-choice treatment for women with UUI alone (<LINK REF="REF-Moore-2013" TYPE="REFERENCE">Moore 2013</LINK>).</P>
<P>The four pre-specified diagnostic subgroups were trials that recruited women with:</P>
<OL>
<LI>stress urinary incontinence (SUI) alone (symptoms, signs, urodynamic stress incontinence (USI));</LI>
<LI>urgency urinary incontinence (UUI) alone (symptoms, signs, idiopathic detrusor overactivity incontinence);</LI>
<LI>mixed urinary incontinence (MUI) (symptoms or signs of both SUI and UUI, or idiopathic detrusor overactivity incontinence with USI);</LI>
<LI>a range of diagnoses of urinary incontinence (women could have SUI, UUI or MUI, but data were not reported separately according to these subgroups).</LI>
</OL>
<P>If heterogeneity between trials was sufficiently large, an investigation to identify its causes would be conducted. The investigation of heterogeneity addressed the populations and interventions in the individual trials. The investigation could also include subgroup analyses, meta-regression and sensitivity analyses. If heterogeneity remained after appropriate investigation, and possible removal of outlying trials, a random-effects model could be used in the meta analysis.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-08-16 22:09:10 +0100" MODIFIED_BY="[Empty name]">
<P>The effects of including or excluding trials at high risk of bias were investigated by means of sensitivity analyses.<BR/>
</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-05-13 14:07:09 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2014-05-06 11:06:46 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-05-06 11:05:58 +0100" MODIFIED_BY="[Empty name]">
<P>The literature search produced 704 records which were screened, from which 54 potentially relevant full-text articles were retrieved. There were 34 reports of 21 trials that met the inclusion criteria and 19 reports of 19 studies were excluded with reasons given in the<B> </B>
<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. Additionally, one study (<LINK REF="STD-Miller-2009" TYPE="STUDY">Miller 2009</LINK>) was not fully assessable as the manuscript was still in preparation and this study is in <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>. The flow of literature through the assessment process is shown in the PRISMA flowchart (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Included and excluded trials</HEADING>
<P>Of the 21 included trials, three trials contained no data usable in forest plots ((<LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>) and 18 contributed to forest plots. Twelve trials contributed to the analysis of primary outcomes:</P>
<OL>
<LI>cure (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>);</LI>
<LI>cure or improvement (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>);</LI>
<LI>symptom or condition specific health measures (<LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>).</LI>
</OL>
<P>Fourteen trials had more than two treatment arms (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>; <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Yoon-1999" TYPE="STUDY">Yoon 1999</LINK>). Only descriptions and data relating to the PFMT and control arms were given in this review. Of the 21 included trials, 15 were included in the previous version of the review (<LINK REF="REF-Dumoulin-2010" TYPE="REFERENCE">Dumoulin 2010</LINK>). One trial from the previous review was excluded (<LINK REF="STD-van-Leeuwen-2004" TYPE="STUDY">van Leeuwen 2004</LINK>), as reported earlier, because it was considered to be confounded by the choice of sham PFMT.<BR/>
</P>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-05-06 11:06:46 +0100" MODIFIED_BY="[Empty name]">
<P>More details of the trials are given in the &#8216;<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>&#8217; table.</P>
<SUBSECTION>
<HEADING LEVEL="4">Design</HEADING>
<P>All included trials were randomised controlled trials except one (<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>), which was considered to be quasi-randomised.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sample sizes</HEADING>
<P>Sample size ranged from a total of 15 to 143 participants per study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>The settings were single centres (14 trials) in Turkey, Brazil, USA, UK, Germany, Japan or Korea, or multiple centres (two trials) in Norway and the Netherlands. In two other trials, participants came from either a multiple counties register in the USA or a single resident register in Tokyo, Japan.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>All the women had urinary incontinence. Nine trials diagnosed the type of urinary incontinence based on symptoms or signs, or both; the symptomatic diagnoses were:</P>
<UL>
<LI>urinary incontinence (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>), and</LI>
<LI>SUI (<LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>).</LI>
</UL>
<P>The other 12 trials reported urodynamic diagnoses:</P>
<UL>
<LI>eight of these included women with USI only (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>; <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>);</LI>
<LI>Wells and co-workers included women with SUI or MUI (<LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>);</LI>
<LI>Lagro-Janssen and co-workers included women with SUI, UUI, or MUI although a subset of data was available for women with USI only (<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>);</LI>
<LI>Burns et al included women with USI with or without detrusor overactivity incontinence, but the proportion with mixed symptoms was small (9%) (<LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>);</LI>
<LI>Burgio et al included women with detrusor overactivity incontinence with or without USI, and about half had MUI (51%) (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>).</LI>
</UL>
<P>Based on diagnosis, the incontinence subgroups used in the analysis were:</P>
<UL>
<LI>SUI, 15 trials (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>; <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>);</LI>
</UL>
<UL>
<LI>Urinary incontinence, range of diagnoses, six trials (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>);</LI>
</UL>
<P>No trial had participants with UUI or MUI only.</P>
<P>Lagro-Janssen and colleagues recruited women with SUI, UUI or MUI, and those with urgency or mixed urinary incontinence were offered bladder training. However, data from women with SUI (who received PFMT only) were reported separately, so this trial was eligible for the review (<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other characteristics</HEADING>
<P>In nine trials leakage frequency was one of the inclusion criteria, being:</P>
<UL>
<LI>more than once a month (<LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>);</LI>
<LI>twice or more per month (<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>);</LI>
<LI>once or more per week (<LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>);</LI>
<LI>twice or more per week (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>);</LI>
<LI>three times or more per week (<LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>); or</LI>
<LI>one to five leakage episodes per day (<LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>).</LI>
</UL>
<P>Three trials used amount of leakage from a pad test:</P>
<UL>
<LI>more than 1 g during a 30 minute test (<LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>);</LI>
<LI>more than 2 g during a 60 minute pad test (<LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>); or</LI>
<LI>more than 4 g on a short clinic-based pad test, with standardised bladder volume (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>).</LI>
</UL>
<P>Aside from diagnosis and some measure of leakage severity, no other inclusion criteria were reported consistently, although nine trials restricted participation based on age. These trials recruited women aged:</P>
<UL>
<LI>20 to 65 years (<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>);</LI>
<LI>35 to 50 years (<LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>);</LI>
<LI>35 to 55 years (<LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>);</LI>
<LI>55 years and older (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>);</LI>
<LI>60 years or more (<LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>);</LI>
<LI>70 years and older (<LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>).</LI>
</UL>
<P>Common exclusion criteria were untreated urinary tract infection, post-void residual greater than a specified amount, neurological disorders, and cognitive impairments.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>The individual characteristics of the active interventions and control interventions are detailed in the PFMT protocol table that can be found in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table and are summarised in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Active intervention: pelvic floor muscle training (PFMT)</HEADING>
<P>Three trials gave no details of the PFMT programme used (<LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>; <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>). Of the 18 remaining trials, 13 stated that a correct VPFMC was confirmed prior to training using either vaginal, rectal or physical examination (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>: <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>). Three trials (<LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>) reported that participants were taught to do a VPFMC but did not say how they were taught.</P>
<P>PFMT was taught by specialist nurses in 10 trials, physiotherapists in 10 trials, and in one it was by a family doctor.</P>
<P>Based on the descriptions of training, two trials had PFMT programmes that clearly or predominantly targeted co-ordination (<LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>) or strength training (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>). Miller and colleagues described a short (one week) programme to improve co-ordination between a VPFMC and a rise in intra-abdominal pressure. Bø et al recommended a programme that comprised 8 to 12 high intensity (close to maximal) VPFMC, with 6 to 8 second hold and three to four fast contractions added at the end of each hold, 6 second rest between contractions, three times per day. Exercises were done in different body positions that included lying, kneeling, sitting and standing, all with legs apart (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>).</P>
<P>It was more difficult to characterise or categorise the other PFMT programmes because they were either a mixed (for example strength and endurance) programme or had not described a key training parameter (for example amount of voluntary effort per contraction). The individual characteristics of each exercise program (that is the number of voluntary pelvic floor muscle contractions; duration of holding time; duration of rest time; number of sets per day; types of contraction strength; endurance; co-ordination; body position; and adherence strategies) are detailed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>Of interest, many of the recent trials described a mixed program of short or short and rapid contractions of 1 to 3 sec and long sustained contractions of 6 to 10 sec (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>) in addition to contraction prior to and during a cough (<LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>) and in different body positions (<LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Control interventions</HEADING>
<P>Control interventions included:</P>
<UL>
<LI>no treatment (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>);</LI>
<LI>placebo drug (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>);</LI>
<LI>sham electrical stimulation (<LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>);</LI>
<LI>other inactive control treatments that comprised:</LI>
</UL>
<UL>
<UL>
<LI>use of an anti-incontinence device (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>),</LI>
<LI>advice on incontinence pads (<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>),</LI>
<LI>motivational phone calls once per month (<LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>),</LI>
<LI>advice on simple lifestyle alterations (<LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>),</LI>
<LI>general education class (cognitive function, osteoporosis, and oral hygiene) (<LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>);</LI>
<LI>refraining from special exercises aiming to increase muscle strength, walking speed, to reduce body mass index (BMI) or to improve dietary habits (<LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>).</LI>
</UL>
</UL>
<P>More details are available in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Overall there was no consistency in the choice of outcome measures by trialists. This limited the possibilities for considering together the results from individual trials. It was disappointing that three eligible trials did not contribute any data to the main analyses because they did not report any pre-specified outcome of interest or they did not report their outcome data in a usable way (for example mean without a measure of dispersion, P values without raw data) (<LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>).</P>
<P>As the length of intervention and timing of post-intervention assessment varied, no attempt was made to report outcomes at a particular time point. Post-intervention outcomes were used as it was assumed that the trialists would choose to complete treatment and measure outcomes when maximum benefit was likely to have been gained. Data from after treatment stopped or any longer-term follow-up are reported as secondary outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcomes - participant-reported measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Measurement of symptomatic cure or symptomatic cure or improvement of urinary incontinence:</HEADING>
<P>Many different scales were used to measure a participant's response to treatment, including Likert scales, visual analogue scales, and per cent reduction in symptoms. Whatever the scale, data were included in the formal comparisons when the trialists stated the number of women who perceived they were cured or improved (as defined by the trialists) after treatment. Where more than one level of improvement was reported (for example much better and somewhat better), data for the greater degree of improvement was entered in the comparison. It was thought this was more likely to capture those who had improvement that was clinically important. As some trial reports did not differentiate cure from improvement, two measures (cure only, and cure or improvement) were used so that important data were not lost.</P>
<P>The following definitions were used.</P>
<UL>
<LI>Participant perceived cure defined as no urine loss or 'dry' (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>).</LI>
<LI>Participant perceived cure as 'incontinence is now unproblematic' (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>).</LI>
<LI>Cure was also reported by women as no leakage in a urinary diary (<LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>).</LI>
<LI>Participant perceived cure and improvement defined as much better and somewhat better (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>).</LI>
<LI>Participant perceived cure and improvement defined as '75% or more perceived improvement' (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>).</LI>
<LI>Participant perceived cure and improvement defined as 'dry' or 'improved' (<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>).</LI>
<LI>Participant perceived cure and improvement defined as 'continent' or 'almost continent' (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Measurement of symptoms and condition-specific health measure (specific instruments designed to assess incontinence)</HEADING>
<P>Seven trials used psychometrically robust questionnaires for assessment of incontinence symptoms or the impact of these symptoms on quality of life, or both.</P>
<SUBSECTION>
<HEADING LEVEL="6">B-FLUTS</HEADING>
<P>Bø and colleagues (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>) used the Bristol Female Lower Urinary Tract Symptoms Questionnaire (B-FLUTS), which has established validity, reliability and responsiveness to change for evaluation of urinary incontinence symptoms in women (<LINK REF="REF-Donovan-2005" TYPE="REFERENCE">Donovan 2005</LINK>). Only two parts of the questionnaire were reported, the lifestyle and sex life questions, therefore they are not presented in the forest plot but rather <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>. The data were reported as frequencies rather than mean scores.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">KING'S HEALTH questionnaire</HEADING>
<P>Beuttenmuller and colleagues (<LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>), Carneiro and colleagues (<LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>) and Pereira and colleagues (<LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>) used the King's Heath questionnaire, which has established validity, reliability and responsiveness to change or evaluation of urinary incontinence symptoms in women (<LINK REF="REF-Kelleher-1997" TYPE="REFERENCE">Kelleher 1997</LINK>; <LINK REF="REF-Margolis-2011" TYPE="REFERENCE">Margolis 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">I-QOL</HEADING>
<P>Castro and colleagues (<LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>) and Sar and colleagues (<LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>) used the urinary incontinence specific quality of life instrument (I-QOL), which has established validity, reliability and responsiveness to change or evaluation of incontinence symptoms in women (<LINK REF="REF-Bushnell-2005" TYPE="REFERENCE">Bushnell 2005</LINK>; <LINK REF="REF-Wagner-1996" TYPE="REFERENCE">Wagner 1996</LINK>). Castro and colleagues reported the total score after treatment (<LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>) while Sar and colleagues only reported change from baseline (<LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">The Social Activity Index</HEADING>
<P>Bo and colleagues (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>) reported a symptom score that addressed activity limitation (difficulty with certain activities and functions) in nine social situations (The Social Activity Index). This index has established reproducibility in women with SUI (<LINK REF="REF-Bo-1994" TYPE="REFERENCE">Bo 1994</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Severity index for urinary incontinence</HEADING>
<P>Diokno and colleagues (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>) reported a urinary severity index score (the Sandvik Severity Index for Urinary Incontinence). This index has been validated in women with urinary incontinence (<LINK REF="REF-Sandvik-2000" TYPE="REFERENCE">Sandvik 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Urine leakage score</HEADING>
<P>Kim and colleagues (<LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>) reported a urine leakage score calculated based on a self reported one week urinary diary. No information was given on the psychometric properties of this instrument.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Urinary incontinence score</HEADING>
<P>Yoon and colleagues (<LINK REF="STD-Yoon-1999" TYPE="STUDY">Yoon 1999</LINK>) reported on a urinary incontinence score calculated from a 5 point Likert type scale regarding severity of leakage with 18 pre-specified activities associated with urine loss. No information was given on the psychometric properties of this instrument.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes - participant-reported measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Longer-term symptomatic cure and improvement after stopping treatment (six months to one year after end of treatment; &gt; one year after end of treatment)</HEADING>
<P>Most of the trials evaluated cure or cure and improvement immediately after the treatment period. Only two trials (<LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>) evaluated cure in the intermediate term: nine months and seven months after treatment respectively.</P>
<P>No trials evaluated cure or improvement one year or more after the end of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Satisfaction and need for further treatment</HEADING>
<P>Three trials reported on patient perceived satisfaction following the intervention (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>) and two reported on the number of women needing further treatment (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participant-reported quantification of symptoms</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Number of leakage episodes</HEADING>
<P>Seven of the trials used diaries to collect data on leakage episodes, for:</P>
<UL>
<LI>two days (<LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>);</LI>
<LI>three days (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>);</LI>
<LI>four days (<LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>);</LI>
<LI>seven days (<LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>); or</LI>
<LI>14 days (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>).</LI>
</UL>
<P>Yoon and colleagues collected but did not report these data directly; rather, leakage per 48 h was reported as an incontinence score (<LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>). Sar reported mean change from baseline (<LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>), and Wells reported means without a measure of dispersion (<LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>). To enable comparison between trials the data were presented as number of leakage episodes in 24 hours.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Number of micturitions during the day (frequency) or during the night (nocturia)</HEADING>
<P>Further, two trials reported on frequency of voids per day and per night (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinician&#8217;s measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Pad and paper towel testing in a short test (up to one hour) or long test (24 hours) (grams of urine lost) and number cured or improved based on pad weights in short office-based pad test</HEADING>
<P>Eight trials reported data on pad and paper towel tests:</P>
<UL>
<LI>eight trials used office-based short pad tests (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>);</LI>
<LI>in addition to the short pad test, Bø used a a 24 hour home-based pad test (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>);</LI>
<LI>one used a paper towel test (<LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>); and</LI>
<LI>one further trial reported only a 24 hour pad test (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>).</LI>
</UL>
<P>Aside from differences in the type of test, trialists also presented their data differently. Data were usually categorised (such as cured, improved, not improved) or reported as a mean with standard deviation. The former data were used to report the number of women with objective cure or improvement of incontinence, while the latter were reported as grams of urine lost.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life (not condition-specific)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">General health status measures</HEADING>
<P>Two trials reported non-condition specific quality of life (QOL) data (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>). Burgio and colleagues (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>) used the Hopkins Symptom Checklist for psychological distress with 90 items and a total score (Global Severity Index) (<LINK REF="REF-Derogatis-1983" TYPE="REFERENCE">Derogatis 1983</LINK>). Bo and colleagues (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>) used the Norwegian Quality of Life Scale to assess general health and QOL prior to and after the intervention (<LINK REF="REF-Wahl-1998" TYPE="REFERENCE">Wahl 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Measures of sexual function</HEADING>
<P>One trial reported the effect of PFMT on urinary incontinence during intercourse and in terms of interference with sexual satisfaction (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>Four trials reported on adverse effects (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>;<B>
<I> </I>
</B>
<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Socioeconomic measures</HEADING>
<P>No trials reported on costs of interventions, cost-effectiveness of interventions (formal economic analysis, cost utility) or resource implications.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Measure of likely moderator variables</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Measurement of pelvic floor muscle function</HEADING>
<UL>
<LI>Five trials used perineometry to measure vaginal squeeze pressure (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>)</LI>
<LI>Three trials used vaginal electromyography (<LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>)</LI>
<LI>Eight trials used digital palpation (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>)</LI>
<LI>One trial used perineal ultrasound (<LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Measurement of adherence</HEADING>
<P>Six trials attempted to measure adherence to home PFMT using either exercise or training diaries (<LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>) or self-reported adherence (<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>). Three trials attempted to measure attendance at exercise sessions (<LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-02-02 19:11:35 +0000" MODIFIED_BY="[Empty name]">
<P>Full details of the studies are given in the &#8216;<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>&#8217; table.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-05-11 19:44:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> summarize the results of the risk of bias analysis.</P>
<P>Due to brevity of reporting it was difficult to assess the two trials that were published as conference abstracts (<LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>). Seven of the trials were small, with fewer than 25 women per comparison group (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK> <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>); 10 were of moderate size with around 25 to 50 per group (<LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>); and the other three allocated more than 50 women per group (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>). Bidmead et al randomised participants in a 2:1 ratio, with 40 in the PFMT group and 20 as controls (<LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>). There were no large or very large trials. Five trials, including four recent ones, reported an a priori power calculation (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>).<BR/>
</P>
<ALLOCATION MODIFIED="2014-04-28 12:59:42 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Random sequence generation</HEADING>
<P>A genuine random sequence was generated in nine trials (for example computer generation of random numbers, block size) (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>). Eleven trials stated only that women were allocated at random, with no further description (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>; <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>). The abstract of one study stated that women were randomly allocated to comparison groups, but the methods section of the same paper reported that women were "consecutively assigned" (<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>); it therefore appears this was a quasi-randomised trial rather than a randomised trial.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Four trials reported allocation concealment adequately (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>, <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>). For the remaining 16 trials (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>; <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>) there was not sufficient information, therefore it was not clear if allocation was adequately concealed. One trial (<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>) had inadequate allocation concealment (alternate allocation) which was considered to be quasi-randomised.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2014-05-06 11:06:47 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Blinding of intervention from participants and care providers (performance bias)</HEADING>
<P>Given the nature of PFMT it is difficult, and often impossible, to blind the treatment provider and participants during treatment. We therefore did not report this criterion separately as all the trials were unable to blind the participants or care providers.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of outcome assessment (detection bias)</HEADING>
<P>Ten trials reported using blinded outcome assessors (<LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>).</P>
<P>In nine trials, the authors did not report sufficient information to conclude that the outcome assessment was blinded (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>; <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>).</P>
<P>The two last trials reported that the outcome assessors were not blinded to treatment assignment (<LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>).</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-04-28 13:00:34 +0100" MODIFIED_BY="[Empty name]">
<P>There were no dropouts or losses to follow-up in one trial (<LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>). In six trials it appeared there were no dropouts, but this was not clearly stated in the trial reports (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>; <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>). Fourteen trials reported attrition, dropouts or losses to follow-up. In these 14 trials the proportion was:</P>
<UL>
<LI>less than 10% in five (<LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>, <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>);</LI>
<LI>between 11% and 15% in six (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>); and</LI>
<LI>more than 20% in two (<LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>) to nearly 50% in another (<LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>).</LI>
</UL>
<P>The proportion of withdrawals or losses to follow-up was higher in the control group in two trials (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>), with no clear differences in the other trials. In one trial (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>) the cause of the differential dropout was not thought to be significantly related to the intervention, but in the other (<LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>) there was differential dropout from the groups: 5/22 women were excluded from the control group analysis as they received other treatment for their incontinence and this was not reflected in the analysis of the remaining 17.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-03-28 14:09:49 +0000" MODIFIED_BY="[Empty name]">
<P>It was unclear if there was selective reporting of the outcomes in all 21 trials because the protocols were not available for most studies. We therefore did not report this criterion separately.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-05-11 19:44:15 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Baseline comparability</HEADING>
<P>Seventeen trials were comparable at baseline for all important outcomes and demographic characteristics that might predict outcomes such as symptom severity or duration (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>). Three trials did not give enough information to assess baseline comparability between groups (<LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>; <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>). Finally, one trial (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>) reported a statistically significant difference between the PFMT and control groups for age, with the PFMT group being older than the control group (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Analysis by intention to treat, attrition and dropout</HEADING>
<P>Full intention-to-treat analysis requires that all participants are analysed in the group to which they were randomly assigned whether they adhered to treatment or not, crossed over to other treatments, or withdrew (<LINK REF="REF-Ferguson-2002" TYPE="REFERENCE">Ferguson 2002</LINK>). However, for the purpose of this review we have accepted the results as presented in the reports for those participants who provided outcome data at any time point, unless there was evidence of differential dropout from the groups. This was only the case in one trial (<LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>) but we were unable to adjust the data.</P>
<P>It was not clear if any other included study met the above criteria for intention to treat, but two stated that the primary analysis was by intention to treat (<LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>) and another stated that intention-to-treat analysis (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>) did not alter the findings of the primary analysis. We have assumed that in the absence of information to the contrary, all the trials analysed the participants in their assigned groups, with the exception of <LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK> as noted above.</P>
<P>In six trials, outcome data were reported for all the randomised participants (that is there appeared to be no dropouts) (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Henalla-1990" TYPE="STUDY">Henalla 1990</LINK>; <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>).</P>
<P>In four trials, data were reported only for those participants who reached outcome time points, but there was no evidence of differential dropout from the groups (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>).</P>
<P>In one trial, there was not enough information to inform an opinion on intention-to-treat analysis because the numbers at the outcome time points were not provided (<LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>).</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-05-13 14:07:09 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-one randomised or quasi-randomised trials compared PFMT (665 women) with no treatment, placebo, sham or other non-active control treatments (616 women). Three trials did not contribute any data suitable for meta-analysis (<LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>).<B> </B>In the 18 trials contributing data, the two comparison groups comprised 541 and 510 women respectively.</P>
<P>Readers should note that when referring to the graphs (forest plots) for six of the outcomes (participant perceived cure, participant perceived cure or improvement, number of women with interference with life due to urinary incontinence, number cured, number cured or improved on short pad test (objective) and patient perceived satisfaction) the right hand side of the plot favours PFMT. For the remaining outcomes the left hand side of the plot favours PFMT. This decision was made in order to keep interpretation of the forest plots clinically intuitive.</P>
<P>When a study did measure one of the outcomes but the data could not be included in the analysis for some reason, this was noted and the consistency with the usable data is briefly discussed. Data in 'Other data' tables are only briefly discussed to give an indication of whether the findings were broadly consistent or not.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Participant reported measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Symptomatic cure or improvement</HEADING>
<P>Six trials reported data from women on cure only. The confidence intervals in all six trials were wide. All trials found that PFMT women were statistically significantly more likely to report they were cured (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). In the four trials which included women with SUI alone, PFMT women were eight times more likely to report cure than controls (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Hofbauer-1990" TYPE="STUDY">Hofbauer 1990</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>) (46/82 (56.1%) versus 5/83 (6.0%), RR 8.38, 95% CI 3.68 to 19.07, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.1).</P>
<P>The three trials which included women with any incontinence showed a statistically significant result favouring PFMT (RR 5.34, 95% CI 2.78 to 10.26, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.4) (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>). There was statistical heterogeneity although there was agreement in the direction of effect in all three individually, favouring PFMT. However, the finding still favoured PFMT even if a random-effects model was used (RR 7.50, 95% CI 1.03 to 54.63). Visual inspection of the forest plot suggested a smaller effect size in <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK> while the effect size appeared similar in the two remaining trials. A possible explanation of this difference in treatment effect may come from the percentage of women with urgency symptoms, which was higher in the Burgio trial than in the two others.</P>
<P>Four trials contributed outcome data for cure or improvement (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>). Similarly, all four reported that PFMT was better than the control interventions. In trials which included women with SUI alone (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>), PFMT women were 17 times more likely to report cure or improvement than controls (32/58 (55%) versus 2/63 (3.2%), RR 17.33, 95% CI 4.31 to 69.64, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.1); and in trials which included women with all types of urinary incontinence (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>), PFMT women were twice as likely to report cure or improvement than controls (58/86 versus 23/80, RR 2.39, 95% CI 1.64 to 3.47,)<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.4).</P>
<P>One further trial reported information on cure or improvement (<LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>) but the data were not suitable for meta-analysis (mean without measure of dispersion).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Symptom and condition specific health measures</HEADING>
<P>Three out of four different measures of quality of life specific to the effect of urinary incontinence were in favour of PFMT (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>) in women with urinary incontinence (SUI and all types) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). In the fourth measure (King's Health Questionnaire, incontinence impact after treatment) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>), there was statistical heterogeneity and although all trials were on the same side of the forest plot when a random-effects model was used, the findings did not statistically support PFMT. Visual inspection of the forest plot suggested a smaller effect size in <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK> while the effect size appeared similar in the two remaining trials. A possible explanation of this difference in treatment effect may come from the intensity of the PFMT program, which was higher in the Pereira trial than in the two others.</P>
<P>Further, favouring PFMT was not evident in the three trials that reported the King's Health Questionnaire general health score in SUI women (<LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>) but this may be because measures of general health are less sensitive to changes in continence.</P>
<P>Three trials (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>) reported other measures of symptoms and their effect on incontinence-specific quality of life outcomes. These are given in detail in <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Patient reported measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Longer-term cure and improvement after stopping treatment</HEADING>
<P>There was limited information from two small to moderate quality trials (<LINK REF="STD-Henalla-1989" TYPE="STUDY">Henalla 1989</LINK>; <LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>) which indicated that the benefit of PFMT seemed to persist (after treatment stopped) for up to a year in both women with urinary incontinence (all types) (23/59 (38.9%) versus 1/61 (1.6%), RR 23.78, 95% CI 3.32 to 170.49) (<LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>) and SUI women only (14/26 (53.8%) versus 0/25 (0%), RR 27.93, 95% CI 1.75 to 444.45) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). The CIs in both trials were wide and hence these results need further confirmation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Satisfaction</HEADING>
<P>Three trials measured participant satisfaction with treatment for SUI (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>) or for women with urinary incontinence (all types) (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>) (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>). In trials which included women with SUI alone (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>), PFMT women were five times more likely to be satisfied with the intervention than controls (36/51 (70.6%) versus 7/54 (12.9%), RR 5.32, 95% CI 2.63 to 10.74, <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.1). There was statistical heterogeneity but the findings still favoured PFMT if a random-effects model was used (RR 5.54, 95% CI 1.15 to 25.63).</P>
<P>In the one trial with women with all types of urinary incontinence, PFMT women were three times more likely to be satisfied with the intervention than the controls (45/58 (77.6%) versus 14/50 (28%), RR 2.77, 95% CI 1.74 to 4.41, <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>.4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Need for further treatment</HEADING>
<P>Two trials reported that more women needed further treatment in the control groups; one trial in women with SUI (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>) (RR 0.17, 95% CI 0.07 to 0.42) and one in women with urinary incontinence of all types (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>) (RR 0.19, 95% CI 0.10 to 0.36, <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Patient reported quantification of symptoms</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Number of leakage episodes in 24 hours</HEADING>
<P>While all five trials with data showed statistically significant results favouring PFMT, visual inspection of the forest plot suggested the effect size might be greater in the trial by Lagro-Jansen and colleagues, while the effect sizes appeared similar in the four remaining trials. It was not clear why the data from Lagro-Janssen (<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>) and co-workers might be different from the two other trials in women with SUI, or the trials overall. A possible explanation of the overestimate of treatment effect might be an inadequate concealment of the randomisation process (alternation). The point estimates in the other four trials were similar, and all were statistically significant. SUI women doing PFMT experienced about one leakage episode less per 24 hours compared to controls (RR -1.21, 95% CI -1.52 to -0.89). As there was statistical heterogeneity, a random-effects model was used but the finding still favoured PFMT (RR -1.45, 95% CI -2.38 to -0.52).</P>
<P>Similarly, those with urinary incontinence of any type (detrusor overactivity with or without USI, <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>) experienced about one less leakage episode per 24 hours compared to controls (RR -0.80, 95% CI -1.26 to -0.34, <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Number of voids per day (frequency) and per night (nocturia)</HEADING>
<P>Two trials in women with urinary incontinence (all types) reported data on frequency (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>). PFMT women reported about two and a half fewer voids per day than controls (MD -2.56, 95% CI -3.65 to -1.48, <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>). However, there was no statistically significant difference in the number of night-time voids between the PFMT and control groups although the CI was wide (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>) (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>).</P>
<P>Two trials (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>) reported leakage episodes through a leakage index rather than the number of leakages. These are reported in detail in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinicians' measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Pad and paper towel tests (up to one hour or 24 hour)</HEADING>
<P>Up to one hour: four trials reported urine loss on pad tests in SUI women (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>) and one in women with urinary incontinence (all types) (<LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>). Women with SUI in the PFMT groups lost significantly less urine on the one hour pad tests. There was statistical heterogeneity but the finding still favoured PFMT if a random-effects model was used (RR -13.22, 95% CI -26.36 to -0.09). Yoon (<LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>) in women with with unspecified urinary incontinence reported that PFMT women had about 5 g less urine loss than controls but with wide CIs that included no difference (MD -5.1, 95% CI -11.3 to 1.1, <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>).</P>
<P>Test over 24 hours: one trial reported urine loss on a 24 h pad test with SUI women (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>) and one trial with women with urinary incontinence (all types) (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>). There was no difference between PFMT and control on the 24 hour test for SUI women (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>) or in all types of urinary incontinence (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>) (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Number cured or improved based on pad weights in short office-based pad test (objectively diagnosed urinary incontinence)</HEADING>
<P>When urine leakage was objectively assessed based on the number of women who had dry pads (short pad test) SUI women were more likely to be cured in the PFMT arms (number cured 38/71 (53.5%) versus 4/64 (6.3%) in the control group, RR 7.5, 95% CI 2.89 to 19.47, <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>.1) and similarly for cure or improvement (41/54 (75.9%) versus 2/42 (4.8%), RR 8.22, 95% CI 3.17 to 21.28, <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>.1).</P>
<P>Four trials (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>) reported pad or paper towel tests in other ways or reported data where the mean difference was not estimable. These data are given in detail in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>. The data were generally in agreement with the findings above.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life (not condition specific)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">General health status measures</HEADING>
<P>Validated measures were used to assess generic quality of life (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>) and psychological distress (<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>). Neither study found any statistically significant difference between PFMT and control groups in either SUI women or women with urinary incontinence (all types) (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Effect of urinary incontinence (UI) on sexual function</HEADING>
<P>One trial (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>) in SUI women suggested that sexual function was improved by PFMT, in general effect on sex life (<LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>) and in terms of reduction of urine leakage during intercourse (<LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>Four trials specifically mentioned adverse events, and three did not report any in the PFMT group (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>;<I>
<B> </B>
</I>
<LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>). Lagro-Janssen (<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK>) was the only trial to report adverse events with PFMT. These were: pain (one participant), uncomfortable feeling during exercise (three participants) and 'not wanting to be continuously bothered with the problem' (two participants).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Socioeconomic measures</HEADING>
<P>None of the included trials reported a formal economic analysis, nor any economic data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Measures of likely moderator variables</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Measures of pelvic floor muscle (PFM) function</HEADING>
<P>Eleven trials (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>) reported measures of pelvic floor muscle function.</P>
<UL>
<LI>One trial (<LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>) used perineal ultrasound to measure morphological changes in pelvic floor muscles after treatment.</LI>
<LI>Five trials (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Yoon-2003" TYPE="STUDY">Yoon 2003</LINK>) used vaginal squeeze pressure to measure functional changes in pelvic floor muscles.</LI>
<LI>Eight trials (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Beuttenmuller-2010" TYPE="STUDY">Beuttenmuller 2010</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>; <LINK REF="STD-Miller-1998" TYPE="STUDY">Miller 1998</LINK>; <LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>) used vaginal digital assessment to measure functional changes in pelvic floor muscles.</LI>
<LI>Finally three trials (<LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Carneiro-2010" TYPE="STUDY">Carneiro 2010</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>) used electromyography (EMG) measures of pelvic floor muscle function.</LI>
</UL>
<P>Of the 11 trials, two did not report the data in such a way that it was possible to calculate the mean difference in vaginal squeeze pressure, EMG activity, or digital palpation score (<LINK REF="STD-Aksac-2003" TYPE="STUDY">Aksac 2003</LINK>; <LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>). Overall, there were no consistent patterns in measures of pelvic floor muscle function. Details are given in <LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Measures of adherence</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">From diaries</HEADING>
<P>Bø (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>) and co-workers reported the highest rate of adherence to PFMT (95%) using exercise and training diaries. <LINK REF="STD-Bidmead-2002" TYPE="STUDY">Bidmead 2002</LINK> found that 75% of women allocated to PFMT had excellent (daily) or good (training more than three times a week) adherence to exercise on using exercise and training diaries. Women in the study by <LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK> rated their adherence as excellent or good (62%), reasonable (20%), or poor or none (18%). Kim (<LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>) reported adherence to home PFMT only in the follow-up period (after the intervention to the follow-up assessment) using exercise and training diaries with 30% of women doing their pelvic floor muscle exercises every day; two to three times per week in 45.5%, and once or less per week in 24.2% (<LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>). In their 2011 trial, the same research group (<LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>) reported adherence using exercise and training diaries for home PFMT in the follow-up period, again with 35.7% of women doing their pelvic floor muscle exercises every day, two to three times per week in 42.9%, and once or less per week in 21.4% (<LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>). Wells reported a greater exercise frequency in the treatment group at the beginning of the trial although no raw data were available to support this finding (<LINK REF="STD-Wells-1999" TYPE="STUDY">Wells 1999</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">From attendance at appointments</HEADING>
<P>Three trials attempted to measure attendance at exercise sessions (<LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>; <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>; <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>). Two trials reported very good to excellent attendance rates at clinic appointments (70%, <LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>; 92%, <LINK REF="STD-Castro-2008" TYPE="STUDY">Castro 2008</LINK>) and the third (<LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>) did not present any data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Methods to increase adherence</HEADING>
<P>Five trials used adherence strategies to encourage participants to do their PFMT exercises. Sar and colleagues (<LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK>) used a telephone call to encourage participants and answer questions. Diokno and colleagues (<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK>) used as reinforcement a two to four week follow-up which consisted of vaginal examination, measurement of pelvic floor muscle strength, and a test measuring participants' ability to perform correctly the verbally instructed exercise program. Burns (<LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>) used weekly and three and six month telephone reminders for treatment appointments and weekly exercise reminder cards were mailed between visits (<LINK REF="STD-Burns-1993" TYPE="STUDY">Burns 1993</LINK>). Bo and colleagues (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>) used audiotape with verbal guidance for home training (<LINK REF="STD-B_x00f8_-1999" TYPE="STUDY">Bø 1999</LINK>). Kim and colleagues (<LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>) used a pamphlet illustrating the pelvic floor muscles and strengthening exercises (<LINK REF="STD-Kim-2007" TYPE="STUDY">Kim 2007</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">GRADE quality of evidence</HEADING>
<P>Summary of findings tables were prepared separately for women with SUI at baseline (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>) and for women with all types of urinary incontinence (SUI, UUI, MUI) (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). The findings of the review were supported in the tables, but in all cases except one the quality of the evidence was downgraded. The exception was 'Participant perceived cure - stress urinary incontinence' in women with SUI, which was rated as high quality. This suggested that SUI was eight times more likely to be cured in this subgroup (RR 8.38, 95% CI 3.68 to 19.07, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.1), which is a much higher estimate of success than suggested in the other subgroups or other outcomes. However, it has a very wide CI and was derived from two small and two moderate size trials.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-05-13 14:09:08 +0100" MODIFIED_BY="[Empty name]">
<P>This review is the first in a series of reviews of PFMT for urinary incontinence (UI) in women, and it should be viewed in that context. This review considers whether PFMT is better than no treatment, placebo, sham, or non-active control treatments. Other reviews consider whether:</P>
<P>(a) one type of PFMT is better than another (<LINK REF="REF-Hay_x002d_Smith-2011" TYPE="REFERENCE">Hay-Smith 2011</LINK>), or whether feedback or biofeedback has a role to play (<LINK REF="REF-Herderschee-2011" TYPE="REFERENCE">Herderschee 2011</LINK>);</P>
<P>(b) PFMT is better than other treatments (for example other physical therapies, medication, and surgery (<LINK REF="REF-Lins-2013" TYPE="REFERENCE">Lins 2013</LINK>); and</P>
<P>(c) if the addition of PFMT to other therapies adds benefit (<LINK REF="REF-Ayeleke-2013" TYPE="REFERENCE">Ayeleke 2013</LINK>).</P>
<P>A separate review considers the role of PFMT in the treatment and prevention of urinary and faecal incontinence related to childbirth (<LINK REF="REF-Boyle-2012" TYPE="REFERENCE">Boyle 2012</LINK>).</P>
<SUMMARY_OF_RESULTS MODIFIED="2014-05-11 20:16:15 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Is PFMT better than no treatment, placebo or control treatments?</HEADING>
<P>Of the 21 trials that addressed this question, 18 reported data suitable for analysis for the outcomes of interest.</P>
<P>For cure or cure and improvement, in the four trials that included women with SUI alone there was clear information that women undergoing PFMT were eight times more likely to have their incontinence cured (46/82 (56.1%) were cured in the PFMT group versus 5/83 (6.0%) in the untreated groups, RR 8.38, 95% CI 3.68 to 19.07, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.1); and similarly in two trials, women having PFMT were 17 times more likely to have their incontinence cured or improved (32/58 (55%) versus 2/63 (3.2%), RR 17.33, 95% CI 4.31 to 69.64, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.1).</P>
<P>In the three trials including women with all types of urinary incontinence, all reported that the PFMT was better than the control intervention for cure, although because of statistical heterogeneity a random-effects model was used for this subgroup (RR 8.33, 95% CI 1.06 to 65.48, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.4). Visual inspection of the forest plot suggested a smaller effect size in one trial, <LINK REF="STD-Burgio-1998" TYPE="STUDY">Burgio 1998</LINK> (RR 2.34, 95% CI 1.11 to 4.94), where the urgency component of urinary incontinence was more prevalent than in the two other trials (RR 16.74, 95% CI 0.97 to 288.47 (<LINK REF="STD-Kim-2011" TYPE="STUDY">Kim 2011</LINK>) and RR 26.88, 95% CI 3.77 to 191.79 (<LINK REF="STD-Kim-2011a" TYPE="STUDY">Kim 2011a</LINK>)). Additionaly, two trials contributed outcome data for cure and improvement in women with all types of urinary incontinence and PFMT women were twice as likely to report cure or improvement as the control group women (58/86 versus 23/80, RR 2.39, 95% CI 1.64 to 3.47, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.4).</P>
<P>Where reported, quality of life due to incontinence was also improved by the active PFMT intervention both in women with SUI and women with all types of urinary incontinence. Women were also more satisfied with the active treatment, while women in the control groups were more likely to seek further treatment. PFMT women leaked urine less often, lost smaller amounts on short office-based pad tests, emptied their bladders less often during the day, and their sexual outcomes were better. Adverse events were rare and in the one trial that did report any they were minor. However, there was no shift in generic quality of life measures, perhaps because measures of general health are less sensitive to changes in continence status.</P>
<P>The improvement in pelvic floor muscle function as the mechanism by which urinary incontinence improved was supported by many trials. Attendance at treatment sessions was generally good, and women were also motivated to practice their pelvic floor exercises during the intervention period. However, the information about persistence of benefit in the long term was only presented in two trials, and the need for further treatment such as incontinence surgery or drugs was scanty. Finally, no trial reported formal economic analysis.</P>
<P>The findings of the review were largely supported in the summary of findings tables, but most of the evidence was downgraded to moderate on methodological grounds (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). 
<BR/>

</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-05-13 14:07:46 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Types of incontinence in participants</HEADING>
<P>Although we pre-specified four clinical subgroups for baseline type of urinary incontinence (SUI, UUI, MUI, urinary incontinence of all types) in the analysis, we only obtained data contributing to the forest plot from two of them (SUI, urinary incontinence of all types). No trials investigated the effect of PFMT versus control in two subgroups, women with urgency urinary incontinence (UUI) only or with mixed (SUI and UUI) incontinence only.</P>
<P>Further, participants were selected for the trials solely on the basis of the type of incontinence, diagnosed according to signs, symptoms or urodynamics. Theoretically, women with rupture of ligaments or fascia, partial or complete avulsion of the PFM, or even severe peripheral nerve damage may have responded differently to PFMT than women without such major anatomical defects, which may affect the estimate of treatment effect. Use of new imaging techniques may improve the researcher's ability to give a more specific diagnosis and use a more homogenous sample of participants, or present their data according to women who did and did not have such defects (<LINK REF="REF-Dumoulin-2011" TYPE="REFERENCE">Dumoulin 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Variation in interventions</HEADING>
<P>There was large variation in the PFMT programmes, as reported in Table 1. Further, the exercise regimen in both the clinic-based and home PFMT programmes was often incompletely reported (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). It was difficult to make judgements about the similarities and differences between the training programmes, and hence their potential relative effectiveness. Including trials with a suboptimal exercise 'dose' could adversely affect the estimate of differences in treatment effect. Although assessment of the interactions between the quality of the exercise programmes and their effects has been recommended (<LINK REF="REF-Herbert-2005" TYPE="REFERENCE">Herbert 2005</LINK>), it was not possible to explore this aspect in this review. Nevertheless, the more recent trials reported PFMT exercise regimens that were more in line with the literature on skeletal muscle training theory and pelvic floor muscle dysfunction.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>Some important secondary outcomes were either missing or were rarely reported. Medium-term follow-up (less than one year) was reported only in two trials, both of which favoured the active PFMT but with very wide confidence intervals (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). There was no report of long-term follow-up after one year. Arguably, the need for further treatment (for example the use of another conservative intervention, pessary, surgery or a drug) would provide a robust and objective measure of the ultimate success of treatment: unfortunately this was not reported in any of the trials.</P>
<P>Treatment adherence (for example performance of pelvic floor muscles exercise) was reported only in the short term (during the intervention) and in some trials not in the control groups, so it could not be compared between the groups. It was, therefore, not possible to assess the interactions between the effect size and the adherence to treatment.<I>
<B>
<BR/>
</B>
</I>
</P>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-05-06 11:21:10 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Trial quality and reporting</HEADING>
<P>Twenty-one small to moderate trials (n = 1281) contributed data to the review for the SUI and all urinary incontinence subgroups; none contributed to the UUI only and MUI only population subgroups.</P>
<P>The major limitations in reporting of the the included trials were the absence of details on participant selection and the lack of a clear description of the PFMT programs. Another problem was the absence of long-term follow-up.</P>
<P>The results were consistent for most of the outcomes, favouring PFMT over control. The only outcome that was consistently not different between the experimental and control conditions was generic quality of life; but these measures may not be sensitive enough to pick up changes due to improvement in urinary incontinence.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">GRADE summary of findings</HEADING>
<P>The main reasons for downgrading the quality of the evidence in the GRADE summary of findings tables were:</P>
<UL>
<LI>random sequence generation and allocation concealment was high risk or unclear in some trials;</LI>
<LI>results were inconsistent for the quality of life outcomes;</LI>
<LI>results were imprecise (heterogeneity due to variation in results, although these were generally in favour of PFMT).</LI>
</UL>
</SUBSECTION>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-04-28 13:07:32 +0100" MODIFIED_BY="[Empty name]">
<P>Of the 21 included trials, four were at high risk of bias:</P>
<UL>
<LI>
<LINK REF="STD-Lagro_x002d_Janssen-1991" TYPE="STUDY">Lagro-Janssen 1991</LINK> for its lack of genuine randomisation and inadequate allocation concealment;</LI>
<LI>
<LINK REF="STD-Pereira-2011" TYPE="STUDY">Pereira 2011</LINK>for its lack of blinding of outcome assessment;</LI>
<LI>
<LINK REF="STD-Sar-2009" TYPE="STUDY">Sar 2009</LINK> for its management of attrition; and</LI>
<LI>
<LINK REF="STD-Diokno-2010" TYPE="STUDY">Diokno 2010</LINK> for its differences in baseline comparability (especially with regard to age, those in the treatment group were older).</LI>
</UL>
<P>Because of the nature of the intervention, which is a complex interaction between the therapist and the patient, it was not possible to blind either party and therefore we did not score the trials on this element of risk of bias as they would all be at high risk. It was also not possible to assess incomplete outcome data because none of the trials had published protocols. It was clear that most trials could not, and did not intend to, report long-term follow-up because, most often, the untreated groups received treatment after the end of the trial.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-05-13 14:09:08 +0100" MODIFIED_BY="[Empty name]">
<P>The findings of this update of our Cochrane review are consistent with the previous version of this Cochrane review (<LINK REF="REF-Dumoulin-2010" TYPE="REFERENCE">Dumoulin 2010</LINK>) and an HTA Monograph which investigated all conservative methods of managing SUI (<LINK REF="REF-Imamura-2010" TYPE="REFERENCE">Imamura 2010</LINK>).</P>
<P>The scope of this review did not include comparisons of different PFMT regimens. Other Cochrane reviews to consider are:</P>
<UL>
<LI>different approaches to PFMT (<LINK REF="REF-Hay_x002d_Smith-2011" TYPE="REFERENCE">Hay-Smith 2011</LINK>);</LI>
<LI>biofeedback (<LINK REF="REF-Herderschee-2011" TYPE="REFERENCE">Herderschee 2011</LINK>);</LI>
<LI>cones (<LINK REF="REF-Herbison-2002" TYPE="REFERENCE">Herbison 2002</LINK>);</LI>
<LI>PFMT in antenatal and postnatal women (<LINK REF="REF-Boyle-2012" TYPE="REFERENCE">Boyle 2012</LINK>).</LI>
</UL>
<P>Two relevant related Cochrane reviews are:</P>
<UL>
<LI>Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women (<LINK REF="REF-Ayeleke-2013" TYPE="REFERENCE">Ayeleke 2013</LINK>);</LI>
<LI>Pelvic floor muscle training versus other treatments for urinary incontinence in women (<LINK REF="REF-Lins-2013" TYPE="REFERENCE">Lins 2013</LINK>).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="2">Considerations for future research</HEADING>
<P>The outcomes of incontinence research would be much more useful if trialists selected a primary outcome measure that mattered to women, chose secondary measures to cover a range of important domains, and opted for standardised tools with established validity, reliability and responsiveness to measure outcomes. One domain that requires particular attention in future is socioeconomic, as it has been poorly addressed to date. Two trials included in the review asked women if they wanted further treatment or were satisfied with the treatment outcome, or both. Questions such as these have potential merit, but asking women if they are cured or better with treatment may not differentiate those who are better and do not want any further intervention from those who are better but not sufficiently so to be satisfied with the treatment outcome. There is also scope for the use of validated questionnaires that evaluate the bother or distress associated with symptoms (for example the Urogenital Distress Inventory).</P>
<P>Duration of follow-up beyond the end of supervised treatment needs attention. As the aim of treatment is long-term continence, it would be appropriate if the outcome was measured at least one year after the end of treatment. As PFMT generally precedes other more invasive treatment options, such as surgery, the proportion of women satisfied with the outcome of PFMT (and for how long they remain so) would provide essential information for women, clinicians and service planners.</P>
<P>The reporting of methods and data could be much improved. Some included trials collected data for outcomes of interest but did not report it in a useful manner (for example point estimates without a measure of dispersion). It was also difficult to assess one of the primary ways to minimise risk of bias, allocation concealment, because the methods of randomisation were usually poorly described. Trialists are referred to the CONSORT and revised CONSORT statements for appropriate standards of trial reporting (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>; <LINK REF="REF-Boutron-2008" TYPE="REFERENCE">Boutron 2008</LINK>; <LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>).</P>
<P>In essence, there is a need for at least one large, pragmatic, well-conducted and explicitly reported trial comparing PFMT with control to investigate the longer-term (more than one year), clinical effectiveness and cost-effectiveness of PFMT. An important primary outcome measure should be added to cure and improvment of incontinence: the need to use extra interventions (such as pessaries, drugs or surgery) after the end of the PFMT intervention. </P>
<P>Such a trial could recruit separate groups of women with symptoms of stress, urgency, or mixed urinary incontinence based on clinical history and physical examination; and with a sample size based on a clinically important difference in self reported urinary incontinence and condition specific quality of life outcomes, and sufficient for subgroup analysis on the basis of type of urinary incontinence. Stratification or minimisation procedures could be used to ensure an even distribution of women with different types of urinary incontinence across both arms of the trial.</P>
<P>One arm of the study would comprise a supervised PFMT programme based on sound exercise science with confirmation of a correct voluntary pelvic floor muscle contraction, and incorporate appropriate supervision and adherence measures to promote maintenance of knowledge acquisition, behaviour skills and motivation (<LINK REF="REF-Dumoulin-2011" TYPE="REFERENCE">Dumoulin 2011</LINK>). The choice of programme would have to be set against the resource implications of intensively supervised individual programmes and the opportunity cost this represents. Careful clinical judgement is needed about what sort of programme could actually be applied in everyday practice and in different countries with their different healthcare delivery systems. The other arm of the trial would be a control treatment, for example an explanation of the anatomy and physiology of the bladder and pelvic floor, or advice on good bladder and lifestyle habits, with the same explanation and advice given in both arms. Such a trial would require substantial funding and multiple recruitment centres. A formal economic analysis, and process evaluation (for example to check intervention fidelity), would also be an important part of such a trial.</P>
</SUBSECTION>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-05-11 21:44:53 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-05-11 21:44:53 +0100" MODIFIED_BY="[Empty name]">
<P>Based on the data available, PFMT is better than no treatment, placebo drug, or inactive control treatments for women with stress urinary incontinence or urinary incontinence (all types), but there was no information about women with urgency urinary incontinence alone or mixed urinary incontinence. Women treated with PFMT were more likely to report cure or improvement, report better quality of life, have fewer leakage episodes per day, and have less urine leakage on short office-based pad tests than controls. Women were also more satisfied with the active treatment, and their sexual outcomes were better. Overall, there is support for the widespread recommendation that PFMT be included in first-line conservative management programmes for women with stress incontinence or in groups of women with a variety of types of incontinence.</P>
<P>The limited nature of follow-up beyond the end of treatment in the majority of the trials means that the long-term outcomes of use of PFMT remain uncertain. At this time, it is not known whether PFMT is cost-effective in the long term, hence the need for a pragmatic, well-conducted and explicitly reported trial comparing PFMT with control to investigate the longer-term clinical effectiveness and cost-effectiveness of PFMT.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-05-11 19:26:46 +0100" MODIFIED_BY="[Empty name]">
<P>Although the quality of recent trials has improved (choice of outcome, duration of follow-up, reporting method and data), most of the data in this review come from small to moderate sized trials of moderate methodological quality. In planning future research, trialists are encouraged to consider the following.</P>
<UL>
<LI>The choice of primary outcomes important to women (urinary outcomes and quality of life), the size of a clinically important effect, and subsequent estimation of sample size.</LI>
<LI>Choice and reporting of PFMT exercise programmes, including details of number of VPFMC per set, duration of hold, duration of rest, number of sets per day, body position, types of contractions, and other recommended exercises (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</LI>
<LI>The reporting on adherence to outcome and adherence strategies including practice of pelvic floor muscle exercises in both the intervention and control groups.</LI>
<LI>The need for further treatment such as with pessaries, surgery or drugs.</LI>
<LI>The choice and reporting of secondary outcome measures, e.g. sexual function,</LI>
<LI>The duration of follow-up especially long-term.</LI>
<LI>The reporting of formal economic analysis (for example cost-effectiveness, cost utility).</LI>
</UL>
<UL>
<LI>The choice and reporting of secondary outcome measures, e.g. sexual function,</LI>
<LI>The duration of follow-up especially long-term.</LI>
<LI>The reporting of formal economic analysis (for example cost-effectiveness, cost utility).</LI>
</UL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-04-02 13:20:11 +0100" MODIFIED_BY="[Empty name]">
<P>The authors of this review would like to acknowledge the following.</P>
<P>The considerable contribution made by Kari Bø, Bary Berghmans, Erik Hendriks, Rob de Bie and Ernst van Waalwijk van Doorn, co-authors of one of the previous versions of the PFMT review (<LINK REF="REF-Hay_x002d_Smith-2002b" TYPE="REFERENCE">Hay-Smith 2002b</LINK>).</P>
<P>The assistance of Michael Albert and Peter Dietz in translating papers from German to English.</P>
<P>The considerable contribution made by Cathryn Glazener, Muhammad Imran Omar, Suzanne MacDonald and Sheila Wallace to the update of the present version of the PFMT review.</P>
<P>The support of the International Continence Society research fellowship.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-04-28 13:07:32 +0100" MODIFIED_BY="[Empty name]">
<P>Two of the three authors (CD, JHS) have published trials investigating the effects of PFMT; both trials were excluded from this review based on the participants (antenatal and postnatal women) or the comparison interventions (one type of PFMT versus another).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]">
<P>All three review authors were involved in all stages of the review. Chantale Dumoulin wrote the first draft of the review update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-05-13 14:14:38 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-05-13 14:12:42 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-05-13 14:12:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Aksac-2003" MODIFIED="2009-04-28 13:49:59 +0100" MODIFIED_BY="[Empty name]" NAME="Aksac 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-28 13:49:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aksac B, Aki S, Karan A, Yalcin O, Isikoglu M</AU>
<TI>Biofeedback and pelvic floor exercises for the rehabilitation of urinary stress incontinence</TI>
<SO>Gynecologic and Obstetric Investigation</SO>
<YR>2003</YR>
<VL>56</VL>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuttenmuller-2010" MODIFIED="2014-04-02 14:43:50 +0100" MODIFIED_BY="[Empty name]" NAME="Beuttenmuller 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-09 10:41:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beuttenmuller L, Cader SA, Macena RHM, Araujo NDS, Nunes EFC, Dantas EHM</AU>
<TI>Muscle contraction of the pelvic floor and quality of life of women with stress urinary incontinence who underwent kinesitherapy</TI>
<SO>Fizjoterapia</SO>
<YR>2010</YR>
<VL>18</VL>
<NO>1</NO>
<PG>35-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT43326"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-11-07 11:55:53 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bidmead-2002" MODIFIED="2013-11-07 11:56:09 +0000" MODIFIED_BY="[Empty name]" NAME="Bidmead 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-11-07 11:56:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bidmead J, Mantle J, Cardozo L, Hextall A, Boos K</AU>
<TI>Home electrical stimulation in addition to conventional pelvic floor exercises: A useful adjunct or expensive distraction? [abstract 68]</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>372-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 10:20:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Parsons M, Mantle J, Cardozo L, Hextall A, Boos K, Bidmead J</AU>
<TI>A single blind, randomised, controlled trial of pelvic floor muscle training with home electrical stimulation in the treatment of urodynamic stress incontinence [abstract 296]</TI>
<SO>Proceedings of the 34th Annual Meeting of the International Continence Society; 2004; Paris, France</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burgio-1998" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Burgio 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M et al</AU>
<TI>Behavioral vs drug treatment for urge urinary incontinence in older women</TI>
<SO>JAMA</SO>
<YR>1998</YR>
<VL>280</VL>
<PG>1995-2000</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Locher JL, Goode PS</AU>
<TI>Combined behavioral and drug therapy for urge incontinence in older women</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>2000</YR>
<VL>48</VL>
<PG>370-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Locher JL, Roth DL, Goode PS</AU>
<TI>Psychological improvements associated with behavioral and drug treatment of urge incontinence in older women</TI>
<SO>The Journals of Gerontology Series B. Psychological Sciences and Social Sciences</SO>
<YR>2001</YR>
<VL>56</VL>
<PG>46-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd D, Roth DL</AU>
<TI>Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>2002</YR>
<VL>50</VL>
<PG>808-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burns-1993" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Burns 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burns PA, Nochajksi TH, Pranikoff K</AU>
<TI>Factors discriminating between genuine stress and mixed incontinence</TI>
<SO>Journal of the American Academy of Nurse Practitioners</SO>
<YR>1992</YR>
<VL>4</VL>
<PG>15-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burns PA, Pranikoff K, Nochajski T, Desotelle P, Harwood MK</AU>
<TI>Treatment of stress incontinence with pelvic floor exercises and biofeedback</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>1990</YR>
<VL>38</VL>
<PG>341-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Burns PA, Pranikoff K, Nochajski TH, Hadley EC, Levy KJ, Ory MG</AU>
<TI>A comparison of effectiveness of biofeedback and pelvic muscle exercise treatment of stress incontinence in older community dwelling women</TI>
<SO>Journal of Gerontology</SO>
<YR>1993</YR>
<VL>48</VL>
<PG>M167-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-B_x00f8_-1999" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Bø 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bø K, Talseth T, Home I</AU>
<TI>Single blind, randomised controlled trial of pelvic floor exercises, electrical stimulation, vaginal cones, and no treatment in management of genuine stress incontinence in women</TI>
<SO>BMJ</SO>
<YR>1999</YR>
<VL>318</VL>
<PG>487-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carneiro-2010" MODIFIED="2014-05-06 11:21:35 +0100" MODIFIED_BY="[Empty name]" NAME="Carneiro 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-05-06 11:21:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carneiro EF, Araujo Ndos S, Beuttenmull L, Vieira PC, Cader SA, Cader SA et al</AU>
<TI>[The anatomical-functional characteristics of the pelvic floor and quality of life of women with stress urinary incontinence subjected to perineal exercises]. [Spanish]</TI>
<SO>Actas Urologicas Espanolas</SO>
<YR>2010</YR>
<VL>34</VL>
<NO>9</NO>
<PG>788-93</PG>
<IDENTIFIERS MODIFIED="2013-05-23 14:31:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-23 14:31:43 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT40377"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castro-2008" MODIFIED="2014-05-06 10:37:37 +0100" MODIFIED_BY="[Empty name]" NAME="Castro 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-05-06 10:37:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castro RA, Arruda RM, Zanetti MR, Santos PD, Sartori MG, Girao MJ</AU>
<TI>Single-blind, randomized, controlled trial of pelvic floor muscle training, electrical stimulation, vaginal cones, and no active treatment in the management of stress urinary incontinence</TI>
<SO>Clinics (Sao Paulo, Brazil).</SO>
<YR>2008</YR>
<VL>63</VL>
<NO>4</NO>
<PG>465-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diokno-2010" MODIFIED="2014-04-02 14:44:09 +0100" MODIFIED_BY="[Empty name]" NAME="Diokno 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-23 14:32:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diokno AC, Ocampo MS Jr, Ibrahim IA, Karl CR, Lajiness MJ, Hall SA</AU>
<TI>Group session teaching of behavioral modification program (BMP) for urinary incontinence: a randomized controlled trial among incontinent women</TI>
<SO>International Urology and Nephrology</SO>
<YR>2010</YR>
<VL>42</VL>
<NO>2</NO>
<PG>375-81</PG>
<IDENTIFIERS MODIFIED="2013-05-23 14:32:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-23 14:32:55 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT39469"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henalla-1989" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Henalla 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henalla SM, Hutchins CJ, Robinson P, MacVicar J</AU>
<TI>Non-operative methods in the treatment of female genuine stress incontinence of urine</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>1989</YR>
<VL>9</VL>
<PG>222-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henalla-1990" MODIFIED="2013-11-07 11:56:50 +0000" MODIFIED_BY="[Empty name]" NAME="Henalla 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-11-07 11:56:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henalla SM, Millar DR, Wallace KJ</AU>
<TI>Surgical versus conservative management for post-menopausal genuine stress incontinence of urine [abstract 87]</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1990</YR>
<VL>9</VL>
<PG>436-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hofbauer-1990" MODIFIED="2013-06-11 11:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Hofbauer 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-06-11 11:48:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hofbauer VJ, Preisinger F, Nurnberger N</AU>
<TI>[The value of physical therapy in genuine female stress incontinence]. [German]</TI>
<TO>Der stellenwert der physiokotherapie bei der wieblichen genuinen seb-inkontinenz</TO>
<SO>Zeitschrift Fur Urologie Und Nephrologie</SO>
<YR>1990</YR>
<VL>83</VL>
<PG>249-54</PG>
<IDENTIFIERS MODIFIED="2013-06-11 11:48:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-11 11:48:24 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT350"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-06-11 11:47:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Preisinger E, Hofbauer J, Nurnberger N, Sadil S, Schneider B</AU>
<TI>[Possibilities of physiotherapy for urinary stress incontinence]. [German]</TI>
<TO>Moglichkeiten der physikalischen therapie bei strebinkontinenz</TO>
<SO>Zeitschrift fur Physikalische Medizin, Balneologie Med Klimatologie</SO>
<YR>1990</YR>
<VL>19</VL>
<NO>2</NO>
<PG>75-9</PG>
<IDENTIFIERS MODIFIED="2013-06-11 11:47:50 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-11 11:47:50 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT6314"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2007" MODIFIED="2013-11-07 11:57:53 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-11-07 11:57:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim H, Suzuki T, Yoshida Y, Yoshida H</AU>
<TI>Effectiveness of multidimensional exercises for the treatment of stress urinary incontinence in elderly community-dwelling Japanese women: A randomized, controlled, crossover trial</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2007</YR>
<VL>55</VL>
<NO>12</NO>
<PG>1932-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2011" MODIFIED="2014-04-02 14:44:26 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-05-23 14:36:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim H, Yoshida H, Suzuki T</AU>
<TI>Effects of exercise treatment with or without heat and steam generating sheet on urine loss in community-dwelling Japanese elderly women with urinary incontinence</TI>
<SO>Geriatrics &amp; gerontology international</SO>
<YR>2011</YR>
<VL>11</VL>
<NO>4</NO>
<PG>452-9</PG>
<IDENTIFIERS MODIFIED="2013-05-23 14:36:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-23 14:36:33 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT42661"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2011a" MODIFIED="2014-04-02 14:44:18 +0100" MODIFIED_BY="[Empty name]" NAME="Kim 2011a" YEAR="2011">
<REFERENCE MODIFIED="2013-05-23 14:35:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Kim H, Yoshida H, Suzuki T</AU>
<TI>Exercises treatment to reduce the urine leakage in elderly community-dwelling Japanese women with stress, urge, and mixed urinary incontinence (Abstract number 772)</TI>
<SO>Proceedings of the 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 - Oct 3, San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2013-05-23 14:35:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-23 14:35:58 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT35628"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 14:35:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim H, Yoshida H, Suzuki T</AU>
<TI>The effects of multidimensional exercise treatment on community-dwelling elderly Japanese women with stress, urge, and mixed urinary incontinence: a randomized controlled trial</TI>
<SO>International Journal of Nursing Studies</SO>
<YR>2011</YR>
<VL>48</VL>
<NO>10</NO>
<PG>1165-72</PG>
<IDENTIFIERS MODIFIED="2013-05-23 14:35:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-23 14:35:05 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT42657"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lagro_x002d_Janssen-1991" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Lagro-Janssen 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lagro-Janssen ALM, Debruyne FMJ, Smits AJA, van Weel C</AU>
<TI>The effects of treatment of urinary incontinence in general practice</TI>
<SO>Family Practice</SO>
<YR>1992</YR>
<VL>9</VL>
<PG>284-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lagro-Janssen T, van Weel C</AU>
<TI>Long-term effect of treatment of female incontinence in general practice</TI>
<SO>British Journal of General Practice</SO>
<YR>1998</YR>
<VL>48</VL>
<PG>1735-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lagro-Janssen TLM, Debruyne FMJ, Smits AJA, van Weel C</AU>
<TI>Controlled trial of pelvic floor exercises in the treatment of urinary stress incontinence in general practice</TI>
<SO>British Journal of General Practice</SO>
<YR>1991</YR>
<VL>41</VL>
<PG>445-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1998" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller JM, Ashton-Miller JA, DeLancey JOL</AU>
<TI>A pelvic muscle precontraction can reduce cough-related urine loss in selected women with mild SUI</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>1998</YR>
<VL>46</VL>
<PG>870-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pereira-2011" MODIFIED="2014-05-06 10:37:25 +0100" MODIFIED_BY="[Empty name]" NAME="Pereira 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-05-21 09:38:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nascimento-Correia G, Santos-Pereira V, Tahara N, Driusso P</AU>
<TI>[Effects of pelvic floor muscle training on quality of life of a group of women with urinary incontinence: randomized controlled trial]. [Spanish]</TI>
<SO>Actas Urologicas Espanolas</SO>
<YR>2012</YR>
<VL>36</VL>
<NO>4</NO>
<PG>216-21</PG>
<IDENTIFIERS MODIFIED="2013-05-21 09:38:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-21 09:38:34 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="44721"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-06 10:37:25 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21962461&lt;br&gt;ST - MEDLINE&lt;br&gt;AS - Eur J Obstet Gynecol Reprod Biol. 159(2):465-71, 2011 Dec&lt;br&gt;JC - e4l, 0375672&lt;br&gt;CP - Ireland&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;br&gt;DC - 20111128&lt;/p&gt;" NOTES_MODIFIED="2014-05-06 10:37:25 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pereira VS, Correia GN, Driusso P</AU>
<TI>Individual and group pelvic floor muscle training versus no treatment in female stress urinary incontinence: a randomized controlled pilot study</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>2011</YR>
<VL>159</VL>
<NO>2</NO>
<PG>465-71</PG>
<IDENTIFIERS MODIFIED="2013-05-23 14:40:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-23 14:40:28 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT42734"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-06 10:37:19 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20121220&lt;br&gt;IS - 1520-6777 (Electronic)&lt;br&gt;IS - 0733-2467 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-05-06 10:37:19 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pereira VS, de Melo MV, Correia GN, Driusso P</AU>
<TI>Long-term effects of pelvic floor muscle training with vaginal cone in post-menopausal women with urinary incontinence: A randomized controlled trial</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2013</YR>
<VL>32</VL>
<NO>1</NO>
<PG>48-52</PG>
<IDENTIFIERS MODIFIED="2013-05-23 14:39:25 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-23 14:39:25 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT46703"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-23 14:41:04 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22066898&lt;br&gt;ST - In-Data-Review&lt;br&gt;AS - Climacteric. 15(1):45-51, 2012 Feb&lt;br&gt;JC - d0i, 9810959&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20111228&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 14:41:04 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pereira VS, de Melo MV, Correia GN, Driusso P</AU>
<TI>Vaginal cone for postmenopausal women with stress urinary incontinence: randomized, controlled trial</TI>
<SO>Climacteric</SO>
<YR>2012</YR>
<VL>15</VL>
<NO>1</NO>
<PG>45-51</PG>
<IDENTIFIERS MODIFIED="2013-05-23 14:41:04 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-23 14:41:04 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT42979"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-11-07 11:58:43 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sar-2009" MODIFIED="2014-05-06 10:37:14 +0100" MODIFIED_BY="[Empty name]" NAME="Sar 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-05-06 10:37:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sar D, Khorshid L</AU>
<TI>The effects of pelvic floor muscle training on stress and mixed urinary incontinence and quality of life</TI>
<SO>Journal of Wound, Ostomy, and Continence Nursing</SO>
<YR>2009</YR>
<VL>36</VL>
<NO>4</NO>
<PG>429-35</PG>
<IDENTIFIERS MODIFIED="2013-05-23 14:41:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-23 14:41:36 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT32103"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wells-1999" MODIFIED="2014-05-13 14:12:42 +0100" MODIFIED_BY="[Empty name]" NAME="Wells 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-05-13 14:12:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Wells TJ, Mayor RD, Brink CA, Brown R</AU>
<TI>Pelvic floor muscle exercise: a controlled clinical trial</TI>
<SO>Unpublished work however portions were presented at the sixteenth annual scientific meeting of the American Urogynecologic Society, Seattle, October 12-15, 1995.</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-11-07 11:59:06 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoon-2003" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Yoon 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yoon HS, Song HH, Ro YJ</AU>
<TI>A comparison of effectiveness of bladder training and pelvic muscle exercise on female urinary incontinence</TI>
<SO>International Journal of Nursing Studies</SO>
<YR>2003</YR>
<VL>40</VL>
<PG>45-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-05-06 10:37:05 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abdulaziz-2012" MODIFIED="2014-05-06 10:37:05 +0100" MODIFIED_BY="[Empty name]" NAME="Abdulaziz 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-05-06 10:37:05 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;2012340482&lt;br&gt;English&lt;br&gt;Journal: Article&lt;br&gt;201226&lt;/p&gt;" NOTES_MODIFIED="2014-05-06 10:37:05 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Abdulaziz K, Hasan T</AU>
<TI>Role of pelvic floor muscle therapy in obese perimenopausal females with stress incontinence: A randomized control trial</TI>
<SO>Internet Journal of Gynecology and Obstetrics</SO>
<YR>2012</YR>
<VL>16</VL>
<PG>2</PG>
<IDENTIFIERS MODIFIED="2013-06-11 14:40:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-11 14:40:42 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.5580/2ba3"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albers_x002d_Heitner-2008" MODIFIED="2013-05-03 13:34:22 +0100" MODIFIED_BY="[Empty name]" NAME="Albers-Heitner 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-03 13:34:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albers-Heitner P, Berghmans B, Joore M, Lagro-Janssen T, Severens J, Nieman F, et al</AU>
<TI>The effects of involving a nurse practitioner in primary care for adult patients with urinary incontinence: the PromoCon study (Promoting Continence)</TI>
<SO>BMC Health Services Research</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernier-2008" MODIFIED="2013-06-11 14:41:57 +0100" MODIFIED_BY="[Empty name]" NAME="Bernier 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-06-11 14:41:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK">
<AU>Bernier F</AU>
<SO>Pelvic floor muscle retraining: quantitative, experimental, randomized pilot study (PhD thesis)</SO>
<YR>2008</YR>
<PB>University of Virginia</PB>
<CY>Charlottesville, Virginia, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bernier-2008a" MODIFIED="2013-05-03 13:34:22 +0100" MODIFIED_BY="[Empty name]" NAME="Bernier 2008a" YEAR="2008">
<REFERENCE MODIFIED="2013-05-03 13:34:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Bernier F</AU>
<TI>Pelvic floor muscle retraining: quantitative, experimental, randomized pilot study (Abstract)</TI>
<SO>Proceedings of the 39th Annual Conference of the Society of Urologic Nurses and Associates (SUNA), 2008 Oct 3-6, Philadelphia (PA)</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beuttenmuller-2011" MODIFIED="2013-11-21 09:28:22 +0000" MODIFIED_BY="[Empty name]" NAME="Beuttenmuller 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-11-21 09:28:22 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Accession Number: 2011445418. Language: Portuguese. Entry Date: 20120316. Revision Date: 20120316. Publication Type: journal article; randomized controlled trial; research; tables/charts. Journal Subset: Allied Health; Blind Peer Reviewed; Mexico &amp;amp; Central/South America; Peer Reviewed. Special Interest: Physical Therapy; Women's Health. No. of Refs: 30 ref&lt;/p&gt;" NOTES_MODIFIED="2013-11-21 09:28:22 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beuttenmuller L, Cader SA, Macena RHM, Araujo NDS, Nunes EFC, Dantas EHM</AU>
<TI>Floor muscles contraction in women with stress urinary incontinence underwent to exercises and electric stimulation therapy: a randomized study [Portuguese]</TI>
<SO>Fisioterapia e Pesquisa</SO>
<YR>2011</YR>
<VL>18</VL>
<NO>3</NO>
<PG>210-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT47117"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burgio-2002" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Burgio 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Goode PS, Locher JL, Umlauf MG, Roth DL, Richter HE et al</AU>
<TI>Behavioral training with and without biofeedback in the treatment of urge incontinence in older women. A randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>288</VL>
<PG>2293-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-2011" MODIFIED="2013-05-03 13:34:22 +0100" MODIFIED_BY="[Empty name]" NAME="Chang 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-05-03 13:34:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22083987&lt;br&gt;ST - In-Process&lt;br&gt;AS - Am J Chin Med. 39(6):1139-59, 2011&lt;br&gt;JC - 7901431, 3e4&lt;br&gt;CP - Singapore&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20111115&lt;/p&gt;" NOTES_MODIFIED="2013-05-03 13:34:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang KK, Wong TK, Wong TH, Leung AW, Chung JW</AU>
<TI>Effect of acupressure in treating urodynamic stress incontinence: a randomized controlled trial</TI>
<SO>American Journal of Chinese Medicine</SO>
<YR>2011</YR>
<VL>39</VL>
<NO>6</NO>
<PG>1139-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Felicissimo-2010" MODIFIED="2013-05-03 13:34:22 +0100" MODIFIED_BY="[Empty name]" NAME="Felicissimo 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-03 13:34:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Felicissimo MF, Carneiro MM, Saleme CS, Pinto RZ, da Fonseca AM, da Silva-Filho AL</AU>
<TI>Intensive supervised versus unsupervised pelvic floor muscle training for the treatment of stress urinary incontinence: a randomized comparative trial</TI>
<SO>International Urogynecology Journal</SO>
<YR>2010</YR>
<VL>21</VL>
<NO>7</NO>
<PG>835-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferreira-2011" MODIFIED="2014-05-06 10:36:57 +0100" MODIFIED_BY="[Empty name]" NAME="Ferreira 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-05-06 10:36:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ferreira M, Santos P, Duarte J</AU>
<TI>Influence of home-based and supervised exercise programs on women stress urinary incontinence: a randomized trial (Abstract number RR-PO-312-6-Wed)</TI>
<SO>Physiotherapy</SO>
<YR>2011</YR>
<VL>97 Suppl S1</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferreira-2011a" MODIFIED="2014-05-06 10:36:52 +0100" MODIFIED_BY="[Empty name]" NAME="Ferreira 2011a" YEAR="2011">
<REFERENCE MODIFIED="2014-05-06 10:36:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ferreira M, Pitanguy M, Vasconcelos ECLM, Antonio FI</AU>
<TI>Evaluation of urinary incontinence reports and pelvic floor muscle knowledge among women participating in a pelvic floor educational group (Abstract number RR-PO-312-18-Wed)</TI>
<SO>Physiotherapy</SO>
<YR>2011</YR>
<VL>97 Suppl S1</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghoniem-2005" MODIFIED="2014-05-06 10:36:46 +0100" MODIFIED_BY="[Empty name]" NAME="Ghoniem 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-05-06 10:36:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghoniem GM, Van Leeuwen JS et al</AU>
<TI>A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence</TI>
<SO>J Urol</SO>
<YR>2005</YR>
<VL>173 (5)</VL>
<PG>1647-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goode-2003" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Goode 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goode PS, Burgio KL, Locher JL, Roth DL, Umlauf MG, Richter HE et al</AU>
<TI>Effect of behavioral training with or without pelvic floor electrical stimulation on stress incontinence in women. A randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2003</YR>
<VL>290</VL>
<PG>345-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hazewinkel-2009" MODIFIED="2013-06-11 14:45:11 +0100" MODIFIED_BY="[Empty name]" NAME="Hazewinkel 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-06-11 14:45:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Hazewinkel MH</AU>
<TI>A randomized controlled trial to evaluate the effect on pelvic floor function of pelvic physiotherapy following radical hysterectomy in early stage cervical cancer</TI>
<SO>Nederlands Trial Register (http://www.trialregister.nl/trialreg/index.asp) (last accessed 24 October 2011)</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumari-2008" MODIFIED="2013-11-21 09:30:44 +0000" MODIFIED_BY="[Empty name]" NAME="Kumari 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-11-21 09:30:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumari S, Jain V, Mandal AK, Singh A</AU>
<TI>Behavioral therapy for urinary incontinence in India</TI>
<SO>International Journal of Gynaecology and Obstetrics</SO>
<YR>2008</YR>
<VL>103</VL>
<NO>2</NO>
<PG>125-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramsay-1990" MODIFIED="2014-04-22 03:51:54 +0100" MODIFIED_BY="[Empty name]" NAME="Ramsay 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-04-22 03:51:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramsay IN, Thou M</AU>
<TI>A randomised, double blind, placebo controlled trial of pelvic floor exercises in the treatment of genuine stress incontinence [abstract 59]</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1990</YR>
<VL>9</VL>
<PG>398-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rutledge-2012" MODIFIED="2014-05-06 10:36:37 +0100" MODIFIED_BY="[Empty name]" NAME="Rutledge 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-05-06 10:36:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - CCTR&lt;br&gt;AN - CN-00831242 NEW&lt;/p&gt;" NOTES_MODIFIED="2014-05-06 10:36:37 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rutledge T, Lee S, Rogers R, Muller C</AU>
<TI>A pilot randomized controlled trial to evaluate pelvic floor muscle training for urinary incontinence among gynecologic cancer survivors [abstract number 282]</TI>
<SO>Gynecologic Oncology</SO>
<YR>2012</YR>
<VL>125 Suppl 1</VL>
<PG>S117</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Leeuwen-2004" MODIFIED="2013-05-15 09:38:01 +0100" MODIFIED_BY="[Empty name]" NAME="van Leeuwen 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-15 09:38:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schagen van Leeuwen JH, Elser D, Freeman R, Ghoniem G, Zhao Y, Yalcin I et al</AU>
<TI>Controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment in women with stress urinary incontinence (SUI) [Abstract]</TI>
<SO>European Urology Supplements</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>2</NO>
<PG>52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2012" MODIFIED="2013-05-03 13:34:22 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-05-03 13:34:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang EJ, Lim JY, Rah UW, Kim YB</AU>
<TI>Effect of a pelvic floor muscle training program on gynecologic cancer survivors with pelvic floor dysfunction: A randomized controlled trial</TI>
<SO>Gynecologic Oncology</SO>
<YR>2012</YR>
<VL>125</VL>
<NO>3</NO>
<PG>705-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoon-1999" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NAME="Yoon 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Yoon HN, Hong JY, Choi YH, Back SH</AU>
<TI>The effect of pelvic floor muscle exercises on genuine stress incontinence among Korean women: focusing on its effects on the quality of life</TI>
<SO>Proceedings of the 29th Annual Meeting of the International Continence Society</SO>
<YR>1999</YR>
<CY>Denver, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-05-20 13:24:43 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-2009" MODIFIED="2013-05-20 13:24:43 +0100" MODIFIED_BY="[Empty name]" NAME="Miller 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-05-20 13:24:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Miller J, Park L, Tolbert M, Ashton-Miller J, DeLancey J</AU>
<TI>Short term response to Knack therapy (no dedicated muscle strengthening) for treatment of incontinence (Abstract number 548)</TI>
<SO>Proceedings of the 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 - Oct 3, San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-05-10 17:06:33 +0100" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-05-13 14:14:38 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2014-05-13 14:14:38 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Ayeleke-2013" MODIFIED="2014-04-02 13:16:53 +0100" MODIFIED_BY="[Empty name]" NAME="Ayeleke 2013" TYPE="COCHRANE_REVIEW">
<AU>Ayeleke RO, Hay-Smith EJC, Omar MI</AU>
<TI>Pelvic floor muscle training added to another active treatment versus the same active treatment alone for urinary incontinence in women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>11</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2014-04-02 13:16:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-04-02 13:16:02 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD010551.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Balmforth-2004" MODIFIED="2014-05-06 10:36:28 +0100" MODIFIED_BY="[Empty name]" NAME="Balmforth 2004" TYPE="JOURNAL_ARTICLE">
<AU>Balmforth J, Bidmead J et al</AU>
<TI>Raising the tone: A prospective observational study evaluating the effect of pelvic floor muscle training on bladder neck mobility and associated improvement in stress urinary incontinence</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>5</NO>
<PG>553-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2014-05-06 10:36:23 +0100" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg CB, Cho MK, Eastwood S, Horton R, Moher D, Olkin I et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials. The CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berghmans-1998" MODIFIED="2013-11-07 12:00:50 +0000" MODIFIED_BY="[Empty name]" NAME="Berghmans 1998" TYPE="JOURNAL_ARTICLE">
<AU>Berghmans LC, Hendriks HJ, Bø K, Hay-Smith EJ, de Bie RA, van Waalwijk van Doorn ES</AU>
<TI>Conservative treatment of stress urinary incontinence in women: a systematic review of randomized clinical trials</TI>
<SO>British Journal of Urology</SO>
<YR>1998</YR>
<VL>82</VL>
<NO>2</NO>
<PG>181-91</PG>
<IDENTIFIERS MODIFIED="2013-11-07 12:00:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Berghmans-2000" MODIFIED="2013-06-11 14:45:53 +0100" MODIFIED_BY="[Empty name]" NAME="Berghmans 2000" TYPE="JOURNAL_ARTICLE">
<AU>Berghmans LCM, Hendriks HJM, de Bie RA, van Waalwijk van Doorn ESC, Bø K, van Kerrebroeck PhEV</AU>
<TI>Conservative treatment of urge urinary incontinence in women: a systematic review of randomized clinical trials</TI>
<SO>BJU International</SO>
<YR>2000</YR>
<VL>85</VL>
<PG>254-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bo-1994" MODIFIED="2013-11-21 09:55:55 +0000" MODIFIED_BY="[Empty name]" NAME="Bo 1994" NOTES="&lt;p&gt;DA - 19940715&lt;br&gt;IS - 0036-5599 (Print)&lt;br&gt;IS - 0036-5599 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-11-21 09:55:55 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Bo K</AU>
<TI>Reproducibility of instruments designed to measure subjective evaluation of female stress urinary incontinence</TI>
<SO>Scandinavian Journal of Urology and Nephrology</SO>
<YR>1994</YR>
<VL>28</VL>
<NO>1</NO>
<PG>97-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boutron-2008" MODIFIED="2013-11-21 09:55:09 +0000" MODIFIED_BY="[Empty name]" NAME="Boutron 2008" NOTES="&lt;p&gt;DA - 20080219&lt;br&gt;IS - 1539-3704 (Electronic)&lt;br&gt;IS - 0003-4819 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;SB - AIM&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-11-21 09:55:09 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P</AU>
<TI>Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2008</YR>
<VL>148</VL>
<NO>4</NO>
<PG>295-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boyle-2012" MODIFIED="2013-11-07 12:01:52 +0000" MODIFIED_BY="[Empty name]" NAME="Boyle 2012" TYPE="COCHRANE_REVIEW">
<AU>Boyle R, Hay-Smith EJC, Cody JD, Mørkved S</AU>
<TI>Pelvic floor muscle training for prevention and treatment of urinary and faecal incontinence in antenatal and postnatal women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>10</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2013-11-07 12:01:52 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD007471.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bushnell-2005" MODIFIED="2013-11-07 10:56:39 +0000" MODIFIED_BY="[Empty name]" NAME="Bushnell 2005" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R) In-Process &amp;amp; Other Non-Indexed Citations&lt;br&gt;UI - 16155777&lt;br&gt;IN - Health Research Associates, Inc, 6505 216th Street SW, Suite 105, Mountlake Terrace, WA 98403, USA. bushnell@hrainc.net&lt;br&gt;AS - Qual Life Res. 2005 Oct;14(8):1901-13&lt;br&gt;JC - 9210257, bqm&lt;br&gt;SB - IM&lt;br&gt;CP - Netherlands&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2013-11-07 10:56:39 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Bushnell DM, Martin ML, Summers KH, Svihra J, Lionis C, Patrick DL</AU>
<TI>Quality of life of women with urinary incontinence: cross-cultural performance of 15 language versions of the I-QOL</TI>
<SO>Quality of Life Research</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>8</NO>
<PG>1901-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-B_x00f8_-1994" MODIFIED="2014-05-06 10:36:15 +0100" MODIFIED_BY="[Empty name]" NAME="Bø 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bø K, Stien R</AU>
<TI>Needle EMG registration of striated urethral wall and pelvic floor muscle activity patterns during cough, Valsalva, abdominal, hip adductor, and gluteal muscle contractions in nulliparous healthy females</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>1</NO>
<PG>35-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-B_x00f8_-1995" NAME="Bø 1995" TYPE="JOURNAL_ARTICLE">
<AU>Bø K</AU>
<TI>Pelvic floor muscle exercise for the treatment of stress urinary incontinence: an exercise physiology perspective</TI>
<SO>International Urogynecology Journal and Pelvic Floor Dysfunction</SO>
<YR>1995</YR>
<VL>6</VL>
<PG>282-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-B_x00f8_-1996" MODIFIED="2013-11-21 09:42:04 +0000" MODIFIED_BY="[Empty name]" NAME="Bø 1996" TYPE="JOURNAL_ARTICLE">
<AU>Bø K</AU>
<TI>Physiotherapy to treat genuine stress incontinence</TI>
<SO>International Continence Survey</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>2-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-B_x00f8_-2001" MODIFIED="2014-05-06 10:36:08 +0100" MODIFIED_BY="[Empty name]" NAME="Bø 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bø K, Lilleas F et al</AU>
<TI>Dynamic MRI of the pelvic floor muscles in an upright sitting position</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>2</NO>
<PG>167-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-B_x00f8_-2004" NAME="Bø 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bø K</AU>
<TI>Pelvic floor muscle training is effective in treatment of female stress urinary incontinence, but how does it work?</TI>
<SO>International Urogynecology Journal and Pelvic Floor Dysfunction</SO>
<YR>2004</YR>
<VL>15</VL>
<PG>76-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-B_x00f8_-2007" MODIFIED="2013-11-21 09:57:34 +0000" MODIFIED_BY="[Empty name]" NAME="Bø 2007" TYPE="BOOK">
<AU>Bo K, Bergmans B, Morkved S, Van Kampen M</AU>
<SO>Evidence based physical therapy for the pelvic floor</SO>
<YR>2007</YR>
<PB>Harrison H</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carri_x00e8_re-2006" NAME="Carrière 2006" TYPE="BOOK">
<AU>Carrière B</AU>
<SO>The pelvic floor</SO>
<YR>2006</YR>
<PB>Georg Thieme Verlag</PB>
<CY>Stuttgard</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-1984" MODIFIED="2013-11-07 12:04:42 +0000" MODIFIED_BY="[Empty name]" NAME="Chang 1984" TYPE="BOOK">
<AU>Chang S</AU>
<SO>Internal exercise</SO>
<YR>1984</YR>
<PB>Stuyvesant Publishing Company</PB>
<CY>Oslo</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clement-2013" MODIFIED="2013-11-07 10:04:51 +0000" MODIFIED_BY="[Empty name]" NAME="Clement 2013" TYPE="COCHRANE_REVIEW">
<AU>Clement KD, Lapitan MCM, Omar MI, Glazener CMA</AU>
<TI>Urodynamic studies for management of urinary incontinence in children and adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2013-11-07 10:04:51 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-07 10:04:51 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003195.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Constantinou-1982" MODIFIED="2013-11-07 12:06:40 +0000" MODIFIED_BY="[Empty name]" NAME="Constantinou 1982" TYPE="JOURNAL_ARTICLE">
<AU>Constantinou CE, DE Govan</AU>
<TI>Spatial distribution and timing of transmitted and reflexly generated urethral pressures in healthy women</TI>
<SO>Journal of Urology</SO>
<YR>1982</YR>
<VL>127</VL>
<NO>5</NO>
<PG>964-9</PG>
<IDENTIFIERS MODIFIED="2013-11-07 12:06:40 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-11-07 12:06:40 +0000" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7201031"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Groat-1997" NAME="de Groat 1997" TYPE="JOURNAL_ARTICLE">
<AU>de Groat WC</AU>
<TI>A neurologic basis for the overactive bladder</TI>
<SO>Urology</SO>
<YR>1997</YR>
<VL>50</VL>
<NO>6A Suppl</NO>
<PG>36-52; discussion 53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Groat-2001" NAME="de Groat 2001" TYPE="JOURNAL_ARTICLE">
<AU>de Groat WC, MO Fraser et al</AU>
<TI>Neural control of the urethra</TI>
<SO>Scandinavian Journal of Urology and Nephrology. Supplementum</SO>
<YR>2001</YR>
<VL>207</VL>
<PG>35-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Kruif-1996" NAME="de Kruif 1996" TYPE="JOURNAL_ARTICLE">
<AU>de Kruif YP, van Wegen EE</AU>
<TI>Pelvic floor muscle exercise therapy with myofeedback for women with stress urinary incontinence: A meta-analysis</TI>
<SO>Physiotherapy</SO>
<YR>1996</YR>
<VL>82</VL>
<NO>2</NO>
<PG>107-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deindl-1993" MODIFIED="2013-11-21 09:39:56 +0000" MODIFIED_BY="[Empty name]" NAME="Deindl 1993" TYPE="JOURNAL_ARTICLE">
<AU>Deindl FM, DB Vodusek et al</AU>
<TI>Activity patterns of pubococcygeal muscles in nulliparous continent women</TI>
<SO>British Journal of Urology</SO>
<YR>1993</YR>
<VL>72</VL>
<NO>1</NO>
<PG>46-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeLancey-1988a" NAME="DeLancey 1988a" TYPE="JOURNAL_ARTICLE">
<AU>DeLancey JOL</AU>
<TI>Structural aspects of urethrovesical function in the female</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1988</YR>
<VL>7</VL>
<PG>509-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeLancey-1988b" NAME="DeLancey 1988b" TYPE="JOURNAL_ARTICLE">
<AU>DeLancey JOL</AU>
<TI>Anatomy and mechanics of structures around the vesical neck: how vesical neck position might affect its closure</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1988</YR>
<VL>7</VL>
<PG>161-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Derogatis-1974" MODIFIED="2013-06-11 12:51:05 +0100" MODIFIED_BY="[Empty name]" NAME="Derogatis 1974" TYPE="JOURNAL_ARTICLE">
<AU>Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L</AU>
<TI>The Hopkins symptom check-list (HSCL): A self-report symptom inventory</TI>
<SO>Behavioral Science</SO>
<YR>1974</YR>
<VL>19</VL>
<NO>1</NO>
<PG>1-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Derogatis-1983" MODIFIED="2014-03-31 12:14:57 +0100" MODIFIED_BY="[Empty name]" NAME="Derogatis 1983" TYPE="BOOK">
<AU>Derogatis LR</AU>
<SO>The SCL-90-R administration, scoring, and procedures manual II</SO>
<YR>1983</YR>
<PB>Clinical Psychometric Research</PB>
<CY>Towson, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donovan-2005" NAME="Donovan 2005" TYPE="BOOK_SECTION">
<AU>Donovan J,Bosch R, Gotoh M, Jackson S, Naughton M, Radley S et al</AU>
<TI>Symptom and quality of life assessment</TI>
<SO>Incontinence. Volume 1 Basics &amp; Evaluation. Edition 2005</SO>
<YR>2005</YR>
<PB>Health Publication Ltd</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dumoulin-2007" MODIFIED="2013-11-21 09:35:09 +0000" MODIFIED_BY="[Empty name]" NAME="Dumoulin 2007" TYPE="JOURNAL_ARTICLE">
<AU>Dumoulin C, Q Peng et al</AU>
<TI>Changes in levator ani anatomical configuration following physiotherapy in women with stress urinary incontinence</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>178</VL>
<NO>3 Pt 1</NO>
<PG>970-7; quiz 1129</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dumoulin-2011" MODIFIED="2013-06-12 09:37:26 +0100" MODIFIED_BY="[Empty name]" NAME="Dumoulin 2011" TYPE="JOURNAL_ARTICLE">
<AU>Dumoulin C, Glazener C, Jenkinson D</AU>
<TI>Determining the optimal pelvic floor muscle training regimen for women with stress urinary incontinence</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>5</NO>
<PG>746-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fantl-1996" NAME="Fantl 1996" TYPE="BOOK">
<AU>Fantl J, Newman D, Colling J et al</AU>
<TI>Urinary incontinence in adults: acute and chronic management</TI>
<SO>Clinical Practice Guidelines update</SO>
<YR>1996</YR>
<PG>Book chapter 3</PG>
<PB>AHCPR Publication No 96-0682</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fedorkow-1993" NAME="Fedorkow 1993" TYPE="JOURNAL_ARTICLE">
<AU>Fedorkow DM</AU>
<TI>Nonsurgical management of stress urinary incontinence</TI>
<SO>Journal SOGC</SO>
<YR>1993</YR>
<VL>15</VL>
<NO>6</NO>
<PG>695-705</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferguson-2002" NAME="Ferguson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ferguson D, Aaron SD, Guyatt G, Hébert P</AU>
<TI>Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis</TI>
<SO>BMJ</SO>
<YR>2002</YR>
<VL>325</VL>
<PG>652-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Godec-1975" MODIFIED="2014-05-06 10:35:55 +0100" MODIFIED_BY="[Empty name]" NAME="Godec 1975" TYPE="JOURNAL_ARTICLE">
<AU>Godec C, Cass AS, Ayala GF</AU>
<TI>Bladder inhibition with functional electrical stimulation</TI>
<SO>Urology</SO>
<YR>1975</YR>
<VL>6</VL>
<NO>6</NO>
<PG>663-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="76082481"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Griffin-1994" NAME="Griffin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Griffin C, MC Dougherty et al</AU>
<TI>Pelvic muscles during rest: responses to pelvic muscle exercise</TI>
<SO>Nursing Research</SO>
<YR>1994</YR>
<VL>43</VL>
<NO>3</NO>
<PG>164-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2014-05-13 14:12:56 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011a" NOTES="&lt;p&gt;DA - 20111028&lt;br&gt;IS - 1878-5921 (Electronic)&lt;br&gt;- 0895-4356 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-05-13 14:12:56 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P et al</AU>
<TI>GRADE guidelines: 9. Rating up the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1311-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2013-06-11 11:55:04 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011b" NOTES="&lt;p&gt;DA - 20110221&lt;br&gt;IS - 1878-5921 (Electronic)- 0895-4356 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-06-11 11:55:04 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A</AU>
<TI>GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>380-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013a" MODIFIED="2014-05-13 14:13:10 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2013a" NOTES="&lt;p&gt;DA - 20121221&lt;br&gt;IS - 1878-5921 (Electronic)- 0895-4356 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-05-13 14:13:10 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R et al</AU>
<TI>GRADE guidelines: 12. Preparing Summary of Findings tables-binary outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>158-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013b" MODIFIED="2014-05-13 14:13:26 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2013b" NOTES="&lt;p&gt;DA - 20121221&lt;br&gt;IS - 1878-5921 (Electronic)- 0895-4356 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-05-13 14:13:26 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA et al</AU>
<TI>GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles-continuous outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>173-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hannestad-2000" MODIFIED="2014-05-06 10:35:47 +0100" MODIFIED_BY="[Empty name]" NAME="Hannestad 2000" TYPE="JOURNAL_ARTICLE">
<AU>Hannestad YS, Rortveit G, Sandvik H, Hunaskaar S</AU>
<TI>A community-based epidemiological survey of female urinary incontinence: The Norwegian EPICONT study</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2000</YR>
<VL>53</VL>
<PG>1150-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hay_x002d_Smith-2002b" MODIFIED="2013-06-11 14:28:27 +0100" MODIFIED_BY="[Empty name]" NAME="Hay-Smith 2002b" TYPE="COCHRANE_REVIEW">
<AU>Hay-Smith EJC, Bø K, Berghmans LCM, Hendriks HJM, de Bie RA, van Waalwijk van Doorn ESC</AU>
<TI>Pelvic floor muscle training for urinary incontinence in women (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2013-06-11 14:28:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-11 14:28:23 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001407"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hay_x002d_Smith-2011" MODIFIED="2013-06-11 13:43:58 +0100" MODIFIED_BY="[Empty name]" NAME="Hay-Smith 2011" TYPE="COCHRANE_REVIEW">
<AU>Hay-Smith EJC, Herderschee R, Dumoulin C, Herbison GP</AU>
<TI>Comparisons of approaches to pelvic floor muscle training for urinary incontinence in women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>12</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2013-06-11 13:42:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD009508"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD009508"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Haylen-2010" MODIFIED="2014-05-13 14:13:36 +0100" MODIFIED_BY="[Empty name]" NAME="Haylen 2010" NOTES="&lt;p&gt;DA - 20091224&lt;br&gt;IS - 1520-6777 (Electronic)&lt;br&gt;IS - 0733-2467 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Practice Guideline&lt;br&gt;PT - Review&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-05-13 14:13:36 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Haylen BT, De Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J et al</AU>
<TI>An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>1520-6777 (Electronic), 0733-2467 (Linking), 1</NO>
<PG>4-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herbert-2005" NAME="Herbert 2005" TYPE="JOURNAL_ARTICLE">
<AU>Herbert R, Bø K</AU>
<TI>Analysis of quality of interventions in systematic reviews</TI>
<SO>BMJ</SO>
<YR>2005</YR>
<VL>331</VL>
<PG>507-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herbison-2002" MODIFIED="2013-11-07 12:07:33 +0000" MODIFIED_BY="[Empty name]" NAME="Herbison 2002" TYPE="COCHRANE_REVIEW">
<AU>Herbison GP, Dean N</AU>
<TI>Weighted vaginal cones for urinary incontinence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2013-11-07 12:07:33 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD002114"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Herderschee-2011" MODIFIED="2014-05-06 10:35:37 +0100" MODIFIED_BY="[Empty name]" NAME="Herderschee 2011" TYPE="COCHRANE_REVIEW">
<AU>Herderschee R, Hay-Smith EJC, Herbison GP, Roovers JP, Heineman MJ</AU>
<TI>Feedback or biofeedback to augment pelvic floor muscle training for urinary incontinence in women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>7</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2013-11-07 12:07:43 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD009252"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2013-06-11 13:07:47 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-06-11 13:00:20 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoyte-2001" MODIFIED="2014-05-06 10:35:28 +0100" MODIFIED_BY="[Empty name]" NAME="Hoyte 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hoyte L, Schierlitz L et al</AU>
<TI>Two- and 3-dimensional MRI comparison of levator ani structure, volume, and integrity in women with stress incontinence and prolapse</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2001</YR>
<VL>185</VL>
<NO>1</NO>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunskaar-1991" NAME="Hunskaar 1991" TYPE="JOURNAL_ARTICLE">
<AU>Hunskaar S, Vinsnes A</AU>
<TI>The quality of life in women with urinary incontinence as mesured by the sickness impact profile</TI>
<SO>Journal of American Geriatrics Society</SO>
<YR>1991</YR>
<VL>39</VL>
<PG>378-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunskaar-2002" NAME="Hunskaar 2002" TYPE="BOOK_SECTION">
<AU>Hunskaar S, Burgio K, Diokno AC, Herzog AR, Hjalmas K, Lapitan MC</AU>
<TI>Epidemiology and natural history of urinary incontinence (UI)</TI>
<SO>Incontinence</SO>
<YR>2002</YR>
<EN>2nd</EN>
<ED>Abrams P, Cardozo L, Khoury S</ED>
<PB>Health Publication Ltd</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imamura-2010" MODIFIED="2013-06-11 13:35:51 +0100" MODIFIED_BY="[Empty name]" NAME="Imamura 2010" TYPE="JOURNAL_ARTICLE">
<AU>Imamura M, Abrams P, Bain C, Buckley B, Cardozo L, Cody J et al</AU>
<TI>Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence</TI>
<SO>Health Technology Assessment (Winchester, England)</SO>
<YR>2010</YR>
<VL>14</VL>
<NO>40</NO>
<PG>1-506</PG>
<IDENTIFIERS MODIFIED="2013-06-11 13:35:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-06-11 13:35:51 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.3310/hta14400"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jackson-1996" MODIFIED="2013-05-23 14:25:20 +0100" MODIFIED_BY="[Empty name]" NAME="Jackson 1996" NOTES="&lt;p&gt;UI: 96334871&lt;/p&gt;" NOTES_MODIFIED="2013-05-23 14:25:20 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P</AU>
<TI>The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing</TI>
<SO>British Journal of Urology</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>6</NO>
<PG>805-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johnson-1998" MODIFIED="2014-05-06 10:35:20 +0100" MODIFIED_BY="[Empty name]" NAME="Johnson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Johnson TM. Kincade JE. Bernard SL</AU>
<TI>The association of urinary incontinence with poor self-rated health</TI>
<SO>Journal of American Geriatrics Society</SO>
<YR>1998</YR>
<VL>46</VL>
<PG>693-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kegel-1948" NAME="Kegel 1948" TYPE="JOURNAL_ARTICLE">
<AU>Kegel AH</AU>
<TI>Progressive resistance exercise in the functional restoration of the perineal muscles</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>1948</YR>
<VL>56</VL>
<PG>238-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kelleher-1997" MODIFIED="2014-05-06 10:35:13 +0100" MODIFIED_BY="[Empty name]" NAME="Kelleher 1997" NOTES="&lt;p&gt;98083933&lt;br&gt;Journal Article&lt;br&gt;English&lt;/p&gt;" NOTES_MODIFIED="2014-05-06 10:35:13 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Kelleher CJ, Cardozo LD, Khullar V, Salvatore S</AU>
<TI>A new questionnaire to assess the quality of life of urinary incontinent women</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1997</YR>
<VL>104</VL>
<NO>12</NO>
<PG>1374-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lins-2013" MODIFIED="2013-06-11 14:10:47 +0100" MODIFIED_BY="[Empty name]" NAME="Lins 2013" TYPE="OTHER">
<AU>Lins S, Hayder-Beichel D, Kunath F, Rücker G, Motschall E, Antes G</AU>
<TI>Pelvic floor muscle training versus other active treatments for urinary incontinence in women (Protocol in preparation)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<IDENTIFIERS MODIFIED="2013-06-11 14:09:58 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lose-1998" MODIFIED="2014-05-13 14:14:38 +0100" MODIFIED_BY="[Empty name]" NAME="Lose 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lose G, Fantl JA, Victor A, Walter S, Wells TL, Wyman J et al</AU>
<TI>Outcome measures for research in adult women with symptoms of lower urinary tract dysfunction</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>3</NO>
<PG>255-62</PG>
<IDENTIFIERS MODIFIED="2013-11-07 12:08:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lucas-2012" MODIFIED="2014-05-13 14:13:52 +0100" MODIFIED_BY="[Empty name]" NAME="Lucas 2012" NOTES="&lt;p&gt;2012654113&lt;br&gt;133099-04-4 (darifenacin); 133099-07-7 (darifenacin); 16679-58-6 (desmopressin); 116539-59-4 (duloxetine); 136434-34-9 (duloxetine); 286930-02-7 (fesoterodine); 119618-22-3 (oxybutynin); 1508-65-2 (oxybutynin); 230949-16-3 (oxybutynin); 5633-20-5 (oxybutynin); 180272-14-4 (solifenacin); 180272-16-6 (solifenacin); 180468-39-7 (solifenacin); 124937-51-5 (tolterodine)&lt;br&gt;English&lt;br&gt;Journal: Article&lt;br&gt;201247&lt;/p&gt;" NOTES_MODIFIED="2014-05-13 14:13:52 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Lucas MG, Bosch RJL, Burkhard FC, Cruz F, Madden TB, Nambiar AK et al</AU>
<TI>EAU guidelines on assessment and nonsurgical management of urinary incontinence</TI>
<SO>European Urology</SO>
<YR>2012</YR>
<VL>62</VL>
<NO>6</NO>
<PG>1130-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Margolis-2011" MODIFIED="2013-11-07 12:08:38 +0000" MODIFIED_BY="[Empty name]" NAME="Margolis 2011" NOTES="&lt;p&gt;DA - 20110719&lt;br&gt;IS - 1178-1653 (Print)&lt;br&gt;IS - 1178-1653 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-11-07 12:08:38 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Margolis MK, Vats V, Coyne KS, Kelleher C</AU>
<TI>Establishing the content validity of the King's Health Questionnaire in men and women with overactive bladder in the US</TI>
<SO>Patient</SO>
<YR>2011</YR>
<VL>4</VL>
<NO>3</NO>
<PG>177-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Milsom-2013a" MODIFIED="2013-11-07 11:01:11 +0000" MODIFIED_BY="[Empty name]" NAME="Milsom 2013a" TYPE="BOOK_SECTION">
<AU>Milsom I, Altman D, Cartwright R, Lapitan MC, Nelson R, Sillen U, et al</AU>
<TI>Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal incontinence (AI)</TI>
<SO>Incontinence: 5th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence; 2012 Feb 23-25; Paris</SO>
<YR>2013</YR>
<PG>15-107</PG>
<ED>Abrams P, Cardozo L, Khoury S, Wein A</ED>
<PB>International Consultation on Urological Diseases (ICUD)</PB>
<CY>Belgium</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Milsom-2013b" MODIFIED="2013-11-07 11:01:54 +0000" MODIFIED_BY="[Empty name]" NAME="Milsom 2013b" TYPE="BOOK_SECTION">
<AU>Milsom I, Altman D, Cartwright R, Lapitan MC, Nelson R, Sillen U, et al</AU>
<TI>Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal incontinence (AI)</TI>
<SO>Incontinence: 5th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence; 2012 Feb 23-25; Paris</SO>
<YR>2013</YR>
<PG>28</PG>
<ED>Abrams P, Cardozo L, Khoury S, Wein A</ED>
<PB>International Consultation on Urological Diseases (ICUD)</PB>
<CY>Belgium</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher M, Schulz KF, Altman DG, for the CONSORT group</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of parallel group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<PG>1987-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2013" MODIFIED="2013-11-07 09:16:34 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2013" TYPE="BOOK_SECTION">
<AU>Moore K, Dumoulin C, Bradley C, Burgio K, Chambers T, Hagen S, et al</AU>
<TI>Adult conservative management</TI>
<SO>Incontinence: 5th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence; 2012 Feb 23-25; Paris</SO>
<YR>2013</YR>
<PG>1101-227</PG>
<ED>Abrams P, Cardozo L, Khoury S, Wein A</ED>
<PB>International Consultation on Urological Diseases (ICUD)</PB>
<CY>Belgium</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morin-2004" MODIFIED="2014-05-06 10:35:02 +0100" MODIFIED_BY="[Empty name]" NAME="Morin 2004" TYPE="JOURNAL_ARTICLE">
<AU>Morin M, Bourbonnais D</AU>
<TI>Pelvic floor muscle function in continent and stress urinary incontinent women using dynamometric measurements</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>7</NO>
<PG>668-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morris-1936" MODIFIED="2013-11-07 12:09:43 +0000" MODIFIED_BY="[Empty name]" NAME="Morris 1936" TYPE="BOOK">
<AU>Morris M</AU>
<SO>Maternity and post-operative exercises</SO>
<YR>1936</YR>
<PG>5-11, 60-65</PG>
<PB>William Heinemann Ltd</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morrison-1995" MODIFIED="2014-05-06 10:34:54 +0100" MODIFIED_BY="[Empty name]" NAME="Morrison 1995" TYPE="JOURNAL_ARTICLE">
<AU>Morrison JFB</AU>
<TI>The excitability of the micturition reflex</TI>
<SO>Scandinavian Journal of Urology and Nephrology</SO>
<YR>1995</YR>
<VL>29 Suppl 175</VL>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peschers-1997" MODIFIED="2013-11-07 12:18:52 +0000" MODIFIED_BY="[Empty name]" NAME="Peschers 1997" TYPE="JOURNAL_ARTICLE">
<AU>Peschers UM, Schaer GN, DeLancey JO, Schuessler B</AU>
<TI>Levator ani function before and after childbirth</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1997</YR>
<VL>104</VL>
<NO>9</NO>
<PG>1004-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Peschers-2001" NAME="Peschers 2001" TYPE="JOURNAL_ARTICLE">
<AU>Peschers UM, Vodusek DB, Fanger G, Schaer GN, DeLancey JOL, Schuessler B</AU>
<TI>Pelvic muscle activity in nulliparous volunteers</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>269-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pontbriand_x002d_Drolet-2012" MODIFIED="2014-05-06 10:34:45 +0100" MODIFIED_BY="[Empty name]" NAME="Pontbriand-Drolet 2012" TYPE="JOURNAL_ARTICLE">
<AU>Pontbriand-Drolet S, Tang A, Madill S, Bergeron J, Dumoulin C</AU>
<TI>An MRI study: Do pelvic floor morphological and functional deficit differ in women with stress compared to mixed urinary incontinence? [Abstract 270]</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>6</NO>
<PG>1076-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ramsay-1995" MODIFIED="2014-05-06 10:34:39 +0100" MODIFIED_BY="[Empty name]" NAME="Ramsay 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ramsay IN, Ali HM, Hunter M, Stark D, Donaldson K</AU>
<TI>A randomised controlled trial of urodynamic investigations prior to conservative treatment of urinary incontinence in the female [abstract 74]</TI>
<SO>International Urogynecology Journal</SO>
<YR>1995</YR>
<VL>6</VL>
<PG>277-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-Manager-2012" MODIFIED="2014-01-15 12:03:36 +0000" MODIFIED_BY="[Empty name]" NAME="Reference Manager 2012" TYPE="OTHER">
<TI>Reference Manager Professional Edition Version 12</TI>
<SO>New York: Thomson Reuters</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Resnick-1989" MODIFIED="2014-05-13 14:14:02 +0100" MODIFIED_BY="[Empty name]" NAME="Resnick 1989" TYPE="JOURNAL_ARTICLE">
<AU>Resnick NM. Yalla SV. Laurino E</AU>
<TI>The pathophysiology of urinary incontinence among institutionalized elderly persons</TI>
<SO>New England Journal of Medecine</SO>
<YR>1989</YR>
<VL>320</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandvik-2000" MODIFIED="2013-11-21 09:38:39 +0000" MODIFIED_BY="[Empty name]" NAME="Sandvik 2000" NOTES="&lt;p&gt;DA - 20000414&lt;br&gt;IS - 0733-2467 (Print)&lt;br&gt;LA - eng&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - Journal Article&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2013-11-21 09:38:39 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Sandvik H, Seim A, Vanvik A, Hunskaar S</AU>
<TI>A severity index for epidemiological surveys of female urinary incontinence: comparison with 48-hour pad-weighing tests</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>2</NO>
<PG>137-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Temml-2001" MODIFIED="2013-11-07 12:11:28 +0000" MODIFIED_BY="[Empty name]" NAME="Temml 2001" TYPE="JOURNAL_ARTICLE">
<AU>Temml C, Haidinger G, Schmidbauer J</AU>
<TI>Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>259-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thind-1990" MODIFIED="2013-11-07 12:14:29 +0000" MODIFIED_BY="[Empty name]" NAME="Thind 1990" TYPE="JOURNAL_ARTICLE">
<AU>Thind P, Lose G, Jorgensen L, Colstrup H</AU>
<TI>Variations in urethral and bladder pressure during stress episodes in healthy women</TI>
<SO>British Journal of Urology</SO>
<YR>1990</YR>
<VL>66</VL>
<NO>4</NO>
<PG>389-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-2003" MODIFIED="2013-11-07 12:15:06 +0000" MODIFIED_BY="[Empty name]" NAME="Thompson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Thompson JA, O'Sullivan PB</AU>
<TI>Levator plate movement during voluntary pelvic floor muscle contraction in subjects with incontinence and prolapse: a cross-sectional study and review</TI>
<SO>International Urogynecology Journal and Pelvic Floor Dysfunction</SO>
<YR>2003</YR>
<VL>14</VL>
<NO>2</NO>
<PG>84-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verelst-2004" MODIFIED="2013-11-07 12:12:33 +0000" MODIFIED_BY="[Empty name]" NAME="Verelst 2004" TYPE="JOURNAL_ARTICLE">
<AU>Verelst M, Leivseth G</AU>
<TI>Are fatigue and disturbances in pre-programmed activity of pelvic floor muscles associated with female stress urinary incontinence?</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>2</NO>
<PG>143-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wagner-1996" MODIFIED="2013-11-07 10:56:39 +0000" MODIFIED_BY="[Empty name]" NAME="Wagner 1996" NOTES="&lt;p&gt;96149739 Cost and Outcomes Assessment Team, Department of Health Services, University of Washington, Seattle 98103, USA OBJECTIVES. Our objective was to develop a self-report quality of life measure specific to urinary incontinence (I-QOL) that could be used as an outcome measure in clinical trials and in patient care centers. METHODS. The I-QOL was developed from interviews of 20 individuals with urinary incontinence. Refining the questionnaire was accomplished by structured interviews of 17 individuals with urinary incontinence. Testing the I-QOL's psychometric properties involved two administrations (n = 62) along with measures of psychologic well-being and functional status. RESULTS. The rigorous development process ensured that the measure was complete and understandable. The I-QOL proved to be internally consistent (alpha 0.95) and highly reproducible (r = 0.93; 18 days; SD 4). For discriminant validity, severity of incontinence (P &amp;lt; 0.0001) and number of medical appointments in the past year to treat incontinence (P &amp;lt; 0.0001) significantly predicted I-QOL scores. Convergent validity analyses confirmed our predictions that the I-QOL scores were more closely related to overall well-being than bodily pain. CONCLUSIONS. The I-QOL proved to be valid and reproducible as a self-administered measure for assessing quality of life of patients with urinary incontinence&lt;/p&gt;" NOTES_MODIFIED="2013-11-07 10:56:39 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP</AU>
<TI>Quality of life of persons with urinary incontinence: development of a new measure</TI>
<SO>Urology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>1</NO>
<PG>67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wahl-1998" MODIFIED="2014-03-31 12:27:20 +0100" MODIFIED_BY="[Empty name]" NAME="Wahl 1998" NOTES="&lt;p&gt;DA - 20000113&lt;br&gt;IS - 0283-9318 (Print)&lt;br&gt;IS - 0283-9318 (Linking)&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;SB - N&lt;/p&gt;" NOTES_MODIFIED="2014-03-31 12:27:20 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Wahl A, Burckhardt C, Wiklund I, Hanestad BR</AU>
<TI>The Norwegian version of the Quality of Life Scale (QOLS-N). A validation and reliability study in patients suffering from psoriasis</TI>
<SO>Scandinavian Journal of Caring Sciences</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>4</NO>
<PG>215-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ware-1993" MODIFIED="2013-06-11 12:24:58 +0100" MODIFIED_BY="[Empty name]" NAME="Ware 1993" TYPE="BOOK">
<AU>Ware JE, Snow KK, Kosinski M, Gaudek B</AU>
<SO>SF-36 Health Survey Manual and Interpretation Guide</SO>
<YR>1993</YR>
<PB>New England Medical Centre</PB>
<CY>Boston</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" MODIFIED="2013-06-11 13:46:17 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2002" TYPE="BOOK">
<AU>World Health Organization</AU>
<TI>I</TI>
<SO>International classification of functioning, disability and health</SO>
<YR>2002</YR>
<PB>World Health Organization</PB>
<CY>Geneva, Switzerland</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-1999" NAME="Wilson 1999" TYPE="BOOK_SECTION">
<AU>Wilson P, Bø K, Bourcier A, Hay-Smith J, Staskin D, Nygaard I et al</AU>
<TI>Conservative management in women</TI>
<SO>Incontinence</SO>
<YR>1999</YR>
<PG>579-636</PG>
<ED>Abrams P, Khoury S, Wein A</ED>
<PB>Health Publication Ltd</PB>
<CY>UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zigmond-1983" MODIFIED="2013-06-11 12:39:04 +0100" MODIFIED_BY="[Empty name]" NAME="Zigmond 1983" TYPE="JOURNAL_ARTICLE">
<AU>Zigmond AS, Snaith RP</AU>
<TI>The hospital anxiety and depression scale</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1983</YR>
<VL>67</VL>
<NO>6</NO>
<PG>361-70</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-06-11 14:34:45 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Dumoulin-2010" MODIFIED="2013-06-11 14:25:39 +0100" MODIFIED_BY="[Empty name]" NAME="Dumoulin 2010" TYPE="COCHRANE_REVIEW">
<AU>Dumoulin C, Hay-Smith J</AU>
<TI>Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD005654.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hay_x002d_Smith-2006" MODIFIED="2013-06-11 14:34:45 +0100" MODIFIED_BY="[Empty name]" NAME="Hay-Smith 2006" TYPE="COCHRANE_REVIEW">
<AU>Hay-Smith J, Dumoulin C</AU>
<TI>Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<PG>CD005654</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD005654"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-11-21 09:25:30 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-04-28 14:40:50 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-04-28 14:40:50 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aksac-2003">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:32 +0100" MODIFIED_BY="[Empty name]">
<P>3 arm RCT, parallel design<BR/>Not clear if adequate allocation concealment<BR/>Not clear if blinded outcome assessment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:32 +0100" MODIFIED_BY="[Empty name]">
<P>50 women with urodynamic SUI<BR/>No further inclusion or exclusion criteria stated<BR/>Median age, years: PFMT 52.5 (SD7.9), control 54.7 (SD7.8)<BR/>Single centre, Turkey</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:32 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n=20). Use of digital palpation to teach VPFMC with abdominal and buttock muscle relaxation. Weekly clinic visits for 8 weeks. Details of PFMT programme in Data Table 01.03<BR/>2. Control (n=10). No PFMT<BR/>3. PFMT with biofeedback (n=20)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:32 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: not stated<BR/>Other outcomes: pad test cure (weight gain of 1g or less), pad test improvement (50% or greater reduction in pad weight), vaginal squeeze pressure, digital palpation score, incontinence frequency (four point ordinal scale), Social Activity Index</P>
<P>On a four-point ordinal scale (1=urine loss once a day to 4=urine loss once a month), the median (standard deviation) score in the PFMT group was 3.5 (0.5) and in controls it was 2.4 (0.9)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:32 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment evaluation at 8 weeks, no longer-term follow-up<BR/>Dropouts: not stated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 14:40:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beuttenmuller-2010">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:32 +0100" MODIFIED_BY="[Empty name]">
<P>3 arm RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-05-13 11:08:33 +0100" MODIFIED_BY="[Empty name]">
<P>75 female patient with SUI</P>
<P>Method of diagnosis: not reported 'women with a diagnosis of SUI'</P>
<P>Inclusion: not reported</P>
<P>Exclusion: not reported</P>
<P>Mean age (SD): Group PFMT: 49.96 (5.26); Group Control : 44.82 (4.88)</P>
<P>Single Center: the rehabilitation unit of PF disorders in Fortaleza-Ceara</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 14:40:50 +0100" MODIFIED_BY="[Empty name]">
<P>Group A (n = 25): PFMT intervention</P>
<P>Taught by: physiotherapist</P>
<P>Correct VPFMC confirmed? not reported but assessed by the evaluator prior to treatment</P>
<P>Number VPFMC per set: 8</P>
<P>Number sets per day: not reported</P>
<P>Duration of hold: 5 sec</P>
<P>Duration of rest: not reported</P>
<P>Type(s) of contraction, e.g. submaximal, maximal ?: long and short contraction with the participant in supine lying position with knee bent, sitting in the chair or on the gym ball, on all fours, standing</P>
<P>Duration of programme: 20 minutes (in groups of 4) twice weekly for 6 weeks except during menstrual periods or due to other complications</P>
<P>Number and type of contact with health professional(s): twice/ weekly</P>
<P>Measure of adherence? Not reported</P>
<P>Reported level of adherence: Not reported</P>
<P>Other information:<B> </B>
</P>
<P>Kinesitherapy was accomplished through standing or sitting exercises using a Swiss ball of varying size, according to the height and weight of the patient. Proprioceptive exercises such as hopping on a ball, moves to raise the pelvis (anteversion, retroversion, lateralisation and circumduction) were used. Additionnaly exercises were used to contract the PFM to the original position, working the two fiber types I and II by performing contract-relax perineal exercises and hold-relax training, respectively, up to 6 sec</P>
<P>Group B (n =25): Control intervention</P>
<P>'no physical therapy at that time.'</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]">
<P>KHQ, PFM 1finger intravaginal evaluation using the Oxford scale, intra-vaginal pressure perineometry</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bidmead-2002">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:32 +0100" MODIFIED_BY="[Empty name]">
<P>4 arm RCT, parallel design (after treatment period control patients crossed over into group 3)<BR/>Not clear if adequate random allocation concealment<BR/>Blinded outcome assessment<BR/>Primary analysis by intention to treat</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>Women with urodynamic SUI (number recruited not clear, 170 or 173?)<BR/>Inclusion: new diagnosis of SUI or no treatment for SUI in previous 6 months<BR/>Exclusion: not further criteria reported<BR/>Mean age, years: PFMT 46.2 (SD 8.5), control 47.5 (SD 11.5)<BR/>Single centre, UK</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n=40). Conventional PFMT supervised by physiotherapist. Individually tailored lifestyle advice. Five clinic visits in 14 weeks (weeks 1, 3, 6, 10 and 14)<BR/>2. Control (n=20). No treatment for 14 weeks. Thereafter crossed over into group 3<BR/>3. PFMT with electrical stimulation (n=?)<BR/>4. PFMT with sham electrical stimulation (n=42)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure: not stated<BR/>Other outcome measures: pad test, King's Health Questionnaire</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment evaluation at 14 weeks, no longer-term follow-up<BR/>Dropouts: 10/40 PFMT, 7/20 control, 15/? PFMT + electrical stimulation, 12/42 PFMT + sham stimulation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burgio-1998">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>3 arm RCT, parallel design<BR/>Stratified by type (UUI, MUI) and severity of incontinence (number of leakage episodes)<BR/>Not clear if adequate allocation concealment<BR/>Blinded outcome assessment<BR/>Primary analysis by intention-to-treat</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>197 women, with DO with or without urodynamic SUI<BR/>Inclusion: community dwelling women aged 55 years or more, 2 or more urge accidents per week, urge incontinence predominant pattern<BR/>Exclusion: continual leakage, uterine prolapse past introitus, unstable angina, decompensated heart failure, history of malignant arrhythmias, impaired mental status (MMSE&lt;20)<BR/>Mean age, years: PFMT 67.3 (SD 7.6), control 67.6 (SD 7.6)<BR/>Mean duration symptoms, years: 9.4 (10.8), control 12.7 (15.9)<BR/>More than 10 leakage episodes per week: PFMT 52%, control 54%<BR/>Diagnosis: 96 UUI only (49%), 101 MUI (51%)<BR/>Single centre, USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n=65). Use of anorectal biofeedback to teach VPFMC with abdominal muscle relaxation. Response to urge (pause, sit, relax, repeated VPFMC to suppress urge). Use of bladder-sphincter biofeedback at third visit for those with &lt;50% reduction in leakage episodes to teach VPFMC against increasing fluid volume and urge. Fortnightly clinic visit with nurse practitioner, 8 weeks. Details of PFMT programme in Data Table 01.03<BR/>2. Controls (n=65). Placebo drug, three times a day, for 8 weeks. Capsule contained 500 mg riboflavin phosphate marker. Fortnightly clinic visit with nurse practitioner<BR/>3. Drug (n=67)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: change in leakage frequency (2 week urinary diary)<BR/>Secondary outcomes: Hopkins Symptom checklist for psychological distress, self report (worse to much better), satisfaction with progress (not at all to completely), perceived improvement (none or 0% to dry or 100%), willingness to continue PFMT, desire for other treatment, leakage episodes (2 week urinary diary), cystometry (for 105/197)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment evaluation at 10 weeks, no longer-term follow-up<BR/>Dropouts: 4/65 PFMT, 12/65 control, 12/67 drug<BR/>ITTA: for primary outcome, most recent urinary diary data carried forward</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burns-1993">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>3 arm RCT, parallel design<BR/>Not clear if adequate allocation concealment<BR/>Blinded outcome assessment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>135 women, with urodynamic SUI with or without DO<BR/>Inclusion: women with SUI or MUI, 55 years or older, minimum of 3 leakage episodes per week, demonstrates leakage with stress manoeuvres during physical examination, MMSE&gt;23, absence of glycosuria or pyuria, post void residual &lt;50 ml, maximum uroflow &gt;15 ml/s.<BR/>Exclusion: no additional criteria reported<BR/>Mean age, years: PFMT 63 (SD 6), control 63 (5)<BR/>Mean leakage episodes 24 hours: PFMT 2.6 (SD 2.1), control 2.6 (2.6)<BR/>Diagnosis: 123 urodynamic SUI (91%), 12 (9%)<BR/>Single centre, USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n=43, after dropouts). Booklet explaining anatomy, PFMT, and completion of exercise and urinary diaries. Videotape describing exercise protocol. Weekly exercise reminder cards mailed between visits. Weekly clinic visits with nurse, 8 weeks. Details of PFMT programme in Data Table 01.03<BR/>2. Control (n=40, after dropouts). No treatment<BR/>3. PFMT with weekly clinic biofeedback (n=40, after dropouts)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: leakage episodes ( 2-week urinary diary)<BR/>Secondary outcomes: incontinence severity (based on number of leakage episodes from diary), pelvic floor muscle EMG, cystometry</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment evaluation at 8 weeks, with longer term follow up at 12 weeks and 6 months<BR/>Dropouts: 10/135 and 2/135 excluded from analysis (no urinary diary); group not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-B_x00f8_-1999">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>4 arm RCT, parallel design<BR/>Stratified by severity of leakage on pad test<BR/>Adequate allocation concealment<BR/>Blinded outcome assessment<BR/>Secondary analysis by intention to treat<BR/>A priori power calculation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>122 women, with urodynamic SUI<BR/>Inclusion: women with a history of SUI, waiting for surgery or recruited through advertising, &gt;4g leakage on pad test with standardised bladder volume<BR/>Exclusion: other types of incontinence, DO on urodynamics, residual urine &gt;50 ml, maximum uroflow &lt; 15 ml/s, previous surgery for urodynamic SUI, neurological or psychiatric disease, ongoing urinary tract infection, other disease that could interfere with participation, use of concomitant treatments during trial, inability to understand instructions given in Norwegian<BR/>Mean age, years: PFMT 49.6 (SD 10.0), control 51.7 (SD 8.8)<BR/>Mean duration symptoms, years: PFMT 10.2 (SD 7.7), control 9.9 (SD 7.8)<BR/>Mean leakage episodes 24 hours: PFMT 0.9 (SD 0.6), control 1.0 (SD 1.0)<BR/>Diagnosis: 122 urodynamic SUI (100%)<BR/>5 centres, Norway</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n=29). Explanation of anatomy, physiology, and continence mechanism by physiotherapist. Audiotape of home training programme. Weekly 45 minute exercise class with PFMT in a variety of body positions, and back, abdominal, buttock and thigh muscle exercises. Monthly clinic visit with physiotherapist, 6 months. Details of PFMT programme in Data Table 01.03<BR/>2. Controls (n=32). Explanation of anatomy, physiology, and continence mechanism. Correct VPFMC confirmed by palpation. No clinic visits. Offered instruction in use of the Continence Guard (14 accepted)<BR/>3. Electrical stimulation (n=32)<BR/>4. Vaginal cones (n=29)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: 60 second pad test with standardised bladder volume, self-report (very problematic to unproblematic)<BR/>Secondary outcomes: Norwegian Quality of Life Scale, Bristol Female Lower Urinary Tract Symptoms Questionnaire, Leakage Index, Social Activity Index, leakage episodes (3 day urinary diary), 24 hour pad test, vaginal squeeze pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment evaluation at 6 months, no longer-term follow-up<BR/>Dropouts: 4/29 PFMT, 2/32 controls, 7/32 electrical stimulation, 2/29 vaginal cones<BR/>ITTA: baseline values used for losses to follow up</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carneiro-2010">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-02 11:52:12 +0000" MODIFIED_BY="[Empty name]">
<P>50 women aged 30-55 with SUI</P>
<P>Method of diagnosis: urodynamic</P>
<P>Inclusion: women referred by urologists and gynaecologists with urodynamic diagnosis of SUI due to bladder neck hypermobility or pressure drop under stress (PDS) of 90 cm H<SUB>2</SUB>O or higher</P>
<P>Exclusion: SUI due to intrinsic insufficiency (PDS) less than 60 cm H<SUB>2</SUB>O), prior surgical correction of SUI and genital prolapse of any grade in physical examination</P>
<P>Mean age (SD): Group PFMT: 49.24 (7.37); Group Control : 45.25 (6.60)</P>
<P>Single Center: Cafisio physical therapy clinic</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>Group A (n = 25): Experimental group</P>
<P>Taught by: physical therapist</P>
<P>Correct VPFMC confirmed? Yes and maximum voluntary contraction was verified by inittial assessment, individually for each women</P>
<P>Number VPFMC per set: 8-12 repetitions of 5 perineal exercises<B> </B>
</P>
<P>Number sets per day: once</P>
<P>Duration of hold: 6-10</P>
<P>Duration of rest: not mentioned</P>
<P>Type(s) of contraction, e.g. submaximal, maximal?: not reported</P>
<P>Duration of programme: 30 minutes, twice weekly for 8 consecutive weeks</P>
<P>Number and type of contact with health professional(s): twice/ weekly</P>
<P>Measure of adherence? Not reported</P>
<P>Reported level of adherence: Not reported</P>
<P>Other information:<B> </B>
</P>
<P>- Verbal information about the PFM function,visualisation of PF component with anatomical figures</P>
<P>-5 minutes of proprioception sitting on a 75-cm diameter therapeutic ball. During that time, participant were asked to make lateral movements of the pelvis, pelvic anteversion movements, short jumps, and figure of 8 movement with the pelvis</P>
<P>Group B (n = 25): Control group</P>
<P>'The control group carried out no activity during the 8 weeks, as they were on the waiting list'</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-02-02 19:28:47 +0000" MODIFIED_BY="[Empty name]">
<P>Ultrasound examination, surface EMG with an intra-vaginal probe, PFM bi-digital muscle strength test, KHQ</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-08 11:45:40 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Castro-2008">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>4 arm RCT, parallel design<BR/>Adequate allocation concealment<BR/>Blinded outcome assessment<BR/>A priori power calculation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]">
<P>118 women, with urodynamic SUI without DO<BR/>Inclusion: women with urodynamic stress urinary incontinence, no detrusor overactivity, a positive cough test, more than 3 g leakage measured on pad test with standardize bladder volume (200ml); average of 3 episodes of UI per week<BR/>Exclusion: Chronic degenerative disease that would affect muscular or nerve tissues, advanced genital prolapse, pregnancy, active or recurrent UTI, vulvovaginitis, atrophic vaginitis, continence surgery within a year, subjects with pacemaker,Valsalva leak point pressure less than 60 mmH<SUB>2</SUB>O in sitting with 250 ml in bladder or UCP less than 20 cmH<SUB>2</SUB>O in sitting position at maximal cystometric capacity<BR/>Mean age, years: PFMT 56.2 (SD 12.5), Control 52.6 (11.2)<BR/>Leakage episodes in 7 days: PFMT 10.3 (SD 10.1), Control 10.5 (7.0).<BR/>Mean BMI: PFMT 25.9 (SD 5.0), Control 26.9 (SD 5.1)<BR/>
</P>
<P>Single centre?, Sao Paulo, Brazil</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-07-21 21:39:27 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n=26): Three 45 minute exercises classes per week (including PFMT) for 6 months with supervision by physiotherapist</P>
<P>2. Control (n=24): No visit with therapist but motivational phone calls once per month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: Objective cure of stress incontinence based on a negative pad test with a standardized bladder volume (&lt;2g in weight)</P>
<P>Secondary outcomes: I-QoL, voiding diary (number of leakage in 7 days), PFM digital evaluation using oxford scale, urodynamics evaluation, subjective cure &#8220;satisfied&#8221; or &#8220;dissatisfied&#8221; </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment evaluation at 6 months, no longer-term follow-up<BR/>Dropouts and withdrawal: 3/26 PFMT, 5/24 controls<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Diokno-2010">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>45 adult incontinent ambulatory females</P>
<P>Method of diagnosis: symptoms of incontinence on the Medical Epeidemiological and Social aspects of Aging questionnaire (MESA)</P>
<P>Inclusion: MESA score showing incontinence. 'Previously failed anti-incontinence surgery was not considered exclusion.'</P>
<P>Exclusion: 'Currently under treatment for UI, history of bladder cancer, stroke, multiple sclerosis, Parkinson's, epilepsy, spinal cord tumour or trauma, pregnancy, MESA of 72% or higher for urge score or MESA of 70% or higher for stress score, in addition to urge percentage higher than stress percentage (to eliminate those with total incontinence and those with urge predominant symptoms, respectively)</P>
<P>Mean age (SD): Group PFMT: 60.6 (14.4) Group Control: 52.2 (12.6)</P>
<P>Setting: Four Michigan Counties</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>Group A (n = 23): PFMT intervention</P>
<P>Taught by: urology nurse</P>
<P>Correct VPFMC confirmed? Yes vaginal examination to test for PFM strength were performed by two nurses</P>
<P>Number VPFMC per set: 25 contractions in<B> </B>lying and other positions <B>(</B>5<B> </B>short contractions (quick squeezes) and 20 long contractions (hold up to 6 seconds) +knack when needed (sneezing)</P>
<P>Number sets per day: twice per day</P>
<P>Duration of rest: not reported</P>
<P>Type(s) of contraction, e.g. submaximal, maximal?: maximal</P>
<P>Duration of programme: 1 teaching session, 1 follow-up session and daily exercises with an audiotape of PFMT</P>
<P>Number and type of contact with health professional(s): Once after 2-4 weeks with vaginal exam if needed and written test on new knowledge acquired</P>
<P>Measure of adherence? Not reported</P>
<P>Reported level of adherence: Not reported</P>
<P>Other important information:<B> </B>
</P>
<P>Bladder training tips if needed:Progressive voiding schedule based on patient&lt;s diary done before attending the class, interval increased by 15-30 minutes, use pelvic muscle contraction and distraction to inhibit detrusor. Goal: voiding interval of 3.5 to 4 hours while awake<BR/>This was not applicable if they already have the 3-5-4 hour interval at baseline</P>
<P>'2-h power point presentation lecture in groups by two trained urology nurses. Paper handouts were distributed'</P>
<P>Group B (n = 18): Control intervention</P>
<P>No information given on behavioral intervention at any time</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>'Improvement, as measured by reduction of severity level on a 3 point scale (severe to moderate or mild and moderate to mild), or 'no-improvement' for those who stayed the same or worsened, voiding frequency/intervoid interval, continence status with pad testing (g), cough test leak diameter (in cm), stress test (percentage positive) and PFM strength with digital score (pressure, displacement, duration)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-08 11:45:58 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henalla-1989">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>4 arm RCT, parallel design<BR/>Not clear if adequate random allocation concealment<BR/>Not clear if blinded outcome assessment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>100 women with urodynamic SUI<BR/>Exclusion: fistula, more than one surgical procedure for incontinence, major degree of prolapse, absolute contraindication to oestrogens<BR/>Single centre, UK.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>A PFMT (n=26). Correct VPFMC taught by physiotherapist. Weekly clinic visit for 12 weeks. Details of PFMT programme in Data Table 01.03<BR/>B Control (n=25). No treatment<BR/>C Electrical stimulation (n=25)<BR/>D Drug (n=24). Oestrogen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure: not stated<BR/>Other outcome measures: pad test cure (negative following positive result), pad test improvement (50% or greater reduction in pad weight), cystometry</P>
<P>Cured or improved at 3 months: A 17/26, B 0/25, C 8/25, D 3/24</P>
<P>Cured or improved at 9 months: A 14/26, B 0/25, C 7/25 D 0/24</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment evaluation at 12 weeks, with longer-term follow-up at 9 months (questionnaire)<BR/>Dropouts: none at 12 weeks?</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Henalla-1990">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>3 arm RCT, parallel design<BR/>Not clear if adequate random allocation concealment<BR/>Not clear if blinded outcome assessment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>26 women with urodynamic SUI<BR/>Inclusion: postmenopausal<BR/>Exclusion: no further criteria stated<BR/>Mean age, years: 54 (range 49-64)<BR/>Single centre, UK</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n=8). No detail given<BR/>2. Control (n=7). No treatment<BR/>3. Drug (n=11). Oestrogen</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: not stated<BR/>Other outcome measures: pad test cure or improved (not defined), vaginal pH, vaginal cytology, anal EMG</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment evaluation at 6 weeks, no longer-term follow-up<BR/>Dropouts: none?</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hofbauer-1990">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>4 arm RCT, parallel design<BR/>Not clear if adequate random allocation concealment<BR/>Not clear if blinded outcome assessment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>43 women with urodynamic SUI<BR/>Exclusion: urge incontinence<BR/>Mean age, years: 57.5 (SD 12)<BR/>Grade 3 incontinence: 4 PFMT, 2 control</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n=11). Exercise programme including PFMT, abdominal and hip adductor exercise, twice a week for 20 minutes with therapist, and daily home programme<BR/>2. Control (n=10) Sham electrical stimulation<BR/>3. PFMT + electrical stimulation (n=11)<BR/>4. Electrical stimulation (n=11)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: not stated<BR/>Other outcome measures: incontinence scale (? symptom scale, not defined), leakage episodes (urinary diary), cystometry</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>Not clear when post-treatment evaluation performed. Further follow-up at 6 months<BR/>Dropouts: none?</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2007">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm RCT, crossover design</P>
<P>Stratification: level of physical fitness and leakage episode</P>
<P>Not clear if adequate random allocation concealment<BR/>Not clear if blinded outcome assessment</P>
<P>A priori power calculation<BR/>Single urban centre, Japan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>70 women with SUI symptoms<BR/>Inclusion: Urine leakage more than once per month,UI associated with exertion<BR/>Exclusion: Urge or mixed UI symptoms, No leakage or not enough<BR/>Mean age, years: PFMT 76.6 (SD 5.0), control 76.6 (8.3)<BR/>Frequency score of urine leakage: PFMT 3.4 (SD 1.3), control 3.0 (1.3)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n=35): 60 minute exercise class twice a week for 12 weeks and 30 minutes home exercises twice a week</P>
<P>2. Control (n = 35): </P>
<P>Live normal life and refrain from exercises aiming to increase muscle strength, walking speed, to reduce BMI, or to improve dietary habits for 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: ICIQ, frequency of UI leakage (worse to cured) at 3 and at 12 months</P>
<P>Secondary outcomes: BMI, grip strength, walking speed, hip adductor strength</P>
<P>On a six-point leakage scale of cure (0 = no urine leakage, 1 = less than once per month, 2 = 1 to 3 per month, 3 = 1 to 2 per week, 4 = every two days and 5 = every day), the post-treatment score was significantly better for PFMT group than for the control group with a mean (standard deviation) score post-treatment in the PFMT group of 1.5 (1.8) compared to controls 2.4 (1.4) (MD -0.9, 95% CI -1.7 to -0.1)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>Post treatment evaluation at 3 months, with longer-term follow up at 12 months</P>
<P>Dropouts: 2/35y: PFMT, 3/35 Control</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2011">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>4 arm RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>147 community-dwelling women aged 70 years and older with SUI, MUI or UUI</P>
<P>Method of diagnosis: symptoms</P>
<P>Inclusion: Urine leakage more than once per month, suffering from stress, urge and mixed UI according to symptoms, being 70 and older.</P>
<P>Exclusion: Unclear type of UI, having urine leakage less than once per month, impaired cognition (MMSE lower than 24), unstable cardiac conditions such as ventricular dysrhythmias, pulmonary edema or other musculoskeletal conditions</P>
<P>Mean age (SD): Group PFMT intervention: 76.7 (3.6) Group Control intervention: 75.8 (3.6)</P>
<P>Setting: Basic Resident Register of 5935 women aged 70 years years and older that resided in the Itabashi ward of Tokyo as of 1 April 2006</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>Group A (n = 37): PFMT intervention</P>
<P>Taught by: clinician giving the PFM and fitness protocol</P>
<P>Correct VPFMC confirmed? not reported</P>
<P>Number VPFMC per set: 10 fast and 10 sustained contractions</P>
<P>Number sets per day: 3</P>
<P>Duration of hold: 3 seconds for fast contractions, 6 to 8 seconds for sustained contractions</P>
<P>Duration of rest: 5 seconds for fast contractions and 10 seconds for sustained contractions</P>
<P>Type(s) of contraction, e.g. submaximal, maximal: PFM contraction without excessively straining the abdomen, performed in lying, sitting, standing position with legs apart</P>
<P>Duration of programme: 60 minutes, twice weekly for 12 weeks in groups</P>
<P>Number and type of contact with health professional(s): twice/ weekly for 12 weeks</P>
<P>Measure of adherence? 'The subjects were asked to document the time and sets of exercises performed at home each day.'</P>
<P>Reported level of adherence: recording sheet. not reported</P>
<P>Other information:</P>
<P>- The participants were informed that straining the abdomen increases abdominal pressure and exerts pressure on the PFM. The subjects were trained to exert force only on the PFM without excessively straining the abdomen</P>
<P>- Warm-up and stretching 10 to 15 min including shoulder rotation, waist rotation and others , PFMT (as above) in addition to fitness: strength training of the thigh and abdominal muscles performed between PFMT, weight bearing exercises, ball exercises and others</P>
<P>-Home exercises two to 3 sets of (PFM +13 exercises) at least 3 times a week (duration approximately 30 minutes)</P>
<P> </P>
<P>Group B (n = 36): Control intervention</P>
<P>General education class once per month for 3 months where participants were educated on cognitive function, osteoporosis and oral hygiene</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>Subjective cure (interview), Complete cessation of urine loss episode was defined as cured, functional fitness, change in frequency of urine loss episodes (5 point scale), ICIQ</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-08 13:20:14 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2011a">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>127 community dwelling women aged 70 and older with SUI, MUI or UUI</P>
<P>Method of diagnosis: symptoms</P>
<P>Inclusion: Urine leakage more than once per week, suffering from stress, urge and mixed UI according to symptoms, being 70 years old or more, completing a 1-week urinary diary</P>
<P>Exclusion: Unclear type of UI, having urine leakage less than once per week, not completing the 1 week bladder diary, Impaired cognition (MMSE lower than 24), unstable cardiac conditions such as ventricular dysrhytmias, pulmonary oedema, or other musculoskeletal conditions</P>
<P>Mean age (SD): Group PFMT intervention: 76.1 (4.3) Group Control intervention: 75.7 (4.4)</P>
<P>Setting: Urban community-based study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>Group A (n = 63): PFMT intervention</P>
<P>Taught by: clinician giving the PFM and fitness protocol</P>
<P>Correct VPFMC confirmed? not reported</P>
<P>Number VPFMC per set: 10 fast and 10 sustained contractions</P>
<P>Number sets per day: 3</P>
<P>Duration of hold: 3 seconds for fast contractions, 6 to 8 seconds for sustained contractions</P>
<P>Duration of rest: 5 seconds for fast contractions and 10 seconds for sustained contractions</P>
<P>Type(s) of contraction, e.g. submaximal, maximal: PFM contraction without excessively straining the abdomen, performed in lying, sitting, standing position with legs apart</P>
<P>Duration of programme: 60 minutes, twice weekly for 12 weeks in groups</P>
<P>Number and type of contact with health professional(s): twice/weekly for 12 weeks</P>
<P>Measure of adherence? 'The subjects were asked to document the time and sets of exercises performed at home each day.'</P>
<P>Reported level of adherence: Recording sheet. Attendence rate to PFMT intervention, home exercise frequency</P>
<P>Other important information:</P>
<P>-Warm-up and stretching 10 to 15 min, PFMT (as above) in addition to fitness: strength training of the thigh and abdominal muscles performed between PFMT, back, legs, trunk and use of an exercise ball</P>
<P>-Home exercises two to 3 sets of (PFM +13 exercises) at least 3 times a week (duration approximately 30 minutes) </P>
<P> </P>
<P>Group B (n = 64): Control intervention</P>
<P>General education class once per month for 3 months where participants were educated on cognitive function, osteoporosis and oral hygiene</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>ICIQ frequency of UI leakage (scale 0 -5) at 3 months and 7 months</P>
<P>Subjective cure (leakage disappeared) at 3 and 7 months according to bladder diary, BMI, waist line, grip strength, walking speed, hip adductor strength</P>
<P>Cure of UI at 3 months: A 26/59, B 1/61</P>
<P>Cure of UI at 7 months: A 23/59, B 1/61</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-10 14:32:42 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lagro_x002d_Janssen-1991">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm RCT, parallel design<BR/>Stratified by type and severity of incontinence<BR/>Inadequate allocation concealment<BR/>Blinded outcome assessment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>110 women, with urodynamic SUI with or without DO<BR/>Inclusion: women between 20 and 65 years of age reporting 2 or more leakage episodes per month<BR/>Exclusion: previous incontinence surgery, neurological causes of incontinence, urinary tract infection, temporary cause of incontinence<BR/>Mean age, years: PFMT 46.1 (SD 10.1), controls 44.6 (SD 8.2)<BR/>Symptoms for more than 5 years: PFMT 55%, control 33%<BR/>Mean leakage episodes 24 hours: PFMT 2.5 (SD 2.0), control 3.3 (SD 2.2)<BR/>Diagnosis: 66 urodynamic SUI (60%), 20 MUI (18%), 18 UUI (16%), 6 other (6%). NB: only data from urodynamic SUI women are included in the review, because women with other diagnoses also had bladder training<BR/>13 general practices, the Netherlands</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n=54, but 33 with urodynamic SUI only). Advice about incontinence pads from practice assistant. Information on PFM function and how to contract by family doctor. PFMT for 12 weeks. Details of PFMT programme in Data Table 01.03<BR/>2. Control (n=56, but 33 with urodynamic SUI only). Advice about incontinence pads only. Offered treatment after 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: not stated<BR/>Other outcomes: incontinence severity (12 point score), subjective assessment, health locus of control questionnaire, general health questionnaire, leakage episodes (7 day diary), self-reported treatment adherence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment evaluation at 12 weeks, with longer term follow up at 6 months, 12 months and 5 years<BR/>Dropouts: 1/54 PFMT, 3/56 control.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-1998">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm RCT, parallel design (after one month controls cross over into treatment group)<BR/>Not clear if adequate allocation concealment<BR/>Blinded outcome assessment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>27 women with symptoms and signs of SUI<BR/>Inclusion: community dwelling women, mild to moderate SUI (at least one and up to 5 leaks per day), 60 years or more, direct visualisation of urine loss on cough with 100ml or more voided after stress test<BR/>Exclusion: systemic neuromuscular disease, previous bladder surgery, active urinary tract infection, delayed leakage after cough, more than moderate leakage with cough, inability to do a VPFMC, prolapse below hymenal ring<BR/>Mean age, years: 68.4 (SD 5.5)<BR/>Mean number leakage episodes per day: 1.4 (SD 1.4)<BR/>Single centre, USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n=13). Education on basic physiology and function of pelvic floor muscles, digital palpation to teach VPFMC. Taught 'The Knack', i.e. VPFMC prior to hard cough maintained throughout cough until abdominal wall relaxed. Practice at home for one week<BR/>2. Control (n=14). No treatment for one week, then cross over to treatment group at one month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome measure: Paper towel test<BR/>Secondary outcome measures: digital palpation</P>
<P>A paper towel test was reported as mean wet area and SD on either a moderate or a deep cough. PFMT women reported about 20 cm<SUP>2</SUP> less of wet area than controls on a medium cough (MD -20.8, 95% CI -46.5 to 4.9) and 21 cm less of wet area than controls on a deep cough (MD -21.4, 95% CI -50 to 7.2). However, in both cases, the wide confidence intervals included no difference.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment evaluation: one week, no longer-term follow-up<BR/>Dropouts: none</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pereira-2011">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>3 arm parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>49 women over 18 years of age</P>
<P>Method of diagnosis: SUI symptoms</P>
<P>Inclusion: complain of urinary leakage on stress (two standard questions about stress and urgency UI used to determine patient eligibility: During the past month, have you involuntary got wet while performing some kind of physical exertion, coughing, lifting, sneezing or laughing? For urgency, the question was During the past month, have you experienced such a strong urge to urinate that it was impossible to get to the toilet on time? Those answering yes to the stress question only and who had not undergone physical therapy for UI before were included</P>
<P>Exclusion: With symptoms of urgency urinary incontinence and mixed urinary incontinence, latex allergies, vaginal or urinary infections, pelvic organ prolapse greater than grade II on Baden-Walker classification system, cognitive or neurological disorder, uncontrolled hypertension and inability to carry out the evaluation or treatment</P>
<P>Mean age (SD): Group PFMT intervention: 60.20 (8.16); Individual PFMT intervention: 60.6 (12.63); Control intervention: 61.53 (10.11)</P>
<P>A single centre study: Labortory for assessment and intervention on Women's health, Federal university of Sao Carlos, Brazil</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>Group A (n = 17): Group PFMT intervention</P>
<P>Taught by: Physical therapist</P>
<P>Correct VPFMC confirmed? Yes with vaginal palpation</P>
<P>Number VPFMC per set: not clear, 100 in total on average in intervention sessions</P>
<P>Number sets per day: not mentioned</P>
<P>Duration of hold during intervention sessions: (mean time of the group was considered as the time of sustained contraction). The time of sustained contraction was increased by 1 s per week up to 10 s</P>
<P>Duration of rest during intervention sessions: double the duration of hold</P>
<P>Type(s) of contraction, e.g. submaximal, maximal: '<I>100 contractions were performed on average, composed of phasic contractions held for 3 sec with 6 sec rest and tonic contractions of 5-10 s followed by 10-20 sec rest. To minimize the muscle fatigue, the resting time was rigidly observed in all sessions and the time of sustained contraction was slowly increased. PFMT was carried out in supine, sitting and standing positions. The degree of difficulty progressed according to the positions adopted, the number of repetitions, and the time of sustained contraction.'</I>
</P>
<P>Group B (n = 17): Individual PFMT intervention:</P>
<P>Taught by: physical therapist</P>
<P>Correct VPFMC confirmed? Yes with vaginal palpation</P>
<P>Number VPFMC per set: not clear, 100 in total on average in intervention sessions</P>
<P>Number sets per day: not mentioned</P>
<P>Duration of hold: 3-10 seconds during intervention sessions. The time of sustained contraction was increased by 1 s per week up to 10 s</P>
<P>Duration of rest: 6-20 seconds in intervention sessions</P>
<P>Type(s) of contraction, e.g. submaximal, maximal: &#8220;<I>100 contractions were performed on average, composed of phasic contractions held for 3 sec with 6 sec rest and tonic contractions of 5-10 s followed by 10-20 sec rest. To minimize the muscle fatigue, the resting time was rigidly observed in all sessions and the time of sustained contraction was slowly increased. PFMT was carried out in supine, sittting and standing positions. The degree of difficulty progressed according to the positions adopted, the number of repetitions, and the time of sustained contraction.</I>&#8220;</P>
<P>Other important information on the group and individual interventions:</P>
<P>Duration of programme: two 1h weekly sessions in clinic for 6 weeks</P>
<P>Number and type of contact with health professional(s): 12 group or individual sessions twice/ weekly for 1h for a total of 6 weeks</P>
<P>Measure of adherence? No</P>
<P>Explanation about anatomy of the PFM and continence mechanism</P>
<P>Group C (n = 15): Control intervention: did not received any treatment during the corresponding treatment time</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-05-09 15:00:52 +0100" MODIFIED_BY="[Empty name]">
<P>1hour pad test, KHQ, PFM pressure perineometry, PFM digital evaluation of strength, subjective satisfaction with tx (The only two response options available were &#8216;satisfied &#8217; and &#8216; dissatisfied &#8217; . Answering &#8216; satisfied &#8217; indicated that the patient did not want a different treatment. Answering &#8216;dissatisfied &#8217; indicated that the patient wanted a different treatment from the initial one), adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-08 11:13:24 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sar-2009">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm parallel RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>41 Women </P>
<P>Diagnosis of urinary incontinence: signs (2g. of urine on a 1h pad test)</P>
<P>Inclusion: women with stress or mixed signs on surgical waiting list between 2005-2007, MMSE score: 25 and more</P>
<P>Exclusion: UTI, previous surgery of UI,neurological disease, diabetes mellitus, comorbid conditions likely to interfere with tx, UI medication, inability to understand Turkish language</P>
<P>Mean age: PFMT group =41.82 (8.65); Control group = 44.64 (6.90)</P>
<P>Two centres: Outpatient urology clinics attached to a country hospital and a university hospital in Izmir, Turkey</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-02-02 19:28:59 +0000" MODIFIED_BY="[Empty name]">
<P>Group A (n = 19): PFMT</P>
<P>Taught by: nurse</P>
<P>Correct VPFMC confirmed? Yes using vaginal palpation</P>
<P>Number VPFMC per set: 30 contractions per set</P>
<P>Number sets per day: 3</P>
<P>Duration of hold: 1 to 10 seconds</P>
<P>Duration of rest: same as contraction time</P>
<P>Type(s) of contraction, e.g. submaximal, maximal: quick flicks (1-2 sec contractions), sustained progressive (5-10 seconds) contractions + knack</P>
<P>Duration of programme: 6 weeks</P>
<P>Position: supine, sitting and standing</P>
<P>Measure of adherence? weekly telephone call to encourage exercises practice and answer questions</P>
<P>Reported level of adherence: not reported</P>
<P>Other important information on the intervention: taught about the anatomy of the pelvic floor, lower urinary tract anatomy and continence mechanism. Information was summarised in an illustrated handbook</P>
<P>Group B (n = 22): control</P>
<P>not contacted</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>Sar reported all outcomes as change scores and SD which we could not use in our forest plot. All outcomes significantly favoured PFMT versus control (P &lt; 0.01)</P>
<P>I-QOL: PFMT A 23.19 (11.43) 17, versus control B 5.74 (6.26) 17</P>
<P>Bladder diary (change in leakage/3 days): PFMT A -3.23 (2.19) 17 versus control B 0.82 (2.81) 17</P>
<P>1h pad test (change in gms from baseline): PFMT A -5.11 (7.29) 17 versus control B 8.88 (12.52) 17</P>
<P>PFM strength: mean and maximum as pressure using intra-vaginal perineometry: PFMT A 9.47 (6.53) 17 versus control B -2.23 (4.43) 17 and PFMT 11.23 (7.60) 17 versus control B -3.70 (4.71) 17 respectively</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-05-08 13:21:07 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wells-1999">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>4 arm RCT, parallel design<BR/>Not clear if adequate allocation concealment<BR/>Outcome assessment not blind</P>
<P>No intention to treat analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>286 community living women, with symptoms of stress or mixed urinary incontinence</P>
<P>Inclusion: aged over 21, self described as having uncontrolled urine loss and-or excessive day toiletting frequency, independent in self care, able to speak and ear a conversation in English adequately over the phone, negative urinalysis, able to contract the PFM as demonstrated on physical examination, able to read, understand and agree to the diagnostic consent form<BR/>Exclusion: diagnosis of degenerative neurological disorder,pregnancy, high risk of infection following urologic instrumentation</P>
<P>Mean age, years: 56 (SD 12.76)</P>
<P>Single centre, USA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n =71): Initial training and active pelvic floor muscle exercises then monthly visits for observation, coaching and encouragement</P>
<P>2. Control (n = 72): directed one week a month to keep a daily record of fluid intake, toileting and urine leakage and discern a pattern and make simple life style alterations if possible. Received diary by mail monthly</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>Pelvic floor muscle strength, urethral pressure and wetting</P>
<P>No details given on primary and secondary outcomes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment evaluation at 5 months, no longer term follow-up</P>
<P>Dropouts: 30/71 PFMT, 35/72 Controls</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yoon-2003">
<CHAR_METHODS MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>3 arm RCT, parallel design<BR/>Not clear if adequate allocation concealment<BR/>Blinded outcome assessment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>50 women with urinary incontinence<BR/>Inclusion: urine loss &gt;1g on 30 minute pad test, 14 voids or more in 48 hours<BR/>Exclusion: women under 35 and over 55 years of age, urinary tract infection, previous surgery for urinary incontinence, hormonal or other drug therapy for incontinence<BR/>Mean voids per day: PFMT 15.1 (SD 1.6), control 16.3 (1.8)<BR/>Diagnosis: urinary incontinence (100%)<BR/>Single centre, Korea</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>1. PFMT (n=15). 20 minutes weekly session of EMG biofeedback with nurse, 8 weeks. Details of PFMT programme in Data Table 01.03<BR/>2. Control (n=14). No treatment or clinic contact</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: not stated<BR/>Other outcomes: urinary incontinence score (severity based on leakage with 18 activities), leakage episodes and frequency (2 day diary), 30 minute pad test, vaginal squeeze pressure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>Post-treatment evaluation at 8 weeks, with no longer-term follow-up<BR/>Dropouts: 2/15 PFMT, 2/21 Bladder training, 2/14 controls</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>DO=detrusor overactivity, EMG=electromyography, ITTA=intention-to-treat analysis, MMSE=mini mental state examination, MUI=mixed urinary incontinence, PFMT=pelvic floor muscle training, SD=standard deviation, SUI=stress urinary incontinence, RCT=randomised controlled trial,USI=urodynamic stress urinary incontinence, UUI=urge urinary incontinence, VPFMC=voluntary pelvic floor muscle contraction.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abdulaziz-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm RCT comparing biofeedback assisted PFMT to a control group. Considered to be a comparison of PFMT + biofeedback to control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Albers_x002d_Heitner-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]">
<P>Qualitative study, not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bernier-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>Electrical stimulation, biofeedback + PFMT used in the treatment arm of the RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bernier-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>Electrical stimulation, biofeedback + PFMT used in the treatment arm of the RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beuttenmuller-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>3 arm RCT comparing PFMT, PFMT + Estim and control. No UI outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burgio-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>3 arm RCT comparing PFMT + biofeedback, PFMT, and self help booklet (including advice on PFMT). Considered to be a comparison of different approaches to PFMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chang-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>3 arm RCT comparing acupressure, sham acupressure and usual care. No PFMT group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Felicissimo-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm RCT comparing two PFMT interventions: intensive supervised and unsupervised PFMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferreira-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm RCT comparing two PFMT interventions: home based and supervised PFMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferreira-2011a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: PFM educational group intervention not PFMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghoniem-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>PFMT versus sham PFMT comparison was considered to be confounded by the choice of sham PFMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goode-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>3 arm RCT comparing PFMT + electrical stimulation, PFMT, and self help booklet (including advice on PFMT). Considered to be a comparison of different approaches to PFMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hazewinkel-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm preventive and therapeutic RCT comparing PFMT to control in women in early stage of cervical cancer with and without pelvic floor symptoms. Data of those with UI not presented separately</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumari-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm RCT comparing PFMT + bladder training to the absence of treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ramsay-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>PFMT versus sham PFMT comparison was considered to be confounded by the choice of sham PFMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rutledge-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm RCT comparing PFMT/behavioural therapy to usual care. Considered to be a comparison of a combined PFMT with bladder training intervention to control, not just PFMT alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Leeuwen-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>4 arm RCT comparing duloxetine alone, duloxetine + imitation PFMT, PFMT + placebo and PFMT alone. Imitation PFMT and PFMT is considered to be a comparison of different approaches to PFMT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>2 arm RCT comparing PFMT + biofeedback and control in gynaecology cancer survivors not specific to UI 'women who scored above 2 on of at least one of the bowel, bladder or sexual function questionnaires were selected</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yoon-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>3 arm, probably quasi-randomised trial, comparing PFMT, electrical stimulation, and control (not defined), for women with urodynamic SUI.<BR/>This abstract contains no data; P values only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>PFMT=pelvic floor muscle training, RCT=randomised controlled trial, SUI=stress urinary incontinence, USI=urodynamic stress urinary incontinence,</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-04-28 13:07:42 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-04-28 13:07:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-2009">
<CHAR_METHODS MODIFIED="2013-05-20 13:51:16 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-28 13:07:41 +0100" MODIFIED_BY="[Empty name]">
<P>Women with UI</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-28 13:07:42 +0100" MODIFIED_BY="[Empty name]">
<P>Knack instruction as provided by a video versus a video on food pyramid instruction</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-28 13:07:42 +0100" MODIFIED_BY="[Empty name]">
<P>Incontinence episode on a diary, leakage volume on quantified stress test, self reported improvement</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-28 13:07:42 +0100" MODIFIED_BY="[Empty name]">
<P>No usable data in abstract; manuscript in preparation</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-05-10 17:06:33 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aksac-2003">
<DESCRIPTION>
<P>"patient was requested to choose a closed letter upon her first admission, and she was enrolled to a group in accordance with the number written in the letter" 'no mention of sealed, opaque, consecutively numbered'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 11:51:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beuttenmuller-2010">
<DESCRIPTION>
<P>'randomly divided in 3 groups'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bidmead-2002">
<DESCRIPTION>
<P>"randomised"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-1998">
<DESCRIPTION>
<P>"within each stratum, randomization was performed with computer-generated random numbers using a block size of 6 to avoid inequity in group size"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burns-1993">
<DESCRIPTION>
<P>"randomized blocking was employed to balance the number of subjects in each group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x00f8_-1999">
<DESCRIPTION>
<P>"computer generated random number"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carneiro-2010">
<DESCRIPTION>
<P>'Using a simple random sampling'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castro-2008">
<DESCRIPTION>
<P>Computer-generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-10 12:00:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diokno-2010">
<DESCRIPTION>
<P>'randomisation was performed in groups of five using the SAS system'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henalla-1989">
<DESCRIPTION>
<P>"were allocated at random"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henalla-1990">
<DESCRIPTION>
<P>"randomized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hofbauer-1990">
<DESCRIPTION>
<P>"randomised"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2007">
<DESCRIPTION>
<P>"computer generated random number"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-10 15:26:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2011">
<DESCRIPTION>
<P>'computer-generated random numbers'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 11:54:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2011a">
<DESCRIPTION>
<P>'computer-generated random number'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lagro_x002d_Janssen-1991">
<DESCRIPTION>
<P>Consecutively (ie: quasi-random because of alternation)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1998">
<DESCRIPTION>
<P>"randomly assigned in blocks of two"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 11:55:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pereira-2011">
<DESCRIPTION>
<P>''participants blindly drew one of the 49 preprinted cards in opaque sealed envelopes from a box'' no mention of successively numbered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sar-2009">
<DESCRIPTION>
<P>'randomly assigned to an intervention or control group'</P>
<P>'stratified based on PFM strength, frequency of UI episodes and severity of UI on a 1h pad test</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1999">
<DESCRIPTION>
<P>Subjects were randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yoon-2003">
<DESCRIPTION>
<P>Using random number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aksac-2003">
<DESCRIPTION>
<P>"patient was requested to choose a closed letter upon her first admission, and she was enrolled to a group in accordance with the number written in the letter"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beuttenmuller-2010">
<DESCRIPTION>
<P>Not clear if allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bidmead-2002">
<DESCRIPTION>
<P>Not clear if adequate random allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 18:43:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-1998">
<DESCRIPTION>
<P>"within each stratum, randomization was performed with computer-generated random numbers using a block size of 6 to avoid inequity in group size"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burns-1993">
<DESCRIPTION>
<P>Not clear if adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x00f8_-1999">
<DESCRIPTION>
<P>Publication states "random". Contact with author confirms random number generation, and sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carneiro-2010">
<DESCRIPTION>
<P>Not clear if adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castro-2008">
<DESCRIPTION>
<P>"Once enrolled by a physician investigator, subjects were assigned to four distinct groups: pelvic floor exercises, electrical stimulation, vaginal cones, or untreated controls. The division of the four groups was undertaken by using computer-generated random numbers prepared by the Biostatistics Center of the Federal University of São Paulo" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Diokno-2010">
<DESCRIPTION>
<P>Adequate allocation concealment<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henalla-1989">
<DESCRIPTION>
<P>Not clear if adequate random allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henalla-1990">
<DESCRIPTION>
<P>Not clear if adequate random allocation concealment<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 21:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hofbauer-1990">
<DESCRIPTION>
<P>Translated from German, "random"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2007">
<DESCRIPTION>
<P>Unclear - what did they actually say, e.g. "random"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-10 15:27:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2011">
<DESCRIPTION>
<P>'The investigators were blind to the allocation of interventions.'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-05-10 15:00:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2011a">
<DESCRIPTION>
<P>'the randomisation procedure was blinded'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lagro_x002d_Janssen-1991">
<DESCRIPTION>
<P>"the patient were assigned consecutively to the treatment or control groups which were stratified on the basis of the severity of their incontinence"</P>
<P>Inadequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-07-21 21:46:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1998">
<DESCRIPTION>
<P>"randomly assigned in blocks of two"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-02 11:55:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pereira-2011">
<DESCRIPTION>
<P>''participants blindly drew one of the 49 preprinted cards in opaque sealed envelopes from a box''</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sar-2009">
<DESCRIPTION>
<P>Not clear if allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1999">
<DESCRIPTION>
<P>Not clear if adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yoon-2003">
<DESCRIPTION>
<P>"assigned randomly to the control and treatment groups by using random numbers". Not clear if adequate allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-05-20 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aksac-2003">
<DESCRIPTION>
<P>No information about study completion or (n) in the results or tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beuttenmuller-2010">
<DESCRIPTION>
<P>Not clear if there was attrition</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-23 11:07:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bidmead-2002">
<DESCRIPTION>
<P>Similar in each of the four groups at around 25%</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-1998">
<DESCRIPTION>
<P>Attrition rate per group and reasons given: not thought to be due to intervention except for one participant in the placebo drug groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-02 19:28:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burns-1993">
<DESCRIPTION>
<P>10/135 dropped out or withdrawn, 2 did not have bladder diary data so excluded from analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x00f8_-1999">
<DESCRIPTION>
<P>Attrition details:</P>
<P>3 could not complete the study (asthma, change of work, death in the family), 2 were excluded because they used other treatment during the trial. Dropout: 2 from PFMT ( 8%) (motivation, travel time) and 0 from control group (0%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carneiro-2010">
<DESCRIPTION>
<P>Attrition not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 11:53:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castro-2008">
<DESCRIPTION>
<P>Drop out (PFM =2, 2 lack of clinical improvement) (Control = 2, 2lack of improvement)</P>
<P>excluded (PFM =1 pregnancy) (Control =3 change in city)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-05-10 12:06:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diokno-2010">
<DESCRIPTION>
<P>Total attrition: One could not contract and did not get randomised, so 44/45 participated to randomisation</P>
<P>Group A: 0/23 (0%) </P>
<P>Group B: 3/21 (14% ) reason: had incomplete data </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henalla-1989">
<DESCRIPTION>
<P>No information about attrition</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henalla-1990">
<DESCRIPTION>
<P>No information about attrition</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hofbauer-1990">
<DESCRIPTION>
<P>No information about attrition</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2007">
<DESCRIPTION>
<P>"5 participants ( 2 = PFMT and 3 = control group) where not able to complete study because of hospitalisation = 1, asthma =1, knee pain =1, or fracture = 2." no information about who is in what group?</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2011">
<DESCRIPTION>
<P>Group A: PFMT intervention = 2/37 (5%)</P>
<P>Group B: Control intervention = 2/36 (6%)</P>
<P>reasons for not completing the study in all 4 cases not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2011a">
<DESCRIPTION>
<P>Total: 7/127 (6%)</P>
<P>Group A: PFMT intervention = 4/63 (6%) hip fracture (n = 1), moving (n=1), knee pain (n=1), spouse care (n=1)</P>
<P>Group B: Control intervention = 3/64 (5%)death (n=1) hospitalisation (n=1), decreased motivation (n=1)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lagro_x002d_Janssen-1991">
<DESCRIPTION>
<P>No dropout reported before 6 months (or end of study first phase which is of interest for us)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-02 11:55:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1998">
<DESCRIPTION>
<P>Evaluation, only one week after and report on all participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-02 19:28:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pereira-2011">
<DESCRIPTION>
<P>Total: 4/34 (8%)</P>
<P>Group intervention= 2/17 (12%)*</P>
<P>Individual intervention = 2/17 (12%)*</P>
<P>control intervention = 0/15 0%</P>
<P>* reasons: health problem or family (information not given per treatment group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sar-2009">
<DESCRIPTION>
<P>Total 7/41 (17%)</P>
<P>Group A = 2 (11%) drop out: non adherence to treatment regimen </P>
<P>Group B = 5 (23%) Excluded: used other treatment during the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1999">
<DESCRIPTION>
<P>Not clear if incomplete outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoon-2003">
<DESCRIPTION>
<P>Two women from the PFM group and 2 women from control withdrew due to family problem</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-05-20 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2013-05-20 15:43:16 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-28 13:07:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Aksac-2003">
<DESCRIPTION>
<P>Not clear if blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-02 19:28:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Beuttenmuller-2010">
<DESCRIPTION>
<P>Not clear if outcome assessment blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bidmead-2002">
<DESCRIPTION>
<P>Blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-1998">
<DESCRIPTION>
<P>Blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burns-1993">
<DESCRIPTION>
<P>Blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x00f8_-1999">
<DESCRIPTION>
<P>"physicians evaluating the effect of the treatment were also blind to allocation of treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-02 19:28:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carneiro-2010">
<DESCRIPTION>
<P>Not clear if outcome assessment blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castro-2008">
<DESCRIPTION>
<P>Blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Diokno-2010">
<DESCRIPTION>
<P>Vaginal examinations to test PFM strength and collection of bladder diary and 24h pad test were performed by tow nurses other than the lecturers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henalla-1989">
<DESCRIPTION>
<P>Not clear if blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-28 13:07:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henalla-1990">
<DESCRIPTION>
<P>Not clear if blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hofbauer-1990">
<DESCRIPTION>
<P>
<BR/>Not clear if blinded outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2007">
<DESCRIPTION>
<P>Not clear if blinded outcome assessment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kim-2011">
<DESCRIPTION>
<P>Not clear if blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-05-13 11:36:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2011a">
<DESCRIPTION>
<P>'the investigators that evaluated the effects of the exercise treatment were blind to the allocation of interventions'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lagro_x002d_Janssen-1991">
<DESCRIPTION>
<P>Blinded outcome assesment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1998">
<DESCRIPTION>
<P>Blinding of outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pereira-2011">
<DESCRIPTION>
<P>Evaluator was not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sar-2009">
<DESCRIPTION>
<P>'this trial was not blinded'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1999">
<DESCRIPTION>
<P>Outcome assessment not blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoon-2003">
<DESCRIPTION>
<P>Blinded outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Baseline comparability</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Aksac-2003">
<DESCRIPTION>
<P>Baseline comparable for age, weight, parity, abortions, maximum birth weight, UI type</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Beuttenmuller-2010">
<DESCRIPTION>
<P>Groups comparable at baseline for age and BMI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bidmead-2002">
<DESCRIPTION>
<P>Groups comparable at baseline for age, severity, severity of GSI on urodynamics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-1998">
<DESCRIPTION>
<P>"Before treatment the groups were comparable on all key parameters except that subject in behavioral treatment had more children, were less likely to have a high school education and more likely to have a rectocele"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 19:28:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burns-1993">
<DESCRIPTION>
<P>Table 1 socio-demographic comparable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-B_x00f8_-1999">
<DESCRIPTION>
<P>Table 1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carneiro-2010">
<DESCRIPTION>
<P>'Groups comparable for age, vaginal delivery, caesarian delivery and time with UI'</P>
<P>'Time with UI was almost significantly different between the two group with the Group A having had UI for a longer time'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Castro-2008">
<DESCRIPTION>
<P>"there were no significant difference between the groups in any of demographics, clinical characteristics or outcome measurements" table 1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Diokno-2010">
<DESCRIPTION>
<P>'The only demographic statistically significant difference between the two groups was in age.' Those in the treatment group were older</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Henalla-1989">
<DESCRIPTION>
<P>"the groups were comparable regarding age weight and parity"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Henalla-1990">
<DESCRIPTION>
<P>Not clear groups comparable at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hofbauer-1990">
<DESCRIPTION>
<P>Not clear groups comparable at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2007">
<DESCRIPTION>
<P>Table 1</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2011">
<DESCRIPTION>
<P>Groups comparable at baseline for anthropometric values, physical fitness, measures and interview survey</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kim-2011a">
<DESCRIPTION>
<P>'Most of the baseline characteristics were similar between the groups'. All those presented in table 1 were similar between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lagro_x002d_Janssen-1991">
<DESCRIPTION>
<P>table 1 "no significant difference were found"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Miller-1998">
<DESCRIPTION>
<P>Groups comparable at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pereira-2011">
<DESCRIPTION>
<P>Group similar at baseline for demographics and clinic characteristics</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-28 13:07:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sar-2009">
<DESCRIPTION>
<P>No significant differences at baseline for age, body mass index, parity, cystocele, rectocele duration of symptoms, menopause status, PFM strength, episode of leakage, 1h pad tests, I-QOL scores</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wells-1999">
<DESCRIPTION>
<P>Not clear if groups were comparable at baseline</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-16 22:09:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yoon-2003">
<DESCRIPTION>
<P>"no baseline difference"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-05-06 11:12:49 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-04-28 13:07:42 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2013-05-23 16:03:35 +0100" MODIFIED_BY="Grade Profiler">PFMT versus no treatment, placebo or control for urinary incontinence in women (SUI)</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>PFMT versus no treatment, placebo or control for urinary incontinence in women</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with urinary incontinence in women<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> PFMT versus no treatment, placebo or control<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>PFMT versus no treatment, placebo or control</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Participant perceived cure - stress urinary incontinence</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 8.38 </B>
<BR/>(3.68 to 19.07)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>165<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>60 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>505 per 1000</B>
<BR/>(222 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>62 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>520 per 1000</B>
<BR/>(228 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Participant perceived cure or improvement after treatment - stress urinary incontinence</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 17 </B>
<BR/>(4.25 to 67.95)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>121<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>32 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>540 per 1000</B>
<BR/>(135 to 1000)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>32 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>544 per 1000</B>
<BR/>(136 to 1000)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life (King's Health Questionnaire/Incontinence impact after treatment) - stress urinary incontinence</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean quality of life (King's health questionnaire/incontinence impact after treatment) - stress urinary incontinence in the intervention groups was<BR/>
<B>11.76 lower</B>
<BR/>(20.83 to 2.69 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>145<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of leakage episodes in 24 hours - stress urinary incontinence</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean number of leakage episodes in 24 hours - stress urinary incontinence in the intervention groups was<BR/>
<B>1.21 lower</B>
<BR/>(1.52 to 0.89 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>253<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Short (up to one hour) pad test measured as grams of urine - stress urinary incontinence</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean short (up to one hour) pad test measured as grams of urine - stress urinary incontinence in the intervention groups was<BR/>
<B>13.22 lower</B>
<BR/>(26.36 to 0.09 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>150<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Treatment adherence</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Formal economic analysis </B>- not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Not applicable. Fewer than 10 trials.<BR/>
<SUP>2</SUP> Random sequence generation and allocation concealment judge to be high risk in1/2 trials (Lagro-Janssen 1991).<BR/>
<SUP>3</SUP> Random sequence generation and allocation concealment is unclear in all trials taking part in meta-analysis.<BR/>
<SUP>4</SUP> Results are inconsistent.<BR/>
<SUP>5</SUP> Random sequence generation and allocation concealment judge to be high risk in1 trial (Lagro-Janssen 1991).<BR/>
<SUP>6</SUP> Random sequence generation and allocation concealment is unclear in 1/3 trials (Periera 2011).</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-05-06 11:12:49 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2014-05-06 11:12:49 +0100" MODIFIED_BY="[Empty name]">PFMT versus no treatment, placebo or control for urinary incontinence in women (all types)</TITLE>
<TABLE COLS="7" ROWS="9">
<TR>
<TD COLSPAN="7">
<P>
<B>PFMT versus no treatment, placebo or control for urinary incontinence in women</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with urinary incontinence in women<BR/>
<B>Settings:</B>
<BR/>
<B>Intervention:</B> PFMT versus no treatment, placebo or control<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>PFMT versus no treatment, placebo or control</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Participant perceived cure - urinary incontinence (all types)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 5.5 </B>
<BR/>(2.87 to 10.52)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>301<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>57 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>315 per 1000</B>
<BR/>(165 to 603)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>16 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>88 per 1000</B>
<BR/>(46 to 168)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Participant perceived cure or improvement after treatment - urinary incontinence (all types)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 2.35 </B>
<BR/>(1.62 to 3.39)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>166<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>288 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>676 per 1000</B>
<BR/>(466 to 975)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>245 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>576 per 1000</B>
<BR/>(397 to 831)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life (King's Health Questionnaire/Incontinence impact after treatment) - urinary Incontinence (all types)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of leakage episodes in 24 hours - urinary incontinence (all types)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean number of leakage episodes in 24 hours - urinary incontinence (all types) in the intervention groups was<BR/>
<B>0.8 lower</B>
<BR/>(1.26 to 0.34 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>125<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Short (up to one hour) pad test measured as grams of urine - urinary incontinence (all types)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean short (up to one hour) pad test measured as grams of urine - urinary incontinence (all types) in the intervention groups was<BR/>
<B>5.1 lower</B>
<BR/>(11.16 lower to 0.96 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>25<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,5,6,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Treatment adherence</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Formal economic analysis </B>- not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Allocation concealment is unclear in Burgio 1998 which is the biggest trial.<BR/>
<SUP>2</SUP> Not applicable. Fewer than 10 trials.<BR/>
<SUP>3</SUP> Allocation concealment is unclear in both the trials.<BR/>
<SUP>4</SUP> Allocation concealment is unclear in Burgio1998.<BR/>
<SUP>5</SUP> Not applicable as there is only one trial.<BR/>
<SUP>6</SUP> Random sequence generation and allocation concealment judge to be unclear in1 trial which reported this outcome.<BR/>
<SUP>7</SUP> Results are imprecise.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-08-30 10:14:55 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-05-11 23:02:02 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2014-05-11 23:02:02 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>PFMT versus no treatment, placebo or control</NAME>
<DICH_OUTCOME CHI2="10.521123710496976" CI_END="10.753562390713151" CI_START="3.877384661167591" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="6.457220599194352" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="14" I2="42.971871017790896" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.0315523591668152" LOG_CI_START="0.5885388879135021" LOG_EFFECT_SIZE="0.8100456235401587" METHOD="MH" MODIFIED="2014-05-11 23:02:02 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.10435308350671957" P_Q="0.4003047825384993" P_Z="7.635267987842787E-13" Q="0.7074119464310086" RANDOM="NO" SCALE="1000.0" SORT_BY="EFFECT_SIZE" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="226" TOTAL_2="229" WEIGHT="200.0" Z="7.1675483974851195">
<NAME>Participant perceived cure</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PFMT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.1398245087673629" CI_END="19.07456847577948" CI_START="3.6801383254455042" DF="3" EFFECT_SIZE="8.378368008690636" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="5" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="1.2804547216881166" LOG_CI_START="0.5658641428171791" LOG_EFFECT_SIZE="0.9231594322526478" MODIFIED="2014-04-02 14:11:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.767470056886663" P_Z="4.104538079881925E-7" STUDIES="4" TAU2="0.0" TOTAL_1="82" TOTAL_2="83" WEIGHT="100.0" Z="5.064044482821046">
<NAME>stress urinary incontinence</NAME>
<DICH_DATA CI_END="17.856138667626514" CI_START="1.8957760297188078" EFFECT_SIZE="5.818181818181818" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="3" LOG_CI_END="1.2517875499250013" LOG_CI_START="0.2777870277263229" LOG_EFFECT_SIZE="0.7647872888256622" MODIFIED="2013-05-23 10:24:50 +0100" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.5721327281198468" STUDY_ID="STD-Kim-2007" TOTAL_1="33" TOTAL_2="32" VAR="0.32733585858585856" WEIGHT="54.78381405539004"/>
<DICH_DATA CI_END="41.02535208661806" CI_START="0.8551502534972751" EFFECT_SIZE="5.923076923076923" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.613052316930962" LOG_CI_START="-0.06795757119967175" LOG_EFFECT_SIZE="0.7725473728656451" MODIFIED="2013-05-14 13:21:19 +0100" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.9874335294210821" STUDY_ID="STD-Kim-2011" TOTAL_1="13" TOTAL_2="11" VAR="0.975024975024975" WEIGHT="19.483300874076004"/>
<DICH_DATA CI_END="213.652737863238" CI_START="0.884905580386344" EFFECT_SIZE="13.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.329708462476304" LOG_CI_START="-0.05310306614374119" LOG_EFFECT_SIZE="1.1383026981662814" MODIFIED="2013-05-21 11:38:28 +0100" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="1.3996752870187104" STUDY_ID="STD-Hofbauer-1990" TOTAL_1="11" TOTAL_2="10" VAR="1.959090909090909" WEIGHT="9.383261959421219"/>
<DICH_DATA CI_END="119.04187820152758" CI_START="2.370930333627568" EFFECT_SIZE="16.8" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="1" LOG_CI_END="2.07569977040379" LOG_CI_START="0.3749187930479362" LOG_EFFECT_SIZE="1.2253092817258628" MODIFIED="2009-05-01 16:47:01 +0100" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.9990471651004461" STUDY_ID="STD-B_x00f8_-1999" TOTAL_1="25" TOTAL_2="30" VAR="0.998095238095238" WEIGHT="16.34962311111273"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-15 11:50:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-14 17:33:49 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.5617059612725335" CI_END="10.263033799334632" CI_START="2.7754661637507594" DF="2" EFFECT_SIZE="5.337106242851427" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="9" I2="73.55094194031017" ID="CMP-001.01.04" LOG_CI_END="1.0112757591727122" LOG_CI_START="0.44333593713143293" LOG_EFFECT_SIZE="0.7273058481520726" MODIFIED="2014-05-11 23:00:53 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.02280325414034201" P_Z="5.17052934468923E-7" STUDIES="3" TAU2="0.0" TOTAL_1="144" TOTAL_2="146" WEIGHT="100.00000000000001" Z="5.019874334572763">
<NAME>urinary incontinence (all types)</NAME>
<DICH_DATA CI_END="4.937936474013963" CI_START="1.106328268650601" EFFECT_SIZE="2.3373015873015874" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.6935454984831841" LOG_CI_START="0.04388400952793104" LOG_EFFECT_SIZE="0.3687147540055576" MODIFIED="2013-05-14 15:10:21 +0100" MODIFIED_BY="[Empty name]" ORDER="146" O_E="0.0" SE="0.381614374488551" STUDY_ID="STD-Burgio-1998" TOTAL_1="63" TOTAL_2="62" VAR="0.14562953081628804" WEIGHT="84.55759537255871"/>
<DICH_DATA CI_END="196.06807661054194" CI_START="0.6719628960888592" EFFECT_SIZE="11.478260869565217" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.292406888514852" LOG_CI_START="-0.1726547068103756" LOG_EFFECT_SIZE="1.0598760908522382" MODIFIED="2014-05-11 23:00:53 +0100" MODIFIED_BY="[Empty name]" ORDER="59" O_E="0.0" SE="1.4479893833457307" STUDY_ID="STD-Kim-2011" TOTAL_1="22" TOTAL_2="23" VAR="2.0966732542819497" WEIGHT="5.13135525785432"/>
<DICH_DATA CI_END="191.79114849022972" CI_START="3.767678031244582" EFFECT_SIZE="26.88135593220339" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="1" LOG_CI_END="2.2828285598181908" LOG_CI_START="0.5760737828606908" LOG_EFFECT_SIZE="1.4294511713394409" MODIFIED="2014-05-11 21:54:39 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="1.0025562045572383" STUDY_ID="STD-Kim-2011a" TOTAL_1="59" TOTAL_2="61" VAR="1.0051189432962149" WEIGHT="10.311049369586977"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.914886727022015" CI_END="5.065664925316865" CI_START="2.431144625173171" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5093252992722617" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="25" I2="69.74246824400116" I2_Q="86.26684853556463" ID="CMP-001.02" LOG_CI_END="0.7046364594579557" LOG_CI_START="0.3858107951437806" LOG_EFFECT_SIZE="0.5452236273008682" METHOD="MH" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.019303692300733366" P_Q="0.006966280586187534" P_Z="2.035315601583236E-11" Q="7.281649828079826" RANDOM="NO" SCALE="175.12" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="144" TOTAL_2="143" WEIGHT="200.0" Z="6.703467083358506">
<NAME>Participant perceived cure or improvement after treatment</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PFMT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.05473138407162935" CI_END="69.64241026237023" CI_START="4.314101756566909" DF="1" EFFECT_SIZE="17.333333333333336" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="2" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="1.8428737932542159" LOG_CI_START="0.6348903845760581" LOG_EFFECT_SIZE="1.2388820889151368" MODIFIED="2014-04-02 13:22:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8150258190865602" P_Z="5.815005212160648E-5" STUDIES="2" TAU2="0.0" TOTAL_1="58" TOTAL_2="63" WEIGHT="100.0" Z="4.020194744267969">
<NAME>stress urinary incontinence</NAME>
<DICH_DATA CI_END="103.23083872185154" CI_START="2.0087020755369176" EFFECT_SIZE="14.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="1" LOG_CI_END="2.0138094558767956" LOG_CI_START="0.3029155283137036" LOG_EFFECT_SIZE="1.1583624920952498" MODIFIED="2009-05-19 19:03:06 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="1.004987562112089" STUDY_ID="STD-B_x00f8_-1999" TOTAL_1="25" TOTAL_2="30" VAR="1.0099999999999998" WEIGHT="47.61904761904761"/>
<DICH_DATA CI_END="140.50945802142732" CI_START="2.846783452392229" EFFECT_SIZE="20.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" LOG_CI_END="2.1477055586059923" LOG_CI_START="0.45435443272197" LOG_EFFECT_SIZE="1.3010299956639813" MODIFIED="2013-05-23 10:35:10 +0100" MODIFIED_BY="[Empty name]" ORDER="44" O_E="0.0" SE="0.9946828335675345" STUDY_ID="STD-Lagro_x002d_Janssen-1991" TOTAL_1="33" TOTAL_2="33" VAR="0.9893939393939395" WEIGHT="52.38095238095238"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 13:22:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.02.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 13:22:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.30269051670160607" CI_END="3.4663736408862795" CI_START="1.6444505417792958" DF="1" EFFECT_SIZE="2.3875259185535374" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="23" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.5398753735623322" LOG_CI_START="0.21602081624656086" LOG_EFFECT_SIZE="0.37794809490444653" MODIFIED="2014-04-02 13:22:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5822006986604742" P_Z="4.7696006797253224E-6" STUDIES="2" TAU2="0.0" TOTAL_1="86" TOTAL_2="80" WEIGHT="99.99999999999999" Z="4.574674879847165">
<NAME>urinary incontinence (all types)</NAME>
<DICH_DATA CI_END="3.3454833471285292" CI_START="1.5314368029627277" EFFECT_SIZE="2.2634920634920634" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="20" LOG_CI_END="0.5244588724255266" LOG_CI_START="0.18509907969900352" LOG_EFFECT_SIZE="0.35477897606226505" MODIFIED="2013-05-20 21:42:10 +0100" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="0.19934162210562606" STUDY_ID="STD-Burgio-1998" TOTAL_1="63" TOTAL_2="62" VAR="0.03973708230370222" WEIGHT="85.69295844737496"/>
<DICH_DATA CI_END="9.44784381972989" CI_START="1.0372336921681373" EFFECT_SIZE="3.130434782608696" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.9753327054363099" LOG_CI_START="0.01587661539104124" LOG_EFFECT_SIZE="0.4956046604136756" MODIFIED="2013-05-15 12:36:05 +0100" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.5635892566768337" STUDY_ID="STD-Diokno-2010" TOTAL_1="23" TOTAL_2="18" VAR="0.31763285024154586" WEIGHT="14.307041552625028"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.902670171532042" CI_END="-5.183630432617053" CI_START="-21.096177500057763" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-13.139903966337409" ESTIMABLE="YES" I2="48.75303543228007" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.1420844076539013" P_Q="1.0" P_Z="0.001208316636950262" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="80" TOTAL_2="65" UNITS="" WEIGHT="100.0" Z="3.236909644343748">
<NAME>Quality of life (King's Health Questionnaire/Severity measure after treatment)</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.902670171532042" CI_END="-5.183630432617053" CI_START="-21.096177500057763" DF="2" EFFECT_SIZE="-13.139903966337409" ESTIMABLE="YES" I2="48.75303543228007" ID="CMP-001.03.01" MODIFIED="2013-05-21 09:34:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1420844076539013" P_Z="0.001208316636950262" STUDIES="3" TAU2="0.0" TOTAL_1="80" TOTAL_2="65" WEIGHT="100.0" Z="3.236909644343748">
<NAME>Stress Urinary incontinence</NAME>
<CONT_DATA CI_END="5.750134955536758" CI_START="-20.650134955536757" EFFECT_SIZE="-7.449999999999999" ESTIMABLE="YES" MEAN_1="28.52" MEAN_2="35.97" MODIFIED="2013-05-15 13:36:42 +0100" MODIFIED_BY="[Empty name]" ORDER="90" SD_1="24.07" SD_2="23.55" SE="6.734886487536372" STUDY_ID="STD-Beuttenmuller-2010" TOTAL_1="25" TOTAL_2="25" WEIGHT="36.329771677082924"/>
<CONT_DATA CI_END="6.111102909075969" CI_START="-22.011102909075966" EFFECT_SIZE="-7.949999999999999" ESTIMABLE="YES" MEAN_1="26.66" MEAN_2="34.61" MODIFIED="2013-05-15 12:14:33 +0100" MODIFIED_BY="[Empty name]" ORDER="92" SD_1="26.74" SD_2="23.91" SE="7.174163923412957" STUDY_ID="STD-Carneiro-2010" TOTAL_1="25" TOTAL_2="25" WEIGHT="32.01700012773247"/>
<CONT_DATA CI_END="-10.77832991510125" CI_START="-39.06167008489875" EFFECT_SIZE="-24.919999999999998" ESTIMABLE="YES" MEAN_1="20.88" MEAN_2="45.8" MODIFIED="2013-05-21 09:34:40 +0100" MODIFIED_BY="[Empty name]" ORDER="87" SD_1="22.26" SD_2="23.09" SE="7.215270380704155" STUDY_ID="STD-Pereira-2011" TOTAL_1="30" TOTAL_2="15" WEIGHT="31.653228195184596"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.02" MODIFIED="2013-05-14 14:21:06 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urge urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.03" MODIFIED="2013-05-14 14:21:06 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mixed urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.03.04" MODIFIED="2013-05-20 14:39:33 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urinary Incontinence (all types)</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.410155500568811" CI_END="-2.6899164228298034" CI_START="-20.831709258053873" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.760812840441838" ESTIMABLE="YES" I2="76.21922686370387" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.014919648873492952" P_Q="1.0" P_Z="0.011047940789509022" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="80" TOTAL_2="65" UNITS="" WEIGHT="100.00000000000001" Z="2.5411787914838153">
<NAME>Quality of life (King's Health Questionnaire/Incontinence impact after treatment)</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.410155500568811" CI_END="-2.6899164228298034" CI_START="-20.831709258053873" DF="2" EFFECT_SIZE="-11.760812840441838" ESTIMABLE="YES" I2="76.21922686370387" ID="CMP-001.04.01" MODIFIED="2013-05-21 09:34:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.014919648873492952" P_Z="0.011047940789509022" STUDIES="3" TAU2="0.0" TOTAL_1="80" TOTAL_2="65" WEIGHT="100.00000000000001" Z="2.5411787914838153">
<NAME>Stress Urinary incontinence</NAME>
<CONT_DATA CI_END="9.331546925168979" CI_START="-18.931546925168988" EFFECT_SIZE="-4.800000000000004" ESTIMABLE="YES" MEAN_1="48.97" MEAN_2="53.77" MODIFIED="2013-05-15 13:37:51 +0100" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="26.82" SD_2="24.09" SE="7.210105408383431" STUDY_ID="STD-Beuttenmuller-2010" TOTAL_1="25" TOTAL_2="25" WEIGHT="41.202256877219774"/>
<CONT_DATA CI_END="13.014176867945741" CI_START="-18.514176867945743" EFFECT_SIZE="-2.75" ESTIMABLE="YES" MEAN_1="52.66" MEAN_2="55.41" MODIFIED="2013-05-15 12:18:03 +0100" MODIFIED_BY="[Empty name]" ORDER="93" SD_1="28.74" SD_2="28.13" SE="8.04309517536626" STUDY_ID="STD-Carneiro-2010" TOTAL_1="25" TOTAL_2="25" WEIGHT="33.10989608138725"/>
<CONT_DATA CI_END="-16.642747949230806" CI_START="-52.4372520507692" EFFECT_SIZE="-34.540000000000006" ESTIMABLE="YES" MEAN_1="23.3" MEAN_2="57.84" MODIFIED="2013-05-21 09:34:56 +0100" MODIFIED_BY="[Empty name]" ORDER="88" SD_1="27.65" SD_2="29.47" SE="9.131418838274804" STUDY_ID="STD-Pereira-2011" TOTAL_1="30" TOTAL_2="15" WEIGHT="25.68784704139299"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.02" MODIFIED="2013-05-14 14:20:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urge urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.03" MODIFIED="2013-05-14 14:20:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mixed urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.04" MODIFIED="2013-05-20 14:40:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urinary Incontinence (all types)</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.6167463141688267" CI_END="-3.227341458708917" CI_START="-20.55207902584606" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-11.889710242277488" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.4455825662014361" P_Q="1.0" P_Z="0.007141169444251319" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="80" TOTAL_2="65" UNITS="" WEIGHT="100.0" Z="2.690188381922104">
<NAME>Quality of life (King's Health Questionnaire/Physical limitation)</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.6167463141688267" CI_END="-3.227341458708917" CI_START="-20.55207902584606" DF="2" EFFECT_SIZE="-11.889710242277488" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" MODIFIED="2013-05-21 09:35:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4455825662014361" P_Z="0.007141169444251319" STUDIES="3" TAU2="0.0" TOTAL_1="80" TOTAL_2="65" WEIGHT="100.0" Z="2.690188381922104">
<NAME>Stress Urinary incontinence</NAME>
<CONT_DATA CI_END="2.98222461693166" CI_START="-22.422224616931665" EFFECT_SIZE="-9.720000000000002" ESTIMABLE="YES" MEAN_1="21.31" MEAN_2="31.03" MODIFIED="2013-05-20 21:50:50 +0100" MODIFIED_BY="[Empty name]" ORDER="92" SD_1="19.54" SD_2="25.85" SE="6.480845932438141" STUDY_ID="STD-Beuttenmuller-2010" TOTAL_1="25" TOTAL_2="25" WEIGHT="46.506511259959126"/>
<CONT_DATA CI_END="7.108369565927314" CI_START="-23.208369565927313" EFFECT_SIZE="-8.05" ESTIMABLE="YES" MEAN_1="21.11" MEAN_2="29.16" MODIFIED="2013-05-15 12:19:59 +0100" MODIFIED_BY="[Empty name]" ORDER="94" SD_1="26.64" SD_2="28.03" SE="7.7340041375732405" STUDY_ID="STD-Carneiro-2010" TOTAL_1="25" TOTAL_2="25" WEIGHT="32.656403677209795"/>
<CONT_DATA CI_END="-3.7734094671517084" CI_START="-41.72659053284829" EFFECT_SIZE="-22.75" ESTIMABLE="YES" MEAN_1="7.21" MEAN_2="29.96" MODIFIED="2013-05-21 09:35:14 +0100" MODIFIED_BY="[Empty name]" ORDER="89" SD_1="9.97" SD_2="36.83" SE="9.682111856408186" STUDY_ID="STD-Pereira-2011" TOTAL_1="30" TOTAL_2="15" WEIGHT="20.837085062831083"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.02" MODIFIED="2013-05-14 14:21:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urge urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.03" MODIFIED="2013-05-14 14:21:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mixed urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.04" MODIFIED="2013-05-20 14:41:42 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urinary Incontinence (all types)</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.854681504646981" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Number of women with interference with life due to UI</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PFMT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="17" EVENTS_2="25" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 13:23:12 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>stress urinary incontinence</NAME>
<DICH_DATA CI_END="1.115809392512823" CI_START="0.5967470828512028" EFFECT_SIZE="0.816" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" LOG_CI_END="0.047590012836424084" LOG_CI_START="-0.22420969532870189" LOG_EFFECT_SIZE="-0.08830984124613889" MODIFIED="2013-05-22 10:07:46 +0100" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="0.15965649400644924" STUDY_ID="STD-B_x00f8_-1999" TOTAL_1="25" TOTAL_2="30" VAR="0.025490196078431365" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-22 10:01:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.06.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-22 10:01:37 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.06.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-22 10:01:37 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urinary incontinence (all types)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="61.47" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="43" TOTAL_2="41" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>I-QOL</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.01" MODIFIED="2013-05-21 10:38:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Stress urinary incontinence</NAME>
<CONT_DATA CI_END="-11.44502803424557" CI_START="-37.754971965754436" EFFECT_SIZE="-24.6" ESTIMABLE="YES" MEAN_1="-82.2" MEAN_2="-57.6" MODIFIED="2013-05-21 10:38:00 +0100" MODIFIED_BY="[Empty name]" ORDER="93" SD_1="17.6" SD_2="28.2" SE="6.711843722394478" STUDY_ID="STD-Castro-2008" TOTAL_1="26" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.02" MODIFIED="2013-05-15 13:57:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urge urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.03" MODIFIED="2013-05-15 13:57:53 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mixed urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.07.04" MODIFIED="2013-05-22 09:40:36 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Urinary incontinence (all types)</NAME>
<CONT_DATA CI_END="-22.735103831447283" CI_START="-35.124896168552716" EFFECT_SIZE="-28.93" ESTIMABLE="YES" MEAN_1="-23.19" MEAN_2="5.74" MODIFIED="2013-05-22 09:40:36 +0100" MODIFIED_BY="[Empty name]" ORDER="84" SD_1="11.43" SD_2="6.26" SE="3.160719389446575" STUDY_ID="STD-Sar-2009" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.5754616281133265" CI_END="7.02747817706834" CI_START="-3.402925297729957" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.8122764396691917" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.45487598167850085" P_Q="1.0" P_Z="0.4958176060317234" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="80" TOTAL_2="65" UNITS="" WEIGHT="100.0" Z="0.6810851680597678">
<NAME>Quality of life (King's Health Questionnaire/General health score)</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.5754616281133265" CI_END="7.02747817706834" CI_START="-3.402925297729957" DF="2" EFFECT_SIZE="1.8122764396691917" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" MODIFIED="2013-05-21 09:33:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.45487598167850085" P_Z="0.4958176060317234" STUDIES="3" TAU2="0.0" TOTAL_1="80" TOTAL_2="65" WEIGHT="100.0" Z="0.6810851680597678">
<NAME>Stress Urinary incontinence</NAME>
<CONT_DATA CI_END="9.679545452414793" CI_START="-7.8395454524147965" EFFECT_SIZE="0.9199999999999982" ESTIMABLE="YES" MEAN_1="29.33" MEAN_2="28.41" MODIFIED="2013-05-15 13:35:09 +0100" MODIFIED_BY="[Empty name]" ORDER="89" SD_1="15.61" SD_2="15.99" SE="4.469237966365184" STUDY_ID="STD-Beuttenmuller-2010" TOTAL_1="25" TOTAL_2="25" WEIGHT="35.44696728766819"/>
<CONT_DATA CI_END="13.261538771445098" CI_START="-2.761538771445098" EFFECT_SIZE="5.25" ESTIMABLE="YES" MEAN_1="34.0" MEAN_2="28.75" MODIFIED="2013-05-15 12:13:05 +0100" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="14.22" SD_2="14.68" SE="4.087594891864898" STUDY_ID="STD-Carneiro-2010" TOTAL_1="25" TOTAL_2="25" WEIGHT="42.37506212055121"/>
<CONT_DATA CI_END="7.74414513792545" CI_START="-14.404145137925447" EFFECT_SIZE="-3.3299999999999983" ESTIMABLE="YES" MEAN_1="30.0" MEAN_2="33.33" MODIFIED="2013-05-21 09:33:19 +0100" MODIFIED_BY="[Empty name]" ORDER="86" SD_1="15.55" SD_2="18.92" SE="5.6501778733062915" STUDY_ID="STD-Pereira-2011" TOTAL_1="30" TOTAL_2="15" WEIGHT="22.1779705917806"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.02" MODIFIED="2013-05-15 13:53:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urge urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.03" MODIFIED="2013-05-14 14:19:43 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mixed urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.08.04" MODIFIED="2013-05-21 09:31:46 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urinary Incontinence (all types)</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="59" TOTAL_2="61" WEIGHT="0.0" Z="0.0">
<NAME>Cure at up to one year</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PFMT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 13:23:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>stress urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 13:24:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 13:24:55 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="23" EVENTS_2="1" I2="0.0" ID="CMP-001.09.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 13:25:07 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="61" WEIGHT="0.0" Z="0.0">
<NAME>urinary incontinence (all types)</NAME>
<DICH_DATA CI_END="170.49438242841998" CI_START="3.3166622267945844" EFFECT_SIZE="23.779661016949152" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" LOG_CI_END="2.2317100741171934" LOG_CI_START="0.520701244655238" LOG_EFFECT_SIZE="1.3762056593862158" MODIFIED="2013-05-22 12:54:56 +0100" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="1.0050550560562548" STUDY_ID="STD-Kim-2011a" TOTAL_1="59" TOTAL_2="61" VAR="1.0101356657042415" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="860.62" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Cure or improvement at up to one year</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PFMT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="0" I2="0.0" ID="CMP-001.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 13:25:41 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>stress urinary incontinence</NAME>
<DICH_DATA CI_END="444.4476843242169" CI_START="1.7546662213035846" EFFECT_SIZE="27.925925925925927" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.6478206477663897" LOG_CI_START="0.2441945156551841" LOG_EFFECT_SIZE="1.4460075817107867" MODIFIED="2013-05-22 12:46:53 +0100" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="1.4119018881433667" STUDY_ID="STD-Henalla-1989" TOTAL_1="26" TOTAL_2="25" VAR="1.9934669417428037" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.10.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 13:25:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 13:26:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 13:26:13 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urinary incontinence (all types)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.8569117325513105" CI_END="5.290293752098824" CI_START="2.423734642101172" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="3.5808194919394234" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="21" I2="58.82156995780093" I2_Q="56.37315027167129" ID="CMP-001.11" LOG_CI_END="0.7234797876067547" LOG_CI_START="0.38448507020564937" LOG_EFFECT_SIZE="0.5539824289062021" METHOD="MH" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.08817292604125682" P_Q="0.13002844115193357" P_Z="1.4947059338250556E-10" Q="2.292166420970476" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="109" TOTAL_2="104" WEIGHT="200.0" Z="6.405914623380127">
<NAME>Patient perceived satisfaction</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PFMT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.8502144207424034" CI_END="10.741547892530814" CI_START="2.630953875885222" DF="1" EFFECT_SIZE="5.3160621761658025" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="7" I2="74.02742053500546" ID="CMP-001.11.01" LOG_CI_END="1.0310668691425218" LOG_CI_START="0.4201132343935256" LOG_EFFECT_SIZE="0.7255900517680236" MODIFIED="2014-04-02 13:26:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04973968188541189" P_Z="3.2328248658504042E-6" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="54" WEIGHT="99.99999999999999" Z="4.655444498959882">
<NAME>stress urinary incontinence</NAME>
<DICH_DATA CI_END="48.593643954407426" CI_START="3.267093946462529" EFFECT_SIZE="12.6" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="2" LOG_CI_END="1.6865794672859664" LOG_CI_START="0.5141616229491593" LOG_EFFECT_SIZE="1.100370545117563" MODIFIED="2013-05-16 11:27:20 +0100" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.6886840453253685" STUDY_ID="STD-B_x00f8_-1999" TOTAL_1="25" TOTAL_2="30" VAR="0.4742857142857143" WEIGHT="25.906735751295333"/>
<DICH_DATA CI_END="6.4564521107234905" CI_START="1.1877481504923781" EFFECT_SIZE="2.769230769230769" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8099939340928275" LOG_CI_START="0.0747243628280734" LOG_EFFECT_SIZE="0.4423591484604505" MODIFIED="2013-05-16 11:27:30 +0100" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.43190098580399366" STUDY_ID="STD-Castro-2008" TOTAL_1="26" TOTAL_2="24" VAR="0.18653846153846154" WEIGHT="74.09326424870466"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.11.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-16 09:38:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.11.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-16 09:38:33 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.413595476211866" CI_START="1.739644273943998" DF="0" EFFECT_SIZE="2.770935960591133" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="14" I2="0.0" ID="CMP-001.11.04" LOG_CI_END="0.644792525812555" LOG_CI_START="0.24046045192781945" LOG_EFFECT_SIZE="0.4426264888701872" MODIFIED="2013-05-22 11:23:38 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="1.7772173170910512E-5" STUDIES="1" TAU2="0.0" TOTAL_1="58" TOTAL_2="50" WEIGHT="100.0" Z="4.291185551786311">
<NAME>urinary incontinence (all types)</NAME>
<DICH_DATA CI_END="4.413595476211866" CI_START="1.739644273943998" EFFECT_SIZE="2.770935960591133" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="14" LOG_CI_END="0.644792525812555" LOG_CI_START="0.24046045192781945" LOG_EFFECT_SIZE="0.4426264888701872" MODIFIED="2013-05-22 11:23:38 +0100" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.2375066616759387" STUDY_ID="STD-Burgio-1998" TOTAL_1="58" TOTAL_2="50" VAR="0.05640941434044881" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.02012418800787855" CI_END="0.30773392500193786" CI_START="0.10556210918818237" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.18023607350350956" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-0.51182462390531" LOG_CI_START="-0.9764919409260533" LOG_EFFECT_SIZE="-0.7441582824156816" METHOD="MH" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.8871907981184871" P_Q="0.8874288573317283" P_Z="3.4359505554346167E-10" Q="0.02003877315116991" RANDOM="NO" SCALE="175.12" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="79" WEIGHT="200.0" Z="6.27771043456802">
<NAME>Number of women needing further treatment</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.4230169820326551" CI_START="0.0694718092896143" DF="0" EFFECT_SIZE="0.17142857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="28" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="-0.373642197506677" LOG_CI_START="-1.158191390426587" LOG_EFFECT_SIZE="-0.765916793966632" MODIFIED="2014-04-02 13:26:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.298025657604692E-4" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="30" WEIGHT="100.0" Z="3.826832899392784">
<NAME>stress urinary incontinence</NAME>
<DICH_DATA CI_END="0.42301698203265503" CI_START="0.0694718092896143" EFFECT_SIZE="0.17142857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="28" LOG_CI_END="-0.37364219750667704" LOG_CI_START="-1.158191390426587" LOG_EFFECT_SIZE="-0.765916793966632" MODIFIED="2013-05-22 11:12:28 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.4608480795022937" STUDY_ID="STD-B_x00f8_-1999" TOTAL_1="25" TOTAL_2="30" VAR="0.21238095238095236" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-22 11:10:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.12.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-22 11:10:30 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.36033191927640384" CI_START="0.09587739807841741" DF="0" EFFECT_SIZE="0.1858700806069227" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="37" I2="0.0" ID="CMP-001.12.04" LOG_CI_END="-0.4432972650725313" LOG_CI_START="-1.018283760365527" LOG_EFFECT_SIZE="-0.7307905127190292" MODIFIED="2013-05-22 11:12:36 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="6.289454811432775E-7" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="49" WEIGHT="100.0" Z="4.982110351802225">
<NAME>urinary incontinence (all types)</NAME>
<DICH_DATA CI_END="0.36033191927640384" CI_START="0.09587739807841741" EFFECT_SIZE="0.1858700806069227" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="37" LOG_CI_END="-0.4432972650725313" LOG_CI_START="-1.018283760365527" LOG_EFFECT_SIZE="-0.7307905127190292" MODIFIED="2013-05-22 11:12:36 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.33774991356416084" STUDY_ID="STD-Burgio-1998" TOTAL_1="57" TOTAL_2="49" VAR="0.1140750041125981" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="22.32075977366853" CI_END="-0.8157662740101194" CI_START="-1.3344762000078392" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.0751212370089793" ESTIMABLE="YES" I2="82.07946306236967" I2_Q="51.27549080021405" ID="CMP-001.13" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="1.730046860772827E-4" P_Q="0.15197138747019912" P_Z="4.482189179813115E-16" Q="2.052355203619769" RANDOM="NO" SCALE="4.17" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="190" TOTAL_2="188" UNITS="" WEIGHT="200.0" Z="8.12476799821646">
<NAME>Number of leakage episodes in 24 hours</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="20.268404570048762" CI_END="-0.8907821688369373" CI_START="-1.5207073286640183" DF="3" EFFECT_SIZE="-1.2057447487504778" ESTIMABLE="YES" I2="85.19863766468728" ID="CMP-001.13.01" MODIFIED="2013-05-20 22:07:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.493314569347426E-4" P_Z="6.229494108871953E-14" STUDIES="4" TAU2="0.0" TOTAL_1="127" TOTAL_2="126" WEIGHT="100.00000000000001" Z="7.503165241877154">
<NAME>stress urinary incontinence</NAME>
<CONT_DATA CI_END="-0.33812301398696043" CI_START="-2.24187698601304" EFFECT_SIZE="-1.2900000000000003" ESTIMABLE="YES" MEAN_1="1.14" MEAN_2="2.43" MODIFIED="2013-05-20 14:50:41 +0100" MODIFIED_BY="[Empty name]" ORDER="153" SD_1="1.43" SD_2="2.71" SE="0.48566044760073346" STUDY_ID="STD-Burns-1993" TOTAL_1="43" TOTAL_2="39" WEIGHT="10.948541395911601"/>
<CONT_DATA CI_END="0.003354147770053384" CI_START="-1.6033541477700535" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="0.27" MEAN_2="1.07" MODIFIED="2013-05-20 14:48:51 +0100" MODIFIED_BY="[Empty name]" ORDER="154" SD_1="0.7" SD_2="2.11" SE="0.4098820968685182" STUDY_ID="STD-B_x00f8_-1999" TOTAL_1="25" TOTAL_2="30" WEIGHT="15.371060704758586"/>
<CONT_DATA CI_END="-0.46002610052957504" CI_START="-1.2799738994704248" EFFECT_SIZE="-0.87" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="1.26" MODIFIED="2013-05-20 22:05:01 +0100" MODIFIED_BY="[Empty name]" ORDER="47" SD_1="0.51" SD_2="0.9" SE="0.20917420049768604" STUDY_ID="STD-Castro-2008" TOTAL_1="26" TOTAL_2="24" WEIGHT="59.02085558806251"/>
<CONT_DATA CI_END="-2.0973809671384736" CI_START="-3.7426190328615263" EFFECT_SIZE="-2.92" ESTIMABLE="YES" MEAN_1="0.69" MEAN_2="3.61" MODIFIED="2013-05-20 22:07:18 +0100" MODIFIED_BY="[Empty name]" ORDER="155" SD_1="0.84" SD_2="2.26" SE="0.4197113004882948" STUDY_ID="STD-Lagro_x002d_Janssen-1991" TOTAL_1="33" TOTAL_2="33" WEIGHT="14.659542311267312"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.13.02" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.13.03" MODIFIED="2009-05-05 16:43:22 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.3429009283483731" CI_START="-1.2570990716516268" DF="0" EFFECT_SIZE="-0.7999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.04" MODIFIED="2013-05-15 14:33:08 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="6.029908654530765E-4" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0" Z="3.430265526391302">
<NAME>urinary incontinence (all types)</NAME>
<CONT_DATA CI_END="-0.3429009283483731" CI_START="-1.2570990716516268" EFFECT_SIZE="-0.7999999999999999" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="1.2" MODIFIED="2013-05-15 14:33:08 +0100" MODIFIED_BY="[Empty name]" ORDER="156" SD_1="0.7" SD_2="1.7" SE="0.2332180975044266" STUDY_ID="STD-Burgio-1998" TOTAL_1="63" TOTAL_2="62" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8162305333491717" CI_END="-1.482294006720912" CI_START="-3.6461418059078605" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.5642179063143864" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.3662846394021716" P_Q="1.0" P_Z="3.3971392343244114E-6" Q="0.0" RANDOM="NO" SCALE="5.21" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="35" UNITS="" WEIGHT="100.0" Z="4.64522019226796">
<NAME>Number of voids per day (frequency)</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.14.01" MODIFIED="2013-05-16 09:12:11 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>stress urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.14.02" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.14.03" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.8162305333491717" CI_END="-1.482294006720912" CI_START="-3.6461418059078605" DF="1" EFFECT_SIZE="-2.5642179063143864" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.04" MODIFIED="2013-05-15 12:25:05 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3662846394021716" P_Z="3.3971392343244114E-6" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="4.64522019226796">
<NAME>urinary incontinence (all types)</NAME>
<CONT_DATA CI_END="-0.6219040843932642" CI_START="-3.578095915606735" EFFECT_SIZE="-2.0999999999999996" ESTIMABLE="YES" MEAN_1="6.1" MEAN_2="8.2" MODIFIED="2013-05-15 12:25:05 +0100" MODIFIED_BY="[Empty name]" ORDER="95" SD_1="1.9" SD_2="2.91" SE="0.754144426767924" STUDY_ID="STD-Diokno-2010" TOTAL_1="18" TOTAL_2="23" WEIGHT="53.57820936856121"/>
<CONT_DATA CI_END="-1.5120538518320972" CI_START="-4.687946148167899" EFFECT_SIZE="-3.099999999999998" ESTIMABLE="YES" MEAN_1="14.3" MEAN_2="17.4" MODIFIED="2013-05-13 17:05:45 +0100" MODIFIED_BY="[Empty name]" ORDER="157" SD_1="2.4" SD_2="1.6" SE="0.8101914936669333" STUDY_ID="STD-Yoon-2003" TOTAL_1="13" TOTAL_2="12" WEIGHT="46.421790631438796"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.0113955830840233" CI_END="0.48364697955180685" CI_START="-0.3973291961280205" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.04315889171189321" ESTIMABLE="YES" I2="1.1267186919360537" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.31456900719593084" P_Q="1.0" P_Z="0.8477134676742817" Q="0.0" RANDOM="NO" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="31" TOTAL_2="35" UNITS="" WEIGHT="100.0" Z="0.19203668771791482">
<NAME>Number of voids per night (nocturia)</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.01" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>stress urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.02" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.15.03" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0113955830840233" CI_END="0.48364697955180685" CI_START="-0.3973291961280205" DF="1" EFFECT_SIZE="0.04315889171189321" ESTIMABLE="YES" I2="1.1267186919360537" ID="CMP-001.15.04" MODIFIED="2013-05-20 22:15:54 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.31456900719593084" P_Z="0.8477134676742817" STUDIES="2" TAU2="0.0" TOTAL_1="31" TOTAL_2="35" WEIGHT="100.0" Z="0.19203668771791482">
<NAME>urinary incontinence (all types)</NAME>
<CONT_DATA CI_END="0.42141285080202284" CI_START="-0.6214128508020228" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.9" MODIFIED="2013-05-20 22:15:54 +0100" MODIFIED_BY="[Empty name]" ORDER="80" SD_1="0.8" SD_2="0.9" SE="0.2660318530926389" STUDY_ID="STD-Diokno-2010" TOTAL_1="18" TOTAL_2="23" WEIGHT="71.36822165762136"/>
<CONT_DATA CI_END="1.223208804343158" CI_START="-0.4232088043431582" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="1.5" MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]" ORDER="158" SD_1="1.1" SD_2="1.0" SE="0.42001220983473375" STUDY_ID="STD-Yoon-2003" TOTAL_1="13" TOTAL_2="12" WEIGHT="28.631778342378645"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="13.416321239060624" CI_END="-2.2270236876193095" CI_START="-6.7019286920153025" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.464476189817306" ESTIMABLE="YES" I2="77.63917584750638" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.003817572192254093" P_Q="0.8249708592078779" P_Z="9.199376640998421E-5" Q="0.048910038669018066" RANDOM="NO" SCALE="74.57" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="94" TOTAL_2="81" UNITS="" WEIGHT="200.0" Z="3.910792534492964">
<NAME>Short (up to one hour) pad test measured as grams of urine</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="13.367411200391604" CI_END="-1.9566430557533847" CI_START="-6.771720079268708" DF="2" EFFECT_SIZE="-4.3641815675110465" ESTIMABLE="YES" I2="85.03823986546169" ID="CMP-001.16.01" MODIFIED="2013-05-21 09:35:45 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0012511360094720203" P_Z="3.810723741617145E-4" STUDIES="3" TAU2="0.0" TOTAL_1="81" TOTAL_2="69" WEIGHT="100.0" Z="3.552856435127383">
<NAME>Stress urinary incontinence</NAME>
<CONT_DATA CI_END="-13.95686956886362" CI_START="-46.643130431136385" EFFECT_SIZE="-30.300000000000004" ESTIMABLE="YES" MEAN_1="8.4" MEAN_2="38.7" MODIFIED="2013-05-15 14:37:23 +0100" MODIFIED_BY="[Empty name]" ORDER="96" SD_1="11.5" SD_2="43.9" SE="8.338485074240603" STUDY_ID="STD-B_x00f8_-1999" TOTAL_1="25" TOTAL_2="30" WEIGHT="2.1700812394676476"/>
<CONT_DATA CI_END="-3.025830688448682" CI_START="-22.174169311551317" EFFECT_SIZE="-12.6" ESTIMABLE="YES" MEAN_1="8.4" MEAN_2="21.0" MODIFIED="2013-05-15 14:46:02 +0100" MODIFIED_BY="[Empty name]" ORDER="97" SD_1="15.8" SD_2="18.5" SE="4.884870021628531" STUDY_ID="STD-Castro-2008" TOTAL_1="26" TOTAL_2="24" WEIGHT="6.323307169505528"/>
<CONT_DATA CI_END="-0.6632098480617246" CI_START="-5.696790151938275" EFFECT_SIZE="-3.18" ESTIMABLE="YES" MEAN_1="0.46" MEAN_2="3.64" MODIFIED="2013-05-21 09:35:45 +0100" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="0.68" SD_2="4.95" SE="1.2841002037743525" STUDY_ID="STD-Pereira-2011" TOTAL_1="30" TOTAL_2="15" WEIGHT="91.50661159102683"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.16.02" MODIFIED="2013-05-15 10:28:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urge urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.16.03" MODIFIED="2013-05-15 10:29:22 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9603866447282599" CI_START="-11.160386644728261" DF="0" EFFECT_SIZE="-5.1000000000000005" ESTIMABLE="YES" I2="0.0" ID="CMP-001.16.04" MODIFIED="2013-05-20 15:03:30 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.09907197844565678" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0" Z="1.6493694061334063">
<NAME>urinary incontinence (all types)</NAME>
<CONT_DATA CI_END="0.9603866447282599" CI_START="-11.160386644728261" EFFECT_SIZE="-5.1000000000000005" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="8.4" MODIFIED="2013-05-15 14:49:02 +0100" MODIFIED_BY="[Empty name]" ORDER="98" SD_1="4.5" SD_2="9.8" SE="3.0920908203068103" STUDY_ID="STD-Yoon-2003" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.989635506930117" CI_END="7.8795535685975" CI_START="-18.038777543238567" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-5.079611987320534" ESTIMABLE="YES" I2="49.73953789440874" I2_Q="49.73953789440874" ID="CMP-001.17" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.15837933830122397" P_Q="0.15837933830122397" P_Z="0.44233970610361695" Q="1.989635506930117" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="48" TOTAL_2="48" UNITS="" WEIGHT="200.0" Z="0.7682482724390891">
<NAME>24 hour pad test (grams)</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="6.241218795991038" CI_START="-61.24121879599104" DF="0" EFFECT_SIZE="-27.5" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.01" MODIFIED="2013-05-15 15:00:49 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.11017137882499457" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="30" WEIGHT="100.0" Z="1.5974233148108894">
<NAME>Stress urinary incontinence</NAME>
<CONT_DATA CI_END="6.241218795991038" CI_START="-61.24121879599104" EFFECT_SIZE="-27.5" ESTIMABLE="YES" MEAN_1="7.9" MEAN_2="35.4" MODIFIED="2013-05-15 15:00:49 +0100" MODIFIED_BY="[Empty name]" ORDER="99" SD_1="16.7" SD_2="92.5" SE="17.215223882753698" STUDY_ID="STD-B_x00f8_-1999" TOTAL_1="25" TOTAL_2="30" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.02" MODIFIED="2013-05-15 12:29:27 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Urge urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.17.03" MODIFIED="2013-05-15 12:29:40 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Mixed urinary incontinence</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="12.835676510230606" CI_START="-15.235676510230604" DF="0" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.04" MODIFIED="2013-05-15 12:31:16 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8669216598650712" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="18" WEIGHT="100.0" Z="0.16756989089437352">
<NAME>Urinary incontinence (all types)</NAME>
<CONT_DATA CI_END="12.835676510230606" CI_START="-15.235676510230604" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" MEAN_1="12.5" MEAN_2="13.7" MODIFIED="2013-05-15 12:31:16 +0100" MODIFIED_BY="[Empty name]" ORDER="96" SD_1="27.5" SD_2="18.2" SE="7.161191032560919" STUDY_ID="STD-Diokno-2010" TOTAL_1="23" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.5245294959260777" CI_END="19.466101491480526" CI_START="2.8926868590784354" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="7.50395468948826" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="1.2892789833502118" LOG_CI_START="0.4613014226784165" LOG_EFFECT_SIZE="0.8752902030143141" METHOD="MH" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.7693073376641979" P_Q="1.0" P_Z="3.414156984145941E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="71" TOTAL_2="64" WEIGHT="99.99999999999999" Z="4.14392214334136">
<NAME>Number cured on short pad test (objective) after treatment</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PFMT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5245294959260777" CI_END="19.466101491480526" CI_START="2.8926868590784354" DF="2" EFFECT_SIZE="7.50395468948826" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="4" I2="0.0" ID="CMP-001.18.01" LOG_CI_END="1.2892789833502118" LOG_CI_START="0.4613014226784165" LOG_EFFECT_SIZE="0.8752902030143141" MODIFIED="2014-04-02 14:12:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7693073376641979" P_Z="3.414156984145941E-5" STUDIES="3" TAU2="0.0" TOTAL_1="71" TOTAL_2="64" WEIGHT="99.99999999999999" Z="4.14392214334136">
<NAME>stress urinary incontinence</NAME>
<DICH_DATA CI_END="246.50874202075775" CI_START="1.0696405117318237" EFFECT_SIZE="16.238095238095237" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" LOG_CI_END="2.391832325414688" LOG_CI_START="0.0292378431024693" LOG_EFFECT_SIZE="1.2105350842585785" MODIFIED="2009-07-01 19:19:48 +0100" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="1.3877996939414996" STUDY_ID="STD-Aksac-2003" TOTAL_1="20" TOTAL_2="10" VAR="1.9259879905041197" WEIGHT="14.409042141770003"/>
<DICH_DATA CI_END="27.03470488407554" CI_START="1.6112622714686435" EFFECT_SIZE="6.6" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.4319216330972524" LOG_CI_START="0.20716623798648476" LOG_EFFECT_SIZE="0.8195439355418687" MODIFIED="2009-05-19 19:47:37 +0100" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.7194273817250477" STUDY_ID="STD-B_x00f8_-1999" TOTAL_1="25" TOTAL_2="30" VAR="0.5175757575757576" WEIGHT="39.921155717458014"/>
<DICH_DATA CI_END="22.24362586244854" CI_START="1.3790268008779192" EFFECT_SIZE="5.538461538461538" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.3472055816377089" LOG_CI_START="0.13957270661115453" LOG_EFFECT_SIZE="0.7433891441244317" MODIFIED="2009-05-19 19:48:06 +0100" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.7093695286697395" STUDY_ID="STD-Castro-2008" TOTAL_1="26" TOTAL_2="24" VAR="0.5032051282051283" WEIGHT="45.66980214077197"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.18.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 14:12:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.18.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 14:12:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.18.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 14:12:58 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urinary incontinence (all types)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.3620100272299367" CI_END="21.27645590996947" CI_START="3.1735304744211543" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="8.217145563878384" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="2" I2="15.326354378541163" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="1.327899287771057" LOG_CI_START="0.5015426730641556" LOG_EFFECT_SIZE="0.9147209804176064" METHOD="MH" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.30697012754445097" P_Q="1.0" P_Z="1.4307027596762178E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="54" TOTAL_2="42" WEIGHT="100.0" Z="4.33909560500721">
<NAME>Number cured or improved on short pad test (objective) after treatment</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PFMT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3620100272299367" CI_END="21.27645590996947" CI_START="3.1735304744211543" DF="2" EFFECT_SIZE="8.217145563878384" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="2" I2="15.326354378541163" ID="CMP-001.19.01" LOG_CI_END="1.327899287771057" LOG_CI_START="0.5015426730641556" LOG_EFFECT_SIZE="0.9147209804176064" MODIFIED="2014-04-02 14:13:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.30697012754445097" P_Z="1.4307027596762178E-5" STUDIES="3" TAU2="0.0" TOTAL_1="54" TOTAL_2="42" WEIGHT="100.0" Z="4.33909560500721">
<NAME>stress urinary incontinence</NAME>
<DICH_DATA CI_END="12.797026271720286" CI_START="1.4416685488529906" EFFECT_SIZE="4.295238095238095" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="2" LOG_CI_END="1.1071090615365387" LOG_CI_START="0.15886542407950638" LOG_EFFECT_SIZE="0.6329872428080224" MODIFIED="2009-07-01 19:21:57 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.557003006523968" STUDY_ID="STD-Aksac-2003" TOTAL_1="20" TOTAL_2="10" VAR="0.3102523492767395" WEIGHT="75.95317806305546"/>
<DICH_DATA CI_END="532.0122059686371" CI_START="2.1351759049942087" EFFECT_SIZE="33.7037037037037" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="0" LOG_CI_END="2.725921596437933" LOG_CI_START="0.32943365988627954" LOG_EFFECT_SIZE="1.5276776281621063" MODIFIED="2009-05-19 19:46:14 +0100" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="1.407708876737048" STUDY_ID="STD-Henalla-1989" TOTAL_1="26" TOTAL_2="25" VAR="1.9816442816442812" WEIGHT="11.792191526770875"/>
<DICH_DATA CI_END="126.67288957707622" CI_START="0.5052383364244497" EFFECT_SIZE="8.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.102683677496632" LOG_CI_START="-0.29650370351274496" LOG_EFFECT_SIZE="0.9030899869919435" MODIFIED="2009-05-19 19:46:44 +0100" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="1.4092945437739803" STUDY_ID="STD-Henalla-1990" TOTAL_1="8" TOTAL_2="7" VAR="1.9861111111111112" WEIGHT="12.254630410173654"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 14:13:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.19.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 14:13:49 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.19.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 14:14:03 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urinary incontinence (all types)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Number of women with sex life spoilt by UI</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="13" I2="0.0" ID="CMP-001.20.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 14:14:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>stress urinary incontinence</NAME>
<DICH_DATA CI_END="0.9984971505912025" CI_START="0.14815164369297662" EFFECT_SIZE="0.38461538461538464" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" LOG_CI_END="-6.531701365767226E-4" LOG_CI_START="-0.8292935258050592" LOG_EFFECT_SIZE="-0.4149733479708179" MODIFIED="2013-05-22 10:07:25 +0100" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="0.48674744675558074" STUDY_ID="STD-B_x00f8_-1999" TOTAL_1="20" TOTAL_2="25" VAR="0.23692307692307693" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.20.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-22 10:01:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.20.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-22 10:01:10 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.20.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-22 10:01:10 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urinary incontinence (all types)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-04-28 13:57:24 +0100" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Number of women with UI during intercourse</NAME>
<GROUP_LABEL_1>
PFMT
</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="10" I2="0.0" ID="CMP-001.21.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-04-02 14:14:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>stress urinary incontinence</NAME>
<DICH_DATA CI_END="1.0134900715813207" CI_START="0.06166809301099812" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="10" LOG_CI_END="0.00581949858544937" LOG_CI_START="-1.209939481241374" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2013-05-22 10:07:03 +0100" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.714142842854285" STUDY_ID="STD-B_x00f8_-1999" TOTAL_1="20" TOTAL_2="25" VAR="0.5099999999999999" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.21.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-22 10:00:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urge urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.21.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-22 10:00:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>mixed urinary incontinence</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.21.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2013-05-22 10:00:05 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>urinary incontinence (all types)</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-04-28 13:07:42 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-07-25 02:06:05 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PRISMA study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAPGCAYAAADJAhwyAABjVUlEQVR42u2dD4RW2f/Hf6ysZCVG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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-04-28 13:07:42 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASIAAAOdCAIAAACu3/hoAAAoyUlEQVR42u3dvW4lxdrF8S0hIQIH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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-04-28 13:07:42 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAjAAAADOCAMAAAAXKMgdAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2014-05-13 14:12:19 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-05-13 14:11:00 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-04-02 14:15:02 +0100" MODIFIED_BY="[Empty name]">PFMT protocol</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-13 14:11:00 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="167">
<TR>
<TD>
<P>
<B>Study ID</B>
</P>
</TD>
<TD>
<P>
<B>VPFMC taught/confirmed</B>
</P>
</TD>
<TD>
<P>
<B>Description</B>
</P>
</TD>
<TD>
<P>
<B>Total VPFMC</B>
</P>
<P>
<B>per day</B>
</P>
</TD>
<TD>
<P>
<B>Duration of programme</B>
</P>
</TD>
<TD>
<P>
<B>Supervision</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Aksac 2003</B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Therapist</P>
<P> </P>
<P>Confirmed by: Vaginal palpation, while keeping abdominal and buttock muscles relaxed</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 10</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>30</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>8 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Weekly clinic visits</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold:  5 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: 10 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Sustained</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other exercise(s): Contractions progressed at 2 weeks to 10 seconds hold and 20 seconds rest,</P>
<P>home treatment</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s):  Not reported</P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Beuttenmuller</B>
</P>
<P>
<B>2010 </B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Physical therapist</P>
<P> </P>
<P>Confirmed by: Not reported, but assessed by the evaluator prior to treatment</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 8</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>6 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>20-minut twice-weekly clinic visits</P>
<P> </P>
<P>* Except during menstruation or due to other complications</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: 5 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Supine with knee bent, sitting on a chair or gym ball, on all fours, and standing</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Submaximal, maximal/long and short contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other exercise(s):  Proprioceptive exercises such as sitting and hopping around a ball, movements that raise the pelvis (e.g., anteversion, retroversion, lateralisation and circumduction)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s) : Not reported</P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Bidmead 2002</B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Physical therapist</P>
<P> </P>
<P>Confirmed by: Not reported</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: Not reported</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>14 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Five clinic visits over fourteen week period (weeks 1, 3, 6, 10 and 14)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold:  Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest:  Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day:  Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position:  Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): None reported</P>
<P> </P>
<P>Adherence measure: Treatment diary;</P>
<P>compliance with PFM exercices was generally good with three quarters of subject performing the exercises more than 3 times per week</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Burgio 1998</B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Nurse practitioner</P>
<P> </P>
<P>Confirmed by: VPFMC confirmed with anorectal biofeedback while keeping abdominal muscles relaxed</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 15</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>45</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>8 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>4 clinic visits at 2-week intervals</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: Based on each patient&#8217;s ability and gradually increased across multiple sessions to a maximum of 10 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: Based on each patient&#8217;s ability</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s) Supine, sitting, standing</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Knack and interrupting or slowing urine stream once per day</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Not reported</P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Burns 1993</B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Nurse trained in biofeedback techniques</P>
<P> </P>
<P>Confirmed by: Biofeedback to teach the subject to relax and contract the pelvic muscles</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 10 (x 2 sets)</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>200</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>8 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Weekly clinic visits</P>
<P> </P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: 10 contractions held for 3 seconds and 10 contractions held for 10 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: 4</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Sustained</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Videotape describing exercise protocol for home exercises</P>
<P> </P>
<P>Intervention progressed 10 per set to a daily maximum of 200</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Weekly and post treatment 3-and 6-month telephone reminder calls for the appointments; weekly home exercise reminder cards mailed between visits</P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Bø  1999</B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Physical therapist</P>
<P> </P>
<P>Confirmed by: Vaginal palpation</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 8-12 high-intensity (close to maximal) with 3-4 fast contractions added at the end of each hold</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>36</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>6 months</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>45-minute weekly exercise class</P>
<P> </P>
<P>Monthly clinic visit with physical therapist</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: 6-8 seconds for the high intensity contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: 6 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Supine, kneeling, sitting, standing; all with legs apart. Subject used preferred position.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction:  Sustained high-intensity contractions and quick contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Verbal information on the PFM and lower urinary tract anatomy and physiology and on continence mechanisms</P>
<P> </P>
<P>Body awareness, breathing, relaxation exercises and  strength training exercises  for the back, abdominal and thigh muscles</P>
<P> </P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s):  Audiotape with verbal guidance for home training</P>
<P>Adherence measures: Training diary</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Carneiro 2010 </B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Physical therapist</P>
<P> </P>
<P>Confirmed by: Vaginal palpation</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 8-12 ( 5 sets total)</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>50</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>8 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>30-minute, twice-weekly clinic visits</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: 6-10 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: Once</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Sitting, standing</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Sustained</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Verbal information about PFM function and visualization of pelvic floor components using anatomical figures</P>
<P> </P>
<P>5 minutes of proprioceptive exercises sitting on a 75-cm diameter therapeutic ball</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Not reported</P>
<P> </P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="6" VALIGN="TOP">
<P>
<B>Castro 2008</B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P/>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P>Taught by: Physical therapist</P>
<P> </P>
<P>Confirmed by: Vaginal palpation</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC and duration of hold and rest:</P>
<P>- 5 contractions held 10 seconds with 10-second recovery</P>
<P>-10 contractions held 5 seconds with 5-second recovery</P>
<P>-20 contractions held 2 seconds with 2-second recovery</P>
<P>-20 contractions held 1 second with 1-second recovery</P>
<P>-5 contractions with cough</P>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P>60</P>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P>6 months</P>
</TD>
<TD ROWSPAN="6" VALIGN="TOP">
<P>3 group sessions per week</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: Once, 3 times per week</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Sustained and quick contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Verbal information on the PFM and lower urinary tract anatomy and physiology and on continence mechanisms</P>
<P>Warm-up exercises for the joints and stretching exercises targeting the hip, adductor, hamstring and paravertebral muscles</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Not reported</P>
<P>Adherence measures:</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Diokno 2010 </B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Urology nurse</P>
<P> </P>
<P>Confirmed by: Not reported</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 25 (5 short and 20 long contractions) and, when needed, the Knack (sneezing)</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>50</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>6-8 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>1 teaching session</P>
<P> </P>
<P>1 follow-up session after 2 to 4 weeks with a vaginal exam if needed and a written test on new knowledge acquired</P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: Long contractions held up to 6 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: 2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Short and long contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): 2-hour Microsoft PowerPoint presentation, BMP lecture with printed handouts on the lower urinary tract anatomy, the mechanism of urinary bladder function, and UI</P>
<P> </P>
<P>Bladder training tips, if needed</P>
<P>Knack,  if needed</P>
<P>Audiotape for daily use</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): 2-4 week follow-up, including a vaginal examination if needed, measurement of pelvic floor muscle strength and an ability test</P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="7" VALIGN="TOP">
<P>
<B>Henalla 1989</B>
</P>
</TD>
<TD ROWSPAN="7" VALIGN="TOP">
<P>Taught by: Physical therapist</P>
<P> </P>
<P>Confirmed by: Vaginal palpation</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 5</P>
</TD>
<TD ROWSPAN="7" VALIGN="TOP">
<P>~80</P>
</TD>
<TD ROWSPAN="7" VALIGN="TOP">
<P>12 weeks</P>
</TD>
<TD ROWSPAN="7" VALIGN="TOP">
<P>Weekly clinic visit</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: 5 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: 1 set per hour during the day</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Not reported</P>
<P>Adherence strategy(s): Not reported</P>
<P>Adherence measure: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Henalla 1990</B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Physical therapist</P>
<P> </P>
<P>Confirmed by: Not reported</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: Not reported</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>6 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest:  Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Not reported</P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Hofbauer 1990</B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Physical therapist</P>
<P> </P>
<P>Confirmed by: Not reported</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: Not reported</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>??</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>6 months</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>20-minute twice-weekly clinic visits</P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold:  Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest:  Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s):  Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Abdominal wall and adductor exercises and home training</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Not reported</P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="9" VALIGN="TOP">
<P>
<B>Kim 2007</B>
</P>
</TD>
<TD ROWSPAN="9" VALIGN="TOP">
<P>Taught by: Nurse</P>
<P> </P>
<P>Confirmed by: Subjects were trained to exert force only on the PFM but did not give detail on how it was done</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>During the 12 weeks intervention:</B>
</P>
<P>Number of VPFMC per set: 10 (x 2 sets)</P>
</TD>
<TD ROWSPAN="9" VALIGN="TOP">
<P>~30</P>
</TD>
<TD ROWSPAN="9" VALIGN="TOP">
<P>12 weeks</P>
</TD>
<TD ROWSPAN="9" VALIGN="TOP">
<P>Exercise class, twice a week</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: 10 contractions held 3 seconds and 10 additional contractions held 6-8 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: 10 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: twice per week</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Sitting, Supine and standing positions with the legs apart</P>
<P>Type(s) of contraction: Fast and sustained contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Body awareness, breathing, and relaxation exercises. Strength training for the thigh, abdominal, and back muscles (ie: bending the knees, tilting the pelvis backward and forward, lifting the buttocks on the back with the knees bent, raising one leg while lying on the back)</P>
<P>Exercises using two types of training balls </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Home training reinforced through a pamphlet illustrating PFM and strengthening exercises and a record-keeping sheet</P>
<P>Adherence measures: Measured adherence to exercise treatment</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>During one-year follow up:</B>
</P>
<P>Number of VPFMC per set: 13</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sets per day: 2 to 3 sets at least twice a week</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Kim 2011 </B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Nurse</P>
<P> </P>
<P>Confirmed by:  Subjects were trained to exert force on just the PFMs, but details on how this was done were lacking</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 10 fast and 10 sustained contractions</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>60</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>12 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>1-hour, twice-weekly group sessions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: 3 seconds for fast contractions, 6 to 8 seconds for sustained contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: 5 seconds for fast contractions, 10 seconds for sustained contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): PFM contractions, without excessively straining the abdomen, performed in supine, sitting, and standing positions with legs apart</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Fast and sustained contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Warm-up and stretching exercises 10 to 15 minutes. Thigh and abdominal muscle strength training exercises between PFM trainings, and weight bearing and ball exercises</P>
<P> </P>
<P>Home exercises 2 to 3 sets (PFM +13 other exercises) at least 3 times a week (duration: approximately 30 minutes)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Not reported</P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Kim 2011a </B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Nurse</P>
<P> </P>
<P>Confirmed by:  Subjects were trained to exert force on just the PFMs, but details on how this was done were lacking</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 10 fast and 10 sustained contractions</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>60</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>12 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>1-hour, twice- weekly group sessions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: 3 seconds for fast contractions, 6 to 8 seconds for sustained contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: 5 seconds for fast contractions, 10 seconds for sustained contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): PFM contraction without excessively straining the abdomen, performed in supine, sitting, and standing positions with legs apart</P>
<P>Type(s) of contraction: Fast and sustained contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment (s): Warm-up and stretching exercise for 10 to 15 minutes. Strength training of the thigh and abdominal muscles, back, legs, trunk and use of an exercise ball.</P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): ??</P>
<P>Adherence measures: Training diary</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Follow-up:</B>
</P>
<P>After the 12 weeks intervention, participants attended a 1-hour exercise classes once a month for 7 months and continued a home-based program (2-3 sets of PFM plus 13 other exercises taught during the intervention)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Lagro-Janssen 1991</B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: General practitioner</P>
<P> </P>
<P>Confirmed by: Vaginal palpation</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 10</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>50 to 100</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>12 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>No supervision, the participants received written instructions for home practice</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: 6 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: 5 to 10</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Verbal information on PFMs</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Not reported</P>
<P>Adherence measures: Patient were asked how many exercises per day they completed and how well they complied with the exercise programme:</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Miller 1998</B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Nurse</P>
<P> </P>
<P>Confirmed by: Vaginal palpation</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: Not reported</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Not reported</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>One week</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>No supervision</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold:  Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest:  Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s):  Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Coordination</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s):</P>
<P>Verbal information on PFM physiology and functional properties</P>
<P> </P>
<P>Participants were taught to practice the Knack</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Not reported</P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Pereira 2011 </B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Physical therapist </P>
<P> </P>
<P>Confirmed by: Vaginal palpation and instructed not to use compensatory muscles</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>For Group and individual PFMT intervention</B>
</P>
<P>Number of VPFMC per set:  on average, 100 contractions were performed,</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>100</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>6 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Two 1-hour weekly sessions in clinic</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: 5-10 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: 10-20 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Supine, sitting and standing positions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Phasic and tonic contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Verbal information on the PFM anatomy and continence mechanisms. The degree of difficulty progressed according to the positions adopted, the number of repetitions, and the time of sustained contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Not reported</P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Sar 2009 </B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Nurse</P>
<P> </P>
<P>Confirmed by: Vaginal palpation</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 30</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>90</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>6 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Weekly telephone call by the nurse</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: 1-10 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: Same as contraction time</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Supine, sitting and standing</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: quick flicks (1-2 second contractions), sustained progressive (5-10 seconds) contractions</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s):  Verbal information on the  PFM and lower urinary tract anatomy and physiology and on continence mechanisms</P>
<P> </P>
<P>Knack</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Weekly telephone call to encourage exercises practice and answer questions</P>
<P>Adherence measures: Not reported</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Wells  1999</B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Nurse practitioner</P>
<P> </P>
<P>Confirmed by: Able to contract PFM was confirmed through a physical examination</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 80</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>80</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>5 months</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Monthly visits for observation, coaching and encouragement</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold: 10 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: 10 seconds</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: 1 set during the day</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Sustained</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Training diary</P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Yoon 2003</B>
</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Taught by: Nurse</P>
<P> </P>
<P>Confirmed by: Weekly surface electromyography biofeedback</P>
</TD>
<TD VALIGN="TOP">
<P>Number of VPFMC per set: 30 strength and endurance VPFMC per day (unclear if this is 30 for both combined or 30 per type of exercise; i.e., 60), approximately 15 to 20 minutes per day</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Not clear if 30 or 60</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>8 weeks</P>
</TD>
<TD ROWSPAN="8" VALIGN="TOP">
<P>Weekly clinic visit with nurse</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of hold:</P>
<P>
<B>Strength</B>: Burst of intense activity lasting a few seconds.</P>
<P>
<B>Endurance</B>: 6-second hold progressed by 1-second per week to 12 seconds.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of rest: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Number sets per day: Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Body position(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type(s) of contraction: Strength and endurance</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Other treatment(s): Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Adherence strategy(s): Not reported</P>
<P>Adherence measures: Not reported</P>
</TD>
</TR>
</TABLE>
<P>* Voluntary pelvic floor muscle contraction (VPFMC) </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-05-13 14:11:25 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-04-02 14:42:47 +0100" MODIFIED_BY="[Empty name]">Other UI specific quality of life outcomes</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-13 14:11:25 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="16">
<TR>
<TD VALIGN="TOP">
<P>
<B>Study ID</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Outcome</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Measure</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> Subscale</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>PFMT</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Difference</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="10" VALIGN="TOP">
<P>
<B>Bø 1999</B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD ROWSPAN="9" VALIGN="TOP">
<P>
<B>Bristol Female Lower Urinary Tract Symptoms (BFLUTS) Questionnaire </B>
</P>
<P>For analysis, positive findings ('a little', 'somewhat' and 'a lot', or 'a bit of a problem', 'quite a problem' and 'a serious problem') were regrouped and reported as frequencies. Only the lifestyle (28-31, 33) and sex-life questions (21-24) were reported.</P>
</TD>
<TD ROWSPAN="9" VALIGN="TOP">
<P> </P>
<P>Number and %</P>
</TD>
<TD VALIGN="TOP">
<P>Avoiding places and situations</P>
</TD>
<TD VALIGN="TOP">
<P>n=25</P>
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>n=30</P>
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.84, 95%</P>
<P>CI (0.37 to 1.88)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Interference with social life</P>
</TD>
<TD VALIGN="TOP">
<P>n=25</P>
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>n=30</P>
<P>12</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.10, 95%</P>
<P>CI (0.01 to 0.72)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Interference with physical activity</P>
</TD>
<TD VALIGN="TOP">
<P>n=25</P>
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>n=30</P>
<P>24</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.55, 95%</P>
<P>CI (0.34 to 0.89)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Overall interference with life</P>
</TD>
<TD VALIGN="TOP">
<P>n=25</P>
<P>14</P>
</TD>
<TD VALIGN="TOP">
<P>n=30</P>
<P>25</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.67, 95%</P>
<P>CI (0.46 to 0.99)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Unsatisfied if had to spend rest of life as now</P>
</TD>
<TD VALIGN="TOP">
<P>n=25</P>
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>n=30</P>
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.11, 95%</P>
<P>CI (0.02 to 0.79)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Sex-life spoilt by urinary symptoms</P>
</TD>
<TD VALIGN="TOP">
<P>n=20</P>
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>n=25</P>
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.29, 95%</P>
<P>CI (0.10 to 0.87)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Problem with sex-life being spoilt</P>
</TD>
<TD VALIGN="TOP">
<P>n=20</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>n=25</P>
<P>13</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.19, 95%</P>
<P>CI (0.05 to 0.76)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Problem with painful intercourse</P>
</TD>
<TD VALIGN="TOP">
<P>n=20</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>n=25</P>
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.25, 95%</P>
<P>CI (0.06 to 1.01)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Urinary incontinence with intercourse</P>
</TD>
<TD VALIGN="TOP">
<P>n=20</P>
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>n=25</P>
<P>10</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.25, 95%</P>
<P>CI (0.06 to 1.01)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Social Activity Index</B>
</P>
<P> </P>
<P>Provides a summation of scores for a visual analogue scale for perception of difficulty participating in 9 specified social situations. A lower score indicates problem is perceived to be greater.</P>
</TD>
<TD>
<P>Mean score (SD)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>n=25</P>
<P>9.3 (1.0)</P>
</TD>
<TD>
<P>n=30</P>
<P>7.9 (2.2)</P>
</TD>
<TD>
<P>MD 1.4, 95%</P>
<P>CI (0.4 to 2.4)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Diokno 2010 </B>
</P>
</TD>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Sandvik&#8217;s Severity Index for Female Urinary Incontinence </B>(3-point scale)</P>
<P>Questions assess the degree of UI: Frequency: 1. How often do you experience urinary leakage? Scale: 1 = less than once a month, 2 = a few times a month, 3 = a few times a week, 4 = every day and/or night.</P>
<P>Quantity: 2. How much urine do you lose each time? Scale: 1 = drops, 2 = small splashes, and 3 = more. Note: on the 3-level severity index, responses to this question are aggregated into drops (1) or more (2).</P>
<P>The Severity Index is created by multiplying the result of questions 1 (quantity) and 2 (frequency), resulting in the following index values whereby 1-2 = slight, 3-4 = moderate, and 6-8= severe</P>
</TD>
<TD ROWSPAN="4">
<P>Number and %</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
<TD>
<P>n=23</P>
</TD>
<TD>
<P>n=18</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Slight</P>
</TD>
<TD>
<P>13 (56.5%)</P>
</TD>
<TD>
<P>5 (22.2%)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 2.03, 95%</P>
<P>CI (0.89 to 4.65)</P>
</TD>
</TR>
<TR>
<TD>
<P>Moderate</P>
</TD>
<TD>
<P>5 (21.7%)</P>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>7 (38.9%)</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.78, 95%</P>
<P>CI (0.27 to 2.29)</P>
</TD>
</TR>
<TR>
<TD>
<P>Severe</P>
</TD>
<TD>
<P>5 (21.7%)</P>
</TD>
<TD>
<P>7 (38.9%)</P>
</TD>
<TD VALIGN="TOP">
<P>RR 0.78, 95%</P>
<P>CI (0.27 to 2.29)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Kim 2011a </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Urine leakage score </B>
</P>
<P>This is calculated based on the self-reported 1-week urinary diary (score of 0-4; with 0 = no urine leakage, 1 = less than once a week, 2 = once a week, 3 = two or three times a week, and 4 = every day)</P>
</TD>
<TD>
<P>Mean score (SD)</P>
</TD>
<TD>
<P>N.A</P>
</TD>
<TD>
<P> </P>
<P>n = 59</P>
<P>3.0 (2.0)</P>
<P> </P>
<P>
<B> </B>
</P>
</TD>
<TD>
<P>n =61</P>
<P>4.4 (1.6)</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>
<B> </B>
</P>
<P>MD -1.4, 95% CI (-2.1 to -0.8)</P>
</TD>
</TR>
</TABLE>
<P>NA = Not Applicable</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-04-02 14:47:35 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-04-02 13:20:43 +0100" MODIFIED_BY="[Empty name]">Other leakage outcomes</TITLE>
<APPENDIX_BODY MODIFIED="2013-08-06 15:31:17 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="3">
<TR>
<TD>
<P>Study ID</P>
</TD>
<TD>
<P>Outcome</P>
</TD>
<TD>
<P>Measure</P>
</TD>
<TD>
<P>PFMT</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>Difference</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Bø 1999</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Leakage Index</B>
</P>
<P>*Perceived frequency of leakage with 7 prespecified types of exertion. Higher score indicates more perceived leakage.<BR/>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>Mean (SD)<BR/>
<BR/>
</P>
</TD>
<TD>
<P>n=25</P>
<P>1.9 (0.5)<BR/>
<BR/>
</P>
</TD>
<TD>
<P> </P>
<P>n=30</P>
<P>3.1 (0.6)<BR/>
<BR/>
<BR/>
</P>
</TD>
<TD>
<P>MD -1.2, 95%</P>
<P>CI (-1.5 to -0.9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Yoon 2003</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Urinary incontinence score</B>
</P>
<P>*Sum of scores from 5-point Likert scales regarding severity of leakage with 18 prespecified activities.</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD>
<P>n=13</P>
<P>10.8 (6.2)</P>
</TD>
<TD>
<P>n=12</P>
<P>14.2 (3.6)</P>
</TD>
<TD>
<P>MD -3.4, 95%</P>
<P>CI (-7.6 to 0.8)</P>
</TD>
</TR>
</TABLE>
<P> </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-05-13 14:11:36 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2014-04-02 14:15:51 +0100" MODIFIED_BY="[Empty name]">Other pad or paper towel test</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-13 14:11:36 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="6" ROWS="6">
<TR>
<TD>
<P>Study ID</P>
</TD>
<TD>
<P>Outcome</P>
</TD>
<TD>
<P>Measure</P>
</TD>
<TD>
<P>PFMT</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>Difference</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Aksac 2003</B>
</P>
</TD>
<TD>
<P>One-hour pad test (g)</P>
</TD>
<TD>
<P>Median (SD)</P>
</TD>
<TD>
<P>n=20</P>
<P>2.1 (0.4)</P>
</TD>
<TD>
<P>n=20</P>
<P>28.2 (3.7)</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Bidmead 2002</B>
</P>
</TD>
<TD>
<P>Short pad test,</P>
<P>weight change from baseline (g)</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD>
<P>n=40</P>
<P>-9.62 (3.37)</P>
</TD>
<TD>
<P>n=20</P>
<P>3.65 (1.17)</P>
</TD>
<TD>
<P>MD -13.3, 95%</P>
<P>CI (-23.1 to -3.4)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Diokno 2010</B>
</P>
<P/>
</TD>
<TD>
<P>Cough test (cm)</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD>
<P>n=23</P>
<P>12.6 (41.6)</P>
</TD>
<TD>
<P>n=18</P>
<P>19.6 (48.8)</P>
</TD>
<TD VALIGN="TOP">
<P>MD 25.30, 95% CI (-2.9 to 53.5)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Miller 1998</B>
</P>
</TD>
<TD ROWSPAN="2">
<P>Paper towel test, wet area (cm<SUP>2</SUP>)</P>
</TD>
<TD>
<P>Mean (SD) on medium cough</P>
</TD>
<TD>
<P>n=13</P>
<P>0.4 (1.04)</P>
</TD>
<TD>
<P>n=10</P>
<P>21.2 (44.8)</P>
</TD>
<TD>
<P>MD -20.8, 95% CI (-46.5 to 4.9)</P>
</TD>
</TR>
<TR>
<TD>
<P>Mean (SD) on deep cough</P>
</TD>
<TD>
<P>n=13</P>
<P>5.4 (15.3)</P>
</TD>
<TD>
<P>n=10</P>
<P>26.8 (46.7)</P>
</TD>
<TD>
<P>MD -21.4, 95%   CI (-50.0 to 7.2)</P>
</TD>
</TR>
</TABLE>
<P> </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-05-06 10:34:08 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2014-05-06 10:34:08 +0100" MODIFIED_BY="[Empty name]">Other non-specific quality of life outcomes</TITLE>
<APPENDIX_BODY MODIFIED="2013-08-06 15:31:22 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="7" ROWS="13">
<TR>
<TD>
<P>Study ID</P>
</TD>
<TD>
<P>Outcome</P>
</TD>
<TD>
<P>Measure</P>
</TD>
<TD>
<P>Subscale</P>
</TD>
<TD>
<P>PFMT</P>
</TD>
<TD>
<P>Control</P>
</TD>
<TD>
<P>Difference</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="11" VALIGN="TOP">
<P>
<B>Burgio  1998</B>
</P>
</TD>
<TD ROWSPAN="11" VALIGN="TOP">
<P>
<B>Hopkins Symptom Checklist for psychological distress (SCL-90-R)</B>
</P>
<P>
<B> </B>
</P>
<P>* A 90-item self-administered questionnaire with nine clinical subscales aggregated into a total score: the Global Severity Index. A score of 50 is normal. A score of more than 63 is a 'case' on any of the subscales.</P>
</TD>
<TD ROWSPAN="11" VALIGN="TOP">
<P> </P>
<P> </P>
<P>Mean score (SD)</P>
</TD>
<TD>
<P>All</P>
</TD>
<TD>
<P>n=57</P>
</TD>
<TD>
<P>n= 46</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Somatization</P>
</TD>
<TD>
<P>51.8 (11.4)</P>
</TD>
<TD>
<P>49.8 (13.0)</P>
</TD>
<TD>
<P>MD 2.0, 95%</P>
<P>CI (-2.8 to 6.8)</P>
</TD>
</TR>
<TR>
<TD>
<P>Obsessive/compulsive</P>
</TD>
<TD>
<P>53.8 (13.9)</P>
</TD>
<TD>
<P>55.4 (11.0)</P>
</TD>
<TD>
<P>MD -1.6, 95%</P>
<P>CI (-5.7 to 2.5)</P>
</TD>
</TR>
<TR>
<TD>
<P>Interpersonal sensitivity</P>
</TD>
<TD>
<P>49.5 (12.0)</P>
</TD>
<TD>
<P>49.2 (11.3)</P>
</TD>
<TD>
<P>MD 0.3, 95%</P>
<P>CI (-4.3 to 4.9)</P>
</TD>
</TR>
<TR>
<TD>
<P>Depression</P>
</TD>
<TD>
<P>51.5 (11.5)</P>
</TD>
<TD>
<P>51.4 (11.2)</P>
</TD>
<TD>
<P>MD 0.1, 95%</P>
<P>CI (-6.7 to 1.9)</P>
</TD>
</TR>
<TR>
<TD>
<P>Anxiety</P>
</TD>
<TD>
<P>46.1 (14.6)</P>
</TD>
<TD>
<P>45.8 (12.9)</P>
</TD>
<TD>
<P>MD 0.3, 95%</P>
<P>CI (-6.7 to 1.9)</P>
</TD>
</TR>
<TR>
<TD>
<P>Hostility</P>
</TD>
<TD>
<P>44.9 (10.8)</P>
</TD>
<TD>
<P>47.3 (11.2)</P>
</TD>
<TD>
<P>MD (-2.4, 95% CI (-6.7 to 1.9)</P>
</TD>
</TR>
<TR>
<TD>
<P>Phobia</P>
</TD>
<TD>
<P>47.1 (11.2)</P>
</TD>
<TD>
<P>45.1 (8.5)</P>
</TD>
<TD>
<P>MD 2.0, 95%</P>
<P>CI (-2.0 to 6.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>Paranoia ideation</P>
</TD>
<TD>
<P>45.8 (10.9)</P>
</TD>
<TD>
<P>47.2 (12.0)</P>
</TD>
<TD>
<P>MD -1.4, 95%</P>
<P>CI (-5.9 to 3.1)</P>
</TD>
</TR>
<TR>
<TD>
<P>Psychoticism</P>
</TD>
<TD>
<P>49.2 (11.7)</P>
</TD>
<TD>
<P>49.6 (10.3)</P>
</TD>
<TD>
<P>MD -0.4, 95%</P>
<P>CI (-4.8 to 4.0)</P>
</TD>
</TR>
<TR>
<TD>
<P>Global severity</P>
</TD>
<TD>
<P>50.8 (12.8)</P>
</TD>
<TD>
<P>51.4 (10.9)</P>
</TD>
<TD>
<P>MD -0.6, 95%</P>
<P>CI (5.3 to 4.1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Bø 1999</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Quality of Life Scale in Norwegian (QoLS-N)</B>
</P>
<P>
<B> </B>
</P>
<P>* A 16-item scale used in populations with chronic illness. Uses a 7-point satisfaction scale per item whereby a higher score indicates a higher quality of life.</P>
</TD>
<TD>
<P> </P>
<P>Mean total score (SD)</P>
</TD>
<TD>
<P>
<B>NA</B>
</P>
</TD>
<TD>
<P>n=25</P>
<P>90.1 (9.5)</P>
</TD>
<TD>
<P>n=30</P>
<P>85.2 (12.1)</P>
</TD>
<TD>
<P>   MD 4.9, 95%</P>
<P>CI (-1.1 to 10.9)</P>
</TD>
</TR>
</TABLE>
<P>*NA = Not Applicable<B> </B>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2014-05-13 14:12:19 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2014-04-02 14:16:04 +0100" MODIFIED_BY="[Empty name]">PFMT function assessment</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-13 14:12:19 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="9" ROWS="27">
<TR>
<TD VALIGN="TOP">
<P>
<SUP> </SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>PFMT Outcomes and Study ID</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Outcome</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Measure</B>
</P>
<P> </P>
</TD>
<TD COLSPAN="3" VALIGN="TOP">
<P>
<B>PFMT</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Control</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Difference</B>
</P>
<P> </P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>US measurements</B>
</P>
<P> </P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Carneiro 2010 </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Transperineal US</P>
<P> </P>
<P>Bladder neck mobility (mm)</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3">
<P>n=25</P>
<P>12.63 (4.35)</P>
</TD>
<TD>
<P>n=25</P>
<P>17.53 (4.33)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>MD -4.90, 95% CI -7.3 to -2.5)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Transperineal US</P>
<P>PFM thickness (mm)</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3">
<P>n=25</P>
<P>12.87 (1.02)</P>
<P> </P>
</TD>
<TD>
<P>n=25</P>
<P>10.74 (2.26)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>MD 2.13, 95% CI 0.4 to 3.9)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="8" VALIGN="TOP">
<P>
<B>Pressure measurements</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Aksac 2003</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal</P>
<P>(cmH<SUB>2</SUB>O)</P>
</TD>
<TD>
<P>Median (SD)</P>
</TD>
<TD COLSPAN="3" VALIGN="TOP">
<P>n=20</P>
<P>37.5 (8.7)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>n=10</P>
<P>20.0 (3.9)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Non-estimable</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Beuttenmuller 2010</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal (cmH<SUB>2</SUB>O)</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3" VALIGN="TOP">
<P>n=25</P>
<P> </P>
<P>Slow twitch</P>
<P>22.74 (5.65)</P>
<P> </P>
<P>Fast twitch</P>
<P>32.72 (10.34)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>n=25</P>
<P>Slow twitch 17.70 (5.86)</P>
<P>Fast twitch</P>
<P>28.09 (9.89)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>MD 5.04, 95% CI 1.9 to 8.2)</P>
<P> </P>
<P> </P>
<P>MD 4.63, 95% CI -0.03 to 9.3)</P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Bø 1999</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal (cmH<SUB>2</SUB>O)</P>
<P> </P>
<P> </P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3">
<P>19.2 (10.0)</P>
<P>n=25</P>
</TD>
<TD>
<P>16.4 (9.8)</P>
<P>n=30</P>
</TD>
<TD>
<P>MD 2.8, 95%</P>
<P>CI ( -2.6 to 8.2)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pereira 2011</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal (cmH<SUB>2</SUB>O)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P> </P>
<P> Mean (SD)</P>
</TD>
<TD VALIGN="TOP">
<P>Group PFMT</P>
<P>n=15</P>
<P>37.13 (19.24)</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Individual PFMT</P>
<P>n=15</P>
<P>38.53 (19.34)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>n=15</P>
<P>11.91 (5.57)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>MD 25.92, 95%</P>
<P>CI 18.45 to 33.0)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Yoon 2003</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>Average pressure,  intra-vaginal (mm Hg)</P>
</TD>
<TD>
<P> </P>
</TD>
<TD COLSPAN="3">
<P>n=13</P>
</TD>
<TD>
<P>n=12</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3">
<P>26.1 (12.5)</P>
</TD>
<TD>
<P>12.2 (5.3)</P>
</TD>
<TD>
<P> </P>
<P>MD 13.9, 95%</P>
<P>CI (5.8 to 22.0)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Peak pressure, intra-vaginal (mm Hg)</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3">
<P>39.7 (20.0)</P>
</TD>
<TD>
<P>19.9 (7.5)</P>
</TD>
<TD>
<P>MD 19.8, 95%</P>
<P>CI (7.1 to 32.5)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration of PFM contraction(s)</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3">
<P>14.5 (3.0)</P>
</TD>
<TD>
<P>5.9 (1.7)</P>
</TD>
<TD>
<P>MD 8.6, 95%</P>
<P>CI (6.6 to 10.6)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="11" VALIGN="TOP">
<P>
<B>Digital measurements</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Aksac 2003</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal</P>
<P>Number of fingers not stated</P>
<P>Scale: 5-point scale</P>
</TD>
<TD>
<P>Median (SD)</P>
</TD>
<TD COLSPAN="3">
<P>n=20</P>
<P>4.8 (0.4)</P>
<P> </P>
</TD>
<TD>
<P>n=10</P>
<P>3.3 (0.6)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>Not estimable</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Beuttenmuller 2010</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal</P>
<P>1 finger</P>
<P>Scale: Oxford</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3" VALIGN="TOP">
<P>n=25</P>
<P> </P>
<P>Slow twitch</P>
<P>3.84 (0.8)</P>
<P> </P>
<P>Fast twitch</P>
<P>3.80 (0.65)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>n=25</P>
<P>Slow twitch 2.95 (0.90)</P>
<P>Fast twitch 2.86 (0.77)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P> </P>
<P>MD 0.45, 95%</P>
<P>CI (-0.02 to 0.92)</P>
<P> </P>
<P>MD 0.94, 95%</P>
<P>CI 0.6 to 1.3)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Carneiro 2010</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal</P>
<P>2 fingers</P>
<P>Scale: Not stated</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3">
<P>n=25</P>
<P>3.20 (1.05)</P>
<P> </P>
</TD>
<TD>
<P>n=25</P>
<P>2.50 (0.76)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.7, 95%</P>
<P>CI (0.2 to 1.21)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Castro  2008</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal</P>
<P>Number of fingers not stated</P>
<P>Scale: Oxford</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3">
<P>n=26</P>
<P>3.6 (0.71)</P>
</TD>
<TD>
<P>n=24</P>
<P>2.3 (1.07)</P>
</TD>
<TD>
<P>MD 1.30, 95%</P>
<P>CI (0.79, 1.81)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Diokno 2010</B>
</P>
</TD>
<TD COLSPAN="2" VALIGN="TOP">
<P>Intra-vaginal</P>
<P>Number of fingers not stated</P>
<P>Scale: Not stated</P>
</TD>
<TD COLSPAN="3">
<P>n=23</P>
</TD>
<TD>
<P>n=18</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Pressure</P>
</TD>
<TD VALIGN="TOP">
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3" VALIGN="TOP">
<P>4.1 (1.1)</P>
</TD>
<TD VALIGN="TOP">
<P>3.8 (0.9)</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.30 , 95%</P>
<P>CI (-0.3 to 0.9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Displacement</P>
</TD>
<TD VALIGN="TOP">
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3" VALIGN="TOP">
<P>2.3 (1.3)</P>
</TD>
<TD VALIGN="TOP">
<P>2.1 (0.9)</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.20, 95%</P>
<P>CI (-0.5 to 0.9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Duration</P>
</TD>
<TD VALIGN="TOP">
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3" VALIGN="TOP">
<P>7.1 (2.9)</P>
</TD>
<TD VALIGN="TOP">
<P>5.9 (3.1)</P>
</TD>
<TD VALIGN="TOP">
<P>MD 1.2, 95%</P>
<P>CI (-0.7 to 3.1)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Miller 1998</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal</P>
<P>Number of fingers not stated</P>
<P>Score: 0-21</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3">
<P>n=13</P>
<P>10.4 (4.7)</P>
</TD>
<TD>
<P>n=13</P>
<P>11.2 (5.1)</P>
</TD>
<TD>
<P>MD -1.1, 95%</P>
<P>CI (-5.1 to 2.9)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Pereira 2011</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal</P>
<P>2 fingers</P>
<P>Scale: 6-point modified Oxford scale</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="2">
<P>Group PFMT</P>
<P>n=15</P>
<P>3.07 (0.70)</P>
</TD>
<TD>
<P>Individual PFMT</P>
<P>n=15</P>
<P>2.73 (0.96)</P>
</TD>
<TD>
<P>n=15</P>
<P>1.47 (0.52)</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
<P>MD 1.43, 95%</P>
<P>CI (1.0 to 1.46)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Wells 1999</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal</P>
<P>Number of fingers not stated</P>
<P>Scale:  Pressure and displacement digital score (4-12)</P>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD COLSPAN="3">
<P>8.8</P>
</TD>
<TD>
<P>8.2</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>EMG measurements</B>
</P>
</TD>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Burns 1993</B>
</P>
<P>
<B> </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal EMG</P>
<P> </P>
<P>5 fast contractions</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3">
<P>n=38</P>
<P>3.0 (3.4)</P>
</TD>
<TD>
<P>n=40</P>
<P>3.5 (4.4)</P>
</TD>
<TD>
<P>MD -0.5, 95%</P>
<P>CI (-2.3 to 1.3)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Intra-vaginal EMG</P>
<P>5 sustained contractions</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3">
<P>n=33</P>
<P>1.8 (2.0)</P>
</TD>
<TD>
<P>n=34</P>
<P>2.0 (1.8)</P>
</TD>
<TD>
<P>MD -0.2, 95%</P>
<P>CI (-1.1 to 0.7)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Carneiro 2010</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal EMG</P>
<P>3 maximal contractions</P>
</TD>
<TD>
<P>Mean (SD)</P>
</TD>
<TD COLSPAN="3">
<P>n=25</P>
<P>13.56 (5.41)</P>
<P> </P>
</TD>
<TD>
<P>n=25</P>
<P>8.25 (5.70)</P>
<P> </P>
</TD>
<TD>
<P>MD 5.31, 95%</P>
<P>CI 2.23 to 8.39)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Wells 1999</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Intra-vaginal or intra-anal EMG</P>
<P>4 sustained and 4 short contractions</P>
</TD>
<TD>
<P>Mean</P>
</TD>
<TD COLSPAN="3">
<P>48.8</P>
</TD>
<TD>
<P>24.2</P>
</TD>
<TD>
<P>Not estimable</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<P> </P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2009-05-01 16:30:49 +0100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;18 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;34 reports of 21 studies included in qualitative synthesis additionally one study was 'Awaiting Assessment' as the study manuscript is in preparation (&lt;a link_type=&quot;STUDY&quot; protected=&quot;true&quot; href=&quot;Miller 2009&quot;&gt;Miller 2009&lt;/a&gt;)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;54 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;704 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;704 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;704 records identified through searching the Specialised Register&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;650 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;19 reports of 19 full-text articles excluded, with reasons given in the &lt;a link_type=&quot;SECTION&quot; protected=&quot;true&quot; href=&quot;CHARACTERISTICS_OF_EXCLUDED_STUDIES&quot;&gt;Characteristics of excluded studies&lt;/a&gt; table&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>